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(R, S)-lbuprofen is an important non-steroidal anti -infl ammator\ drug widtlý 
used for the treatment of pain and inflammation associated with rheumatic 
disorders. The enantiomers of ibuprofen exhibit differential phanrnacodynamic and 
pharmacokinetic properties in-vivo and in-vitro, and undergo metabolic chiral 
inversion from the inactive R- enantiomer to its active S- antipode. Although the 
enantiomeric disposition of ibuprofen in man has been extensively investigated, few 
studies have presented a comprehensive picture of the drug's disposition following 
the administration as a racemate, as a result of methodological difficulties in the 
determination of the unbound drug enantiomer concentrations and the determination 
of the stereochernical composition of its two major metabolites, hydroxyibuprofen 
and carbox_yibuprofen.. Even less attention has been placed on the disposition of 
ibuprofen in one of the frequent group users, the elderly population. As such it is 
the objective of this investigation to examine the enantioselecti%c disposition and 
pharmacokinetics of ibuprofen in young and elderly volunteers. To achieve this 
objective sensitive and robust analytical methods were developed and validated for 
the enantiospecific analysis of ibuprofen in serum and urine. These methods are 
based on the indirect approach to chiral chromatography, involving derivatisation 
with (R)-(naphthen-1-_yl)eth_ylamide in the presence l-(3-dimethylaminopropyl)-3- 
ethylcarbodiimide and 1-hydroxybenzotriazole (HOBT) as coupling agents. The 
diastereorneric amides were then separated using a reversed phase C1 HPLC 
system. The sensitivity of the method enabled it to be adapted to measure unbound 
drug concentrations in serum following equilibrium dialysis and was validated by 
comparison with a published radiochemical method. The diastereoisomers of 
carboxyibuprofen were resolved on a Chiralpak AD chiral stationary phase and the 
assignment of the stereochemical configuration to the eluted peaks were achieved 
using a combination of metabolic studies, stereoselective synthesis and 
chromatographic separation. The order of elution of the diastereoisomers was found 
to be 2'S2R- 2'R, 2R-, ? 'MS-, and 2'S, 2S-. The chiroptical properties of the 
diastereoisomers were also determined and differences in CD bands were observed 
at the 225 nnm region. The determination of the enantiomeric composition of 
hydroxvibuprofen and carboxvibuprofen in urine was carried out using- a sequential 
normal phase achiral-chiral phase method based on the Chiralpak AD CSP. 
The serum kinetics of ibuprofen enantiomers showed signifiicant differences 
in t1/2, Vd and CL following the administration of the racemic drug (400 mg) to 
healthy young volunteers. Plasma protein binding was found to be stereoselecti\ e 
(1z >S). Pharmacokinetic parameters based on unbound concentrations revealed 
that clearance by inversion was the main pathway of metabolism for the R- 
enantiomer, while clearance by oxidative pathways was stereoselective for the S- 
enantiomer. The metabolite formation clearances based on unbound drug 
enantiomer concentrations also reflected stereoselectiv-e formation of metabolites 
with the S- configuration in the propionic acid moiety. The stereoselectivity for the 
formation of the carboxyibuprofen diastereoisomers indicate that substrate-product 
stereoselectivity, i. e the 2'/?, 21Z- stereoisomer was the preferred product for (I? )- 
ibuprofen while the 2'S', 2. ß'- stereoisomer «-as the preferred product for (S')- 
ibuprofen. Ageing was found to have no significant effect on the pharmacokinetic 
parameters of the enantiomers of ibuprofen based on total serum concentrations. 
However, a significant increase in the free fraction was observed for (S)- but not 
(K)-ibuprofen in the elderly. In addition, ageing resulted in a significant decrease in 
the unbound clearance of (S)-ibuprofen but not in either the unbound inversion or 
non-inversion clearance of the R- enantiorner. The opposing effects of increased 
fraction unbound and reduced clearance of (S)-ibuprofen account for the lack of 
observed effect of ageing on ibuprofen disposition when phannacokinetic 
parameters are based on total serum drug enantiomer concentrations. The 
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Stereochemistrv is the area of chemistry concerned with the three 
dimensional spatial arrangement of the atoms or groups within a molecule. The 
prefix stereo originates from the Greek . stereo. meaning solid. 
The origins of 
stereochemistry stem from the discovery of plane polarised light by Malus in 1809 
and the observation that quartz, and later tartaric acid crystals rotate the plane of 
plane polarised light. It was also early in the 19th century that the ability to rotate 
plane polarised light i. e. optical activity was recognised as a property of crystals of 
compounds such as sodium chlorate and sodium bromate but not of the solutions. 
Much later in 1848, Pasteur extended this observation from crystals to the realm of 
molecules like tartaric acid which show optical activity in both the crystalline form 
and in solution. By crystallisation of sodium ammonium tartrate from aqueous 
solutions, he obtained two types of hemihydric crystals i. e crystals with facets 
arranged such that non-superimposible species were formed, similar to that of quartz 
crystals. After separating the cr` stals by hand, he re-dissolved them individually 
and found that one solution rotated polarised light to the left [(-)-tartrate] and the 
other to the right [(+)-tartrate]. This led him to the conclusion that optical activity 
was a characteristic of the molecule and that the individual molecules of (+)- and 
(-)-tartaric acid are stereochemically dissymmetric. related to each other as non- 
superimposible mirror images and expressed as hemihvdric crystals in their sodium 
ammonium salt form. The two forms are known as enantiomorphs or enantiomers 
(Greek cmhalo. ', opposite; morph, form). Compounds which show this behaviour 
are said to be chiral (Greek chiro. s, handed), because like an individual's hands, the 
individual stereoisomers are not superimposible with their mirror images (Eliel and 
Wilen, 1994). 
The most common source of asynmmetry in molecules of interest in biology 
arises due to the presence of tetrahedral carbon atoms to which four different groups 









Figure 1.1: A pair of enantiomers based on an asymmetric carbon 
Other atoms such as nitrogen, sulphur and phosphorus to which four different 
groups are bonded also \'ield chiral molecules of importance in pharmacology 
(Figure 1.2) (Allenmark. 1988). 
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Figure 1.2: Examples of tetrahedral structures based on asymmetric 
atoms other than carbon. 
Although chiral compounds are usually based on an asymmetric centre, this is not 
essential as asymmetry can occur across an axis or a plane. ho« e" er relativ el', ' few 
chiral compounds of this type are known to be of pharmacological importance. 
1.2 Nomenclature 
In the earliest studies of stereoisomerism, enantiomers were distinguished by 
their ability to rotate the plane of plane polarised light. Single enantiomers rotate 
the plane of plane polarised light either to the left or right of the centre line of a 
polarimeter. This phenomenon gave rise to the notations dextrorotatory (cl or +) and 
laevorotatory (I or -) for the individual stereoisomers respectively. A racemic 
mixture, a 1: 1 mixture of the two enantiomers, being indicated by either a d, l or (±) 
prefix to the name of the compound. This notation describes a physical property of 
the molecule and indicates whether a single isomer or mixture is present but does 
not describe the actual spatial arrangement of the atoms or groups around the chiral 
centre, i. e. it gives no information concerning the three dimensional spatial 
arrangement of the molecule. At the end of the 19th century, while structures could 
be represented in three dimensions it was not possible with the available technology 
to determine the actual structure of compounds and relate the observed optical 
rotations to a particular stereoisomeric structure. Three dimensional spatial 
arrangements, or configurations were arbitrarily assigned to the enantiomers of the 
carbohydrate glyceraldehyde such that the (+)-isomer was said to have the D- 
configuration and the (-)-isomer was said to have the L-configuration when drawn as 









Figure 1.3: Fischer projections of D-(+)-glyceraldehyde and L-(-)- 
glyceraldehyde 
Using this system, the configurations of other compounds were related chemically to 
that of either of the reference compounds D-gl`-ceraldehyde or L-serine, and were 
referred to as relative configurations. It was not until the 1950s that it was shown 
that (+)-glyceraldehyde had the structure assigned to it. Due to the difficulty of 
chemical transformation, the confusion between the small and capital letter 
notations (D and d, L or 1) and the difficulties in applying the system in many 
situations, the notation should now be restricted for the designation of carbohydrates 
and amino acids. 
The most commonly used s`-stein to designate stereoisomers is the Cahn- 
Ingold-Prelog system (Cahn cr ul., 1956). Once the three dimensional structure of a 
stereoisorner has been determined by for example. X-ray crystallography, the 
substituent atoms around the chiral centre are assigned a priority according to their 
atomic number. If this fails to distinguish between the priority of two particular 
substituent groups, then the priority of the next atoms in the groups is considered, 
and so on until the ranking of the four groups has been assigned. The molecule is 
then - iewed from the side opposite the lowest priority group. If the sequence of 
priority, highest to lowest, are arranged in a clockwise manner, then the chiral centre 
is designated the 1? - or rectus absolute configuration and if the sequence is 













Figure 1.4: Assignment of absolute stereochemical configuration 
according to the ('ahn-Ingold-Prelog con,, ention. 
Additional rules concerning the designation of planar and axial symmetry are also 
included in this system (Cahn ct ul., 1956). 
1.3 Properties of enantiomers 
While enantiorners has e identical physical and chemical properties, they 
diner in two important aspects, the direction of rotation of plane polarised light 
(which is equal in magnitude) and different reaction rates with other chiral 
molecules. In chemical reactions with a second optically pure agent, the reaction 
transition states are diastereoisomeric (see below) and thus have different energies 
which gives rise to different reaction rates. Biological reactions are predominantly 
stereoselective, as enzymes, the all important catalysts of biological systems are 
chiral in nature. Thus (+)-glucose, but not (-)-; glucose, is oxidised by animal and 
plant cells for energy. The fundamental principle is that enantiomers show different 
chemical and physical properties only in a chiral en\ ironment. Plane polarised light 
provides such an environment. The solubility, adsorption and reaction rates of 
D 
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enantiomers may also be different in a chiral medium. but not in an achiral 
environment. Thus, enantiomers cannot be , cparated by ordinary chemical methods 
like fractional distillation, fractional cr<stallisation or chromatography, unless in the 
latter two methods, chiral solvents or chiral adsorbents are used. 
When there is more than one chiral centre in a molecule, the number of 
stereoisorners possible are 2r, where n is the number of chiral centres. kith half that 
number of pairs of enantiomers. Those stereoisomers which are not enantiomeric 
are by definition diastereomeric pairs of compounds (Figure 1.5). Diastereomers 
have different physical properties and have similar but not identical chemical 
properties. Thus, in principle, diastereomers can be separated by fractional 































Figure 1.5: Relationships between enantiomers and diastereomers 
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1.4 Stereoselectiv ity in Pharmacology 
Biological environments are invariably chiral as the structural, functional 
and catalytic components of biological systems are composed of chiral 
macromolecules, e. g. proteins, enzymes and receptors, from the chiral building 
blocks of L-amino acids and D-carbohydrates. Differential interactions between a 
chiral biological macromolecule and a pair of enantiomers are therefore expected as 
they are viewed as two different chemical entities. The differential 
pharmacodynamic activity of a pair of enantiomers has resulted in additional 
terminology such that the enantiomer with the greater affinity or activity is termed 
the eutomer and that with the lower affinity or activity is termed the distomer. The 
ratio of their activities, the eudismic ratio is a measure of the stereoselectivity of the 
system. Stereoselective differences in drug effects have long been known, e. g D-(-)- 
isoprenaline is 800 fold more potent as a bronchodilator than L- (+) isomer (Albert, 
1985). The observed differences in biological activities between enantiomers arise 
as a result of their differential interactions at the receptor level. A biologically 
active molecule must complement the receptor at the site of action both sterically 
and chemically. Stereoselectivity in action arises when one enantiomer fits better at 
the receptor than its optical antipode. According to the universally accepted Easson- 
Stedman interaction model (Easson and Stedman, 1933), the more potent 
enantiomer can be involved with a minimum of three molecular interactions with 
the receptor site, while the less active enantiomer may take part in two interactions 
only (Fi(; ure 1.6). While the above model provides a means of understanding 
molecular interactions at the receptor level, it is a simplistic representation of a 
complex process. The model implies that drug molecules assume a particular 
orientation when interacting with the complementary receptor site. It is known that a 
change of conformation may occur in the drug molecule on contact with the 













Figure 1.6: Interaction of two enantiomers with a receptor site. 
The enantiomer on the left is the more potent, with three molecular interactions 
while that on the right interacts at two points only. 
Recent advances in synthetic and analytical chemistry have facilitated 
investigations of the effects of individual enantiomers and this has led to a better 
understanding of the differences in their biological activity, and the factors that 
affect them. Evidence from such studies indicate that the pharmacological and 
toxicological properties of a racemic mixture are not necessarily the sum of the 
contributions of the two enantiomers. The situation is complex and it is important to 
understand the contribution made by each enantiomer to the observed activity. A 
variety of differential enantiomer contributions to pharmacological effects are 
known and these are outlined below. 
a) Pharmacological activity resides only in one enantiomer. 
Although it is a vet' desirable situation if the pharmacological actin itv 
resides only in one enantiomer, while the antipode is totally inacti\ e. 
examples of this are not common Usually the "inactive" isomer possess 
9 
some degree of activity. In the case of the anti hvpertensiv e rf. -methv-ldopa 
(Figure 1.7), the antihypertensiýe activity resides only in the »-enantiomer 
(Gillespie et al.. 1962) and the drug is marketed as a single isomer. 
HO 
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* H CH2- i COON 
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Figure 1.7: Structure of a-methyldopa 
b) Both enantiorners are equally acti\ c. 
Both enantiomers of promethazine (Figure 1.8) display similar 
pharmacological and toxicological properties (Powell ci al., 1988). The 
introduction of the chiral centre in the dimethylaminoethyl moiety results in 
a 100% increase in antihistaminic potency compared to the non-chiral 
analogue. The enantiomers of flecainide (Figure 1.8) are equipotent in their 
antiarrhythmic activity and effect on cardiac sodium channels and the 
pharmacokinetic properties of the individual enantiomers also appear to be 
similar (Kroemer et al., 1989). Often cnantiomers may display 
stereoselectiv ity with respect to one pharmacological effect but be 
equipotent in others. For example, the 0-blocking effects of propranolol 
reside mainly in the . ti'-enantiomer but its inhibition of thyroxine metabolism 














Figure 1.8: Structures of a) promethazine and b) flecainide 
Pharmacological activities of the enantiomers are qualitative1y- different 
The classical example of this is situation is propoxvphene (Figure 1.9). 
1)extropropoxyphene has analgesic properties while the /-isomer has only 
antitussive effects (Drayer, 1986) and the enantiorners are marketed for 
different indications. To reflect their mirror image relationship they ý, N, ere 
given trade names which are also mirror images of each other i. e. Darvon 
and Novrad for cl- and /-propoxyphene respectively. Similarly, 
dextromethorphan is a powerful antitussi,. e and is virtually free from 
analgesic, sedative or other opiate-like effects while the antipode 





Figure 1.9: Structure of propoxyphene 
d) Both enantiomers ha,. e similar activities but with different potencies 
(a) 
e) 
This is the most common case for chiral dru, -, s. The 
ß-blockinz acti% it\ of 
propranolol (Figure 1.10) and other arvloxypropanolamine deri%ati\ 
ß-hlockers resides principally in the S- enantiomers and the eudismic ratios 
vary from 100 for propranolol to 10 for atenolol (Walle ei al., 1988). 
However, with other pharmacological effects of propranolol e. g. the 
suppression of renin release and inhibition of thyroxine synthesis, no 
stereoselectivity was evident (Powell et al., 1988). Other well known 
examples include warfarin (Figure 1.10), whose. '; - enantiomer is two to five 
fold more active in its anticoagulant effect than its R- antipode (O'Reilly gei 
al., 1974) and verapamil where the S- enantiomer is eight times more active 
in depressing cardiac activity (Echizen ct al., 1985). 
off 
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Figure 1.10: Structure of a) propranolol and b) warfarin 
Both enantiomers are acti\ e but toxicity resides in one enantiomer. 
Betamine (Figure I. 1 1) is a useful anaesthetic with analgesic properties and 
does not cause circulatory or respiratory depression. However, the drug is 
addictive and adverse reactions such as post-anaesthesia reactions i. e 
hallucinations and agitation are common. (. S')-Ketamine is 3.4 times more 
potent as an anaesthetic than the R-antipode but incidence of adverse effects 
i. e. psychic emergence reactions and post-operative agitated behaviour are 
`greater with the I? - enantiomer (White ea a/., 1980). For dopa, many of the 
serious side effects like granulocytopenia are associated with the D-isomer 
1? 






Figure 1.11: Structure of ketamine 
f) The individual enantiomers evoke opposite or contrary effects. 
The best example of this situation is indacrinone (Figure 1.12), a loop 
diuretic which shows both diuretic and uricosuric activity. Most diuretics 
increase plasma uric acid levels, which represents an additional risk factor in 
hypertensive states. When administered as a racemate, indacnnone also 
causes uric acid levels to increase. However, evaluation of the 
pharmacological activities of the individual enantiomers reveal that 
(I? )- indacrinone is responsible for the diuretic activity and the S- antipode is 
responsible for uric acid secretion (Vlasses i's' (il., 1981). In man the plasma 
half-life of the S-enantiorner is much shorter than that of its R-antipode (half- 
life of 2 to 5 hr; compared to 10 - 12 hr for the R- enantiomer) and hence 
following the administration of the racemate, the uricosuric activity is too 
short to prevent the increase in serum uric acid. Thus, indacrinone may be a 
useful diuretic if the proportion of the S- enantiomer is increased (Tobert el 
ul., 1981). 
HOOCC C6 H5 
CH3 
l0 
Figure 1.12: Structure of indacrinone 
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g) One enantiomer acts as antagonist to the other at the same receptor site 
Picenadol (Figure 1.13) is a phenvlpiperidine derivative that has both opioid 
agonist and antagonist activity. The analgesic properties principally reside in 
the (+) - enantiomer but the (-) - enantiomer is an antagonist, showing 1; ' 10 
the potency of naloxone as an opioid antagonist (Powell cl al., 1988). The 
racemate acts as a partial agonist due to the more potent acti\ ity of the 
(+)-enantiomer at the la opioid receptor as compared to the weaker 






Figure 1.13: Structure of picenadol 
It is thus clear that racernic mixtures are more than just mixtures with half 
the dose of the active drug, or containing inert ballast. To some the use of 
racernates is regarded as "polypharmacy" and inclusion of the "inactive" enantiomer 
regarded as ha\ inb "50% impurity" in the dosage form (Ariens, 1984, Ariens, 1986). 
To date there is a large body of information regarding the stereoselective differences 
in pharmacodynamic activity of drug enantiomers wý-hich supports the view that the 
use of racemic mixtures may have important pharmacological and toxicological 
implications. This data has prompted a re-evaluation of drugs currently used as 
racemates and a number are being investigated for re-introduction as single isomer 
products. 
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1.5 Stereoselectivity in pharmacokinetics and drug disposition 
Stereoselectivity in drug action is usually attributed to qualitati\e and 
quantitative differences in pharmacodynamic properties. 1-lo, vever, many observed 
differences may be a result of stereoselectivity in pharmacokinetics (Tucker and 
Lennard, 1990; Levy and Boddy, 1991). StereoselectivitN, may occur in virtually all 
phases of drug disposition i. e. absorption, distribution, metabolism and excretion. 
However, compared with the large magnitude of differences between enantiomers in 
their pharmacodynamic activity, the differences in pharmacokinetics tend to be 
relatively smaller, frequently I to 3 fold (Tucker and Lennard, 1990). However, 
these differences are of clinical significance. 
a) Absorption 
Generally drubs are absorbed from the gastro-intestinal tract (GIT), the 
airway passages or through the skin by passive diffusion, a process which depends 
upon the physico-chemical properties of the material, e. g. pKa, lipid solubility, 
molecular size. Since enantiomers do not exhibit differences in their physical 
properties, absorption is usually not stereoselective. However, where absorption 
occurs via active transport mechanisms, stereoselectivity has been observed. Thus 
the absorption of L-dopa and L-methotrexate is favoured over their respective 
D- antipodes (Wade ct al., 1973, Hendel and Brodhagen, 1984, Williams and Lee, 
1985) as the L. - isomers are absorbed by active transport mechanisms while the 
D- antipodes are absorbed by passive diffusion. With cephelexin, the L-isomer is 
preferentially absorbed by the intestinal dipeptide transport system, but only the 
D-isorner is detected in plasma as the L-isomer is also more susceptible to 
hydrolysis by peptidases in the gut wall (Tamai et al., 1988). With drugs like 
terbutaline, other mechanisms may be the cause of the stereoselective difference in 
absorption. It has been suggested that (-)-terbutaline selectively promotes intestine 
membrane permeability for its (+)-antipode, thereby increasing its absorption 
(Borgstrom of al., 1989). With local anaesthetics like bupivacaine, the enantiomers 
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display differential effects on local blood flow, ww hich may account for the different 
rates of absorption (Alps and Reynolds, 1978). 
b) Distribution 
Most drugs penetrate biological membranes via passive diffusion and as such 
are not stereoselective in nature. As with absorption, where the penetration process 
is carrier mediated and energy dependent, stereoselectivity is evident. 
Stereoselective distribution as a result of stereoselectivity in tissue binding of the 
(S)-propranolol has been reported in dogs (Bai et al., 1983). Stereoselective uptake, 
storage and secretion of (S)-propranolol and (. S)-atenolol by adrenergic nerve 
terminals in cardiac tissue has also been reported (Walle ei at., 1988). The 
distribution of ibuprofen in perinephric fat (Williams et al., 1986) and fenoprofen in 
rat hepatocytes (Sallustio ei a/., 1988) favours the R-enantiomer. However, this 
selectivity in distribution is a result of the stereospecific formation of the acyl-CoA 
thioesters of the R-enantiomers of these agents followed by incorporation as hybrid 
triglycerides (see section 1.8.4). 
It is generally accepted that it is the free or unbound drug that is responsible 
for pharmacological activity and available for clearance. Thus, the plasma protein 
binding of drugs is an important factor influencing pharmacodynamics and 
pharmacokinetics. The majority of drugs bind reversibly to plasma proteins, notably 
albumin and/or a, -acid glycoprotein (AGP). For highly protein bound drugs, minor 
differences in binding may have significant effects on unbound drug concentrations 
and hence pharmacological action. Similarly, small differences in the plasma 
protein binding characteristics of enantiomers may result in significant differences 
in their pharmacodynamic and pharmacokinetic properties. Albumin preferentially 
binds acidic drugs and two binding sites are known. Of the two, site II (the 
benzodiazepine site) usually shows greater stereoselectivity than site I (the warfarin 
site) (Fehske et at., 1981). a, -Acid glycoprotein preferentially binds basic drugs and 
only one binding site is recognised. Stereoselecti-N-ve binding for v-erapamil (+ > -), 
diisopvramide (+ >4 mexilitine (- >+) and methadone (+ > -) have been reported 
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(Jamali ei al., 1989). Stereoselecti\ it\ in protein binding for one protein may differ 
from another, e. g. the protein binding of propranolol towards n1-AGP is S>R. 
while for human serum albumin is Il > . 1' (Hutt et at.. 1989). In whole plasma. the 
binding to ix, -AGP is of greater significance such that the R-enantiomer content of 
the free drug fraction exceeds that of (, S' -propranolol. 
Competition for plasma protein binding sites is a common cause of 
enantioselective drug interactions. Sulphinpyrazone enhances the anti prothrornbin 
effect of racemic warfarin by inhibiting the oxidation of (S)-warfarin, thereby 
decreasing total body clearance. However, sulphinpyrazone also stereoselectively 
displaces (R)-warfarin from plasma protein binding sites, causing an increase in 
clearance. The net effect is that the pharmacokinetics of racemic warfarin are 
unchanged but the pharmacological effect is increased (Toon cl al., 1986). In the 
case of disopyramide, the enantiomers shoe- no differences in their kinetic 
properties following their individual administration. However, when administered 
as a racernate, the S-enantiorner shows reduced clearance, longer half-life (t1/2) and 
smaller volume of distribution (VJ) compared to the R-enantiomer. This difference 
arises as a result of enantiomer-enantiomer interactions in the concentration 
dependent plasma protein binding of the drug (Giacomini ei al., 1986). 
c) Drug metabolism 
Stereoselectivity is commonly observed with both phase I and 11 metabolic 
reactions (Caldwell ei at., 1988a). Enantiomers may be metabolised by different 
routes to yield different products, or at different rates to give different isomeric 
compositions of the product. Enantioselective metabolism is best considered from 
the point of view of the stereochemical transformations involved: 
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Prochiral to chiral transformations 
A prochiral molecule contains at least one site where a metabolic change 
occurs to yield a product that is chiral. Product stereoselecti\ it\ is observed 
where one enantiomeric form of the metabolite is favoured ox er the other. 
One of the most frequently cited examples is the biotransformation of 
diphenylhydantoin (phenytoin) to its para-hydroxylated metabolite (Figure 
1.14). In man 90% of the metabolite is excreted as the S-enantiomer 
(Poupaert et al., 1975), whereas in dogs, the R-enantiomer predominates. 
However the major metabolic pathway in dogs is meta-hydroxylation the 1? - 
form being predominant (Maguire, ei al., 1978). Thus, the transformation 









Diphenylhydantoin (S)-4-hyd roxydiphenylhydantoin 
Figure 1.14: Prochiral to chiral biotransformation of diphenylhydantoin. 
Chiral to chiral transformations 
In this case the original chiral centre is retained in the molecule, metabolism 
taking place at a site remote from the chiral centre. With (S)-nirvanol, para- 
hydrox lation again occurs in man to yield the corresponding . ti- para- 
hydroxvlated metabolite (Figure 1.1 5). The reaction is substrate selective for 
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Figure 1.15: Chiral - chiral biotransformation of nirvanol. 
Chiral to achiral transformations 
Here, the chiral centre is lost on metabolism. Although not frequently 
encountered, it is nevertheless important especially if substrate 
stereoselectivity is observed. With rabbit liver microsomes, amphetamine 
undergoes hydroxylation at the a-carbon, followed by deamination to form 
phenvlacetone (Figure 1.16) The reaction appears to be substrate 
stereoselective, the R-enantiorner being metabolised at a faster rate than the 





Figure 1.16: Oxidative deamination of amphetamine to phenylacetone. 
iv) Chiral to diastereomer transformations 
In this transformation, a new chiral centre is introduced into the molecule, 





possible. One of the best known examples is pentobarbitone. The 3'- 
hydroxylation of pentobarbitone in dogs is not substrate selective, and 
therefore similar amounts of the 3'-hvdroxv metabolites are formed from 
both enantiomers. However, a second chiral centre is generated at the 3' 
position. The oxidation of the R-enantiomer yields equal quantities of 
1'R, 3'S- and l'R, 3'R- diastereomers while the S- enantiomer yields the 
1'. ';, 3'R- and I'S', 3'S- diastereomers in a 5: 1 ratio (Figure 1.16) (Palmer c'I al., 
1970). Metabolic conjugation with some amino acids (e. g. glutamine), 
glutathione and glucuronic acid involves reaction of a chiral substrate with a 
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Figure 1.17: Structure of pentobarbitone 
v) Chiral inversion 
The inversion of a chiral centre involves the breaking of one of the bonds 
between the chiral centre and one of the groups attached to it, and migration 
of the leaving group to the other side of the molecule followed by subsequent 
reformation of the bond. Due to the chemical complexity of the situation 
involved, it is not surprising these transformations are of restricted occurance 
in drug metabolism The inactive (R)-enantiomers of the 2-arvlpropionic 
acids (2-APAs) undergo chiral inversion in-vivo to their S- antipodes in man 
animal species, including man (Hutt and Caldwell, 1983). The mechanism is 
thought to proceed via stereoselective formation of (R)-profenyl-CoA- 
thioesters that subsequently epimerize and hvdrolv-se to give either the R- or 
S- enantiomer. The S-enantiomer does not form the corresponding thioester, 
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and thus the im ersion is unidirectional (Nakamura ei ar/.. 1981 º. The chiral 
in\ersion of the 1? -enantiomers of the 2-APAs will be discussed in ;. Treater 
detail in section 1.8.4. 
V) Renal excretion 
Renal excretion involves three mechanisms, i. e. passive glomerular 
filtration, active secretion, active and passive reabsorption. Observed 
stereoselectivity in renal excretion may be a result of stereoselective plasma protein 
binding, resulting in differences in glomerular filtration and passive reabsorption. 
To demonstrate intrinsic stereoselectivity in renal excretion requires the calculation 
of the renal clearance of the unbound drug enantiomers. Stereoselectivity is usually 
associated with active secretion and this is thought to be responsible for the 
stereoselective clearance of pindolol (S > 1? ), chloroquine (+ > -) and disopyramide 
(S > 1? ) (Tucker and Lennard, 1990). It is most likely that stereoselective 
differences arise from the process of active secretion, although active reabsorption 
and renal metabolism may occur. Stereoselective renal tubular reabsorption is 
believed to be responsible for the stereoselective clearance of the 5'- enantiomer of 
terbutaline (Borgstorm ci al., 1989). Generally, the stereoselective differences in 
renal elimination are relatively small compared to those observed with non-renal 
clearance processes. 
From the above, it is therefore apparent that stereoselectivity in 
pharmacokinetics is most significant for those processes that depend on the 
interaction between the stereoisomers with a chiral biological macromolecule e. g. 
binding to plasma proteins, transport by active transport carrier molecules and drug 
metabolism. It has been observed that the stereoselectivity observed for a particular 
pharmacokinetic parameter depends on the level of body organisation it reflects i. e. 
whether it is at macromolecular, organ or whole body le\el. Generally, the degree 
of stereoselectiv itv is maximum with those parameters concerned with processes at 
macromolecular level e. g protein binding and intrinsic formation clearances. 
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Stereoselectivity is at an intermediate level for whole organ parameters e. g. hepatic 
clearance and renal clearance as these parameters represent the net effects of several 
primary interactions between stereoisomers and macromolecules. For parameters 
involved at the whole body level., stereoselectivity is at a minimum e. g. half-life and 
total body clearance as these parameters reflect processes associated with multiple 
organs and are determined by the specific physiological relationships between the 
organs (Levy and Boddy, 1991). As a result of the stereoselectivity in the various 
processes of drug disposition, the plasma profiles of a drug administered as a 
racemate may differ markedly from when enantiomers are administered separately. 
Thus an estimation of pharmacokinetic parameters and concentration-effect 
relationships based on total drug concentrations are of limited value and potentially 
misleading, and has been described as "sophisticated nonsense" (Ariens, 1984). 
1.6 Other factors affecting the stereoselectivit` in both drug action and 
disposition. 
It is apparent that significant differences exist in the pharmacokinetic and 
pharmacodynarnic properties of the drug enantiorners and the possibilities of drug 
interactions are increased with chiral compounds especially if administered as 
racernates. Other factors that are known to affect the pharmacological properties of 
enantiorners include age, sex. disease, genetic predisposition and route of 
administration. 
a) Disease 
Drugs which undergo hepatic metabolism are frequently affected by liver 
dysfunction. Liver cirrhosis has been reported to alter the enantiomeric disposition 
of ibuprofen, and the elimination half-lives of both enantiomers were increased two- 
fold as compared to healthy volunteers (Li ei (il, 1993). In the cirrhotic group of 
patients, the plasma concentrations of the active S- enantiomer were less than those 
of the /R- antipode, a situation which is the reverse of that found in healthy 
)1 
volunteers. The pharmacokinetics of ibuprofen are complicated by metabolic chiral 
inversion of the 1? - to the ý- enantiomer but from the data presented in the report by 
Li el al., (1993), it is not clear if the inversion process is impaired or that the relativ e 
increase in the (R)-ibuprofen concentrations is a result of stereoselective impairment 
of oxidative metabolic pathways, or both (Li et al., 1993). Renal dysfunction has 
also been known to affect ibuprofen disposition by increasing the plasma SR ratios, 
which may further aggravate renal toxicity (Chen and Chen, 1995). 
Oral administration of verapamil to patients with liver cirrhosis is associated 
with therapeutic effects being observed at lower plasma concentrations of racemic 
drug than with normal volunteers (Somogyi et A, 1981). This is attributed to a 
stereoselective reduction in first-pass metabolism (Eichelbaum, 1988). 
h) Age and Gender 
Although age associated differences in drug disposition are well established 
age related differences in the enantiomeric disposition of chiral drugs is a relatively 
new phenomenon brought about by the recent awareness of the significance of drug 
chirality. The plasma clearance of (-)-hexobarbitone after oral administration is 
about two fold greater in the young as compared to the elderly, whereas that of the 
(+)-enantiomer showed no age associated difference (Chandler et al., 1988). Sex 
and age related differences have been observed with methylphenobarbitone. In both 
\'oung and elderly volunteers of both sexes, the R-enantiomer is more rapidly 
cleared as compared to the S- antipode. However, the clearance of the R-enantiomer 
in young males is significantly greater than that found in either young females or 
elderly males. Also, no significant differences are observed between young and 
elderly females or elderly males and females, indicating that the clearance of the 
R-enantiomer is both age and gender dependent. With the S-enantiomer, a shorter 
elimination half-life was observed for young males only, and this difference appears 
to arise as a result of differences in distribution, as no differences in clearance were 
observed with either age or sex. (Hooper and Qing, 1990). 
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C) Genetics 
When a chiral drug, which is a substrate for enzvme(s) that are known to 
exhibit genetic polymorphism is administered as a racemate, the enantiomeric 
composition in plasma as well as the plasma concentrations may % ark with 
phenotype, thus influencing the clinical response to the agent. The ß-blocker 
metoprolol is a known substrate for the CYP 2D6 isoenzyme and examination of the 
"total" drug plasma level-effect relationship following the administration of the 
racemate indicates that the drug is less effective in the poor metabolisers (PMs) 
compared to extensive metabolisers (EMs) phenotype. However, examination of the 
individual enantiomer profiles indicates that the plasma concentrations and the area 
under the plasma concentration-time curve (AUC) of active (S)-metoprolol is greater 
than its antipode in EMs, but the reverse is true in PMs. Thus, the shift of the 
concentration-effect curve to the left for EMs is because of a greater proportion of 
the total plasma concentration is due to the active S- enantiorner (Lennard et (/., 
1983). 
d) Route of administration 
The "total" drug concentration-effect relationship (PR- interval prolongation) 
of verapamil indicates that the drug is more potent when administered intravenously 
as compared to oral administration as the oral "total" concentration-effect curse is 
shifted to the right. The explanation for this shift is the result of stereoselective 
first-pass metabolism. The first-pass metabolism is stereoselective for the more 
active. N- enantiomer as compared to the R-antipode, leading to an enrichment of the 
less active enantiorner after oral administration of the racemate. Thus, for the same 
"total" plasma concentration, the proportion of the more active S- enantiomer is 
approximately 2.5 fold less following oral administration as compared to 
intravenous dosing (Eichelbaum, 1988). With propranolol, a similar mechanism 
occurs but with opposite effects. In this case, the first-pass metabolism is 
stereoselectiv e for the less active R-enantiomer, leading to an opposite shift of the 
concentration effect cure, indicating that the drug is more potent following oral 
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administration as compared to intra\enous administration. This effect is also 
enhanced by the formation of the active metabolite 4-hvdroxvpropranolol as a 
result of the first-pass metabolism (Walle ei al., 1988). 
1.7 The importance of studying enantioselective pharmacokinetics 
It is obvious from the discussion above that stereoselective differences in 
the pharmacodynamic and pharmacokinetic properties of stereoisomers seem to be 
the rule rather than the exception, and that administration of chiral drugs as 
racemates has far reaching pharmacological and toxicological implications. The 
strength of evidence has prompted regulatory agencies to promote the use of single 
isomer preparations for new chemical entities unless it can be proven that the 
racemate gives therapeutic benefits over the single enantiomer or that the 
preparation of a single isomer is not technically feasible on an industrial scale. An 
additional consideration would also be the risk-benefit ratio of a novel compound. 
For example, if a new agent were to be introduced for the treatment of AIDS or 
cancer, then the significance of a racemic mixture or single enantiomer may- become 
somewhat "academic". However, for the majority of compounds still in use, 
racemates continue to be marketed and used. As such the continuing study of the 
pharmacokinetic and pharmacodynamic properties of such drugs, and their 
therapeutic re-evaluation is of immense importance in rational therapeutics as it is 
clear that previous non-stereoselective studies are of limited value and do not reveal 
underlying problems (Ariens, 1990). This is especially so where stereoselecti\ it\ is 
observed at more than one aspect of drug disposition. The 2-ar'lpropionic acids are 
a prime example of such types of drug, displaying stereoselecti\ itv in protein 
binding, chiral inversion and enantioselective oxidation and conjugation. Moreover, 
they are disproportionately used in the elderly population (Johnson cl al., 19933), 
N%here changes in drug disposition have been widely reported, and where multiple 
drug administration and co-morbid disease states are common . 
I; 
1.8 The 2-arvipropionic acid (2-. AP. A) group of anti-inflammatory drugs 
The non-steroidal anti-inflammatory drugs (NSAIDs) are v idely used for the 
treatment of a wide variety of joint and musculoskeletal disorders. especially 
rheumatoid and osteoarthritis. As a group, the NSAIDs are structurally di%er e, and 
includes the salicylates, pyrazoles, oxicams, fenamates, arylacetic acids and 
arylpropionic acids. Of these, the 2-arylpropionic acids (2-APAs) are amongst the 
most commonly used agents and have been the backbone of anti-inflammatory drug 
treatment since the 1970's, when the prototype, ibuprofen was marketed (Williams 
et ul., 1993). Since then a large number of analogues have been developed, the 
structures of some of which are shown in Figure 1.18. 
1.8.1 Chemistry 
The 2-arti-lpropionic acids (profens) have three common structural 
components which are required for antiinflammatory actin itv. These include a 
carboxylic acid group, a substituted aromatic system at the a. - carbon atom and the 
stereochernical configuration at the of. - carbon must be s'-. Being organic acids, 
these compounds are weakly acidic with pKa values between 4-5 (Albert and 
Serjeant., 1984), practically insoluble in water but soluble in organic solvents and 
alkaline solutions. The most widely studied drug of this group is ibuprofen (Figure 
1.19). The majority of these agents are used as racemates_ with the exception of (S)- 
naproxen and (S)-ibuprofen in Austria. 
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Figure 1.18: Structures of some 2-AP; analogues. 
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Absorption of the 2-APAs through the gastric mucosa is by passive diffusion 
and the oral bioavailability is generally very high. For example, the bioavailabilitv 
of racemic ibuprofen has been estimated to be approximately 0.95 and that for (I? )- 
ibuprofen is 0.92, indicating almost complete bioavailability for both enantiomers 
(Hall et u/., 1993). 
b) Distribution 
The profens are highly plasma protein bound (>990o). In most cases the 
binding is stereoselective, the nature of which depends on the particular dr[w, For 
ibuprofen, indoprofen and 2-phenylpropionic acid, plasma protein binding is (greater 
for the R- enantiomer (Lapicque el erl., 1993 ). The re ei-se is true for flurbiprofen 
and carprofen while conflicting results have been reported for ketoprofen (I lavball 
c/ al., 1991; Dubois ('/ al., 1993). Part of this problem of interpreting plasma protein 
binding data is the wide variety of methods and conditions used, the complexity of 
the situation is increased as the binding characteristics for some of these agents are 
dose and concentration dependent and there is mutually competitive displacement of 
protein binding by the drug enantiorners (Evans c/ a/., 1990). The apparent volume 
of distribution of these agents is relativ elv small, between 0.10 to 0.15 11kg, 
indicating that tissue binding is less important than plasma protein binding (Lin ci 
al., 1987). Distribution into the svno\ium appears to be by passive diffusion, being 
influenced by the physicochemical properties of the drug as well as the pathological 
condition of the synov ial membrane (Netter el al., 1989). For ibuprofen and 
naproxen enantiomers, the concentration profiles in sy nov ial fluid is dampened and 
sustained compared to the plasma profiles as a result of slow equilibrium, and 
generally reflects the stereochemical composition of the enantiomers in plasma. 
(hay ct al., 1988h; Seideman c/ al.. 1994). For ketoprofen and tiaprofenic acid. the 
sý novial fluid contains equal enantiorner concentrations. consistent with the lack of 
i0 
enantioselecti%ity in their plasma pharmacokinetics in man i Singh 1986, 
Foster ei ul., 1989; Evans e> ul., 1992). 
C) Mechanism of action 
Inflammation in tissue is caused by the action of cyclo-oxv genast 
(prostaglandin synthetase) and lipoxygenase enzymes on arachidonic acid. 
Prostaglandin synthetase activity leads to formation of prostaglandin D,, E and F, 
prostacyclin and thromboxanes. Prostaglandins, especially prostaglandin E 
produces the features of inflammation. The action of lipoxygenase enzv nies 
produces the leukotrienes, which also play a significant role in the inflammation 
process (Hart and Huskisson, 1984). The 2-APAs and other non-steroidal anti- 
inflammatory drugs (NSAIDs) act predominantly by inhibiting prostaglandin 
synthesis (Vane, 1971, Fereira and Vane, 1979). The in-vitro cyclo-o\v'genase 
inhibitory activity of the profens resides principally in the enantiomers of the 5- 
configuration, as reflected by the high eudismic ratios. Comparison of the relatik e 
potencies of the enantiorners in in-vivo test systems ho, ý\e\er show that the large 
eudismic ratios observed in-vitro are diminished such that the activity ratios for 
ibuprofen and fenoprofen are almost equal for both enantiomers (Table 1.1). This 
difference is due to the fact that chiral inversion occurs in-vivo, involving the 
biotransformation of the relatively inactive R-enantiomers to their 
pharmacologically active S-antipodes. Indeed, a large difference in the eudismic 
ratios in-vivo compared to that in-rinru is a good indication that metabolic chiral 
inversion has taken place (Adams et ul., 1976). 
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Table 1.1 Relative enantiomeric in-vitro and in-vivo acti,, ities of some 2-. -%P. %s 
(adapted from Hutt and Caldwell, 1984) 
Compound Eudismic Ratio (S R) Test System 
in-vi/ro in-vivo 
Carprofen >23 PG synthetase inhibition 
13.5 Acute adjuvant arthritis (rat) 
Fenoprofen 35 -1 PG synthetase inhibition (human) 
Ibuprofen 160 PG synthetase inhibition (bovine) 
1.4 Pain threshold (rat) 
1.1 UV erythema (guinea pig) 
Indoprofen -100 PG synthetase inhibition 
18.3 Carrageenin induced oedema (rat) 
Naproxen 133 PG synthetase inhibition (sheep) 
27.5 Rat paw oedema 
14.7 Antipyretic activity (rat) 
Recently two distinct forms of cvclo-oxvgenases, COX-1 and COX-2, 
encoded by two different genes haue been discovered (Vane, 1994). COX-1 is 
found nonnally in most tissues and is responsible for cellular homeostasis, i. e. 
normal "housekeeping" functions such as maintaining the microvascular integrity of 
the GIT. COX-2 is only produced in inflammatory cells as a result of inflammation 
and tissue trauma. Therefore the prostaglandins derived from COX-2 activation are 
likely to be responsible for the features of inflammation and tissue damage (Dray 
and Bevan, 1993). Thus, development of anti-inflammatory agents with selective 
COX-2 inhibition would be a logical step in order to avoid the gastrointestinal side 
effects associated with these drugs. Indeed preliminary information has shown that 
agents with less inhibitory activity for COX-1, such as naproxen and indomethacin 
are less likely to cause GIT adverse effects than piroxicam, which is a more 
selective COX-] inhibitor (Havilar and B_jarnason, 1995). However, this issue is vet 
to be fully, resolved in view of the multifactorial nature of the pathophvsiology of 
;o 
NSAID -induced ad,, erse effects, and also the fact that iii-rivo data are affected by 
other factors such as enantioselectiy e phannacokinetics. 
In-vitro experiments have shown that the 2-APAs also inhibit lipoxv`7enase 
metabolism. However, the concentrations that are required are not likely to be 
achieved at the unbound concentrations present after normal therapeutic doses 
(Williams ei at., 1993). It has also been observed that the NSAIDs elicit 
pharmacological effects that are independent of cvclo-oxygenase inhibition. These 
include the ability to reduce sulphated glycosaminoglvcan synthesis in articular 
cartilage in-vi/ru, suppression of neutrophil aggregation, degranulation and 
superoxide generation, inhibition of inflammatory oedema by action on 
polymorphonuclear leukocytes (Evans, 1992). It has been suggested that these 
prostaglandin-independent effects arise from the ability of the NSAIDs to partition 
into biological membranes, where they disrupt intercellular signalling events and 
subcellular protein-protein interactions. As such actin ities are based on partitioning 
behaviour, it is likely to be non-stereoselectiv e (Evans. 1992). This is supported by a 
recent report that of the equipotent in-vitro inhibition of human polvmorphonuclear 
cell function by (! z)-, (, ')- and (R. 1')-ibuprofen (Villaneu\ a et al., 1993). 
1.8.3 Metabolic chiral inversion 
A unique characteristic of the 2-APAs is their ability to undergo chiral 
inversion from the less active RR- enantiomer to their more active s-antipodes 
(Caldwell ti al., 1988b). The extent of the in\ersion reaction is substrate and 
species dependent (Hutt and Caldwell, 1983). The generally accepted mechanism of 
inversion is represented in Figure 1.20 for ibuprofen. This involves reaction of (/? )- 
ibuprofen with coenz\ me A (CoA) to form the corresponding thioester. This 
thioester may undergo hydrolysis to regenerate the R- enantiomer, or epimerization 
of the profen moiety to yield the (S)-ibuprofen-CoA thioester \ is the formation of 
an acid enolate tautomer (Sanins ci aal., 1991) The (S)-ibuprofen-CoA thioester 
:ý 
subsequently undergoes hydrolysis to yield (S)-ibuprofen, thus completing, the 
in% ersion reaction (Nakamura (-"i a!... 1981). The mechanistic aspects of the 













11 CH3 CH3 H 
(R) - IBUPROFEN 
(R) - IBUPROFENYL-CoA 
Epimerase 
CH3 C OOH 
H-C- CH2 C 
.,, 'H 
CH3 CH3 
(S) - IBUPROFEN (S) - IBUPROFENYL - COA 
Figure 1.20: Schematic representation of the chiral inversion of 
ibuprofen (adapted from Tracy and Hall, 1991). 
inversion reaction have been extensively investigated in-vitro using tissue 
preparations (Knihinicki e/ ul., 1989; Knadler and Hall, 1990; Knihinicki ei u/., 
1991, Tracy ci u!., 1993), hepatocytes (Muller cl u!., 1990) and perfused liver 
preparations (Nakamura ct u1., 1981). The unidirectional nature of the inversion is 
due to the stereospecitic formation of the CoA-thioester with (R)- ibuprofen but not 
(, ti)-ibuprofen (Knihinicki cl a!., 1989) and appears to be mediated by long chain 
fatty acid svnthetases (Tracy (. ei al., 1993). Recent evidence suggests that the 
formation of (/? )-ibuprofen-adenvIate is the rate limiting step to this reaction 
(Menzel ct u/., 1994). The epimerization reaction appears to be non-stereoselectiv e 
as s`nthetic samples of both diastereoisomeric thioesters yield the alternati%e isomer 
1H3 CO-S-COA 
I 
IN. H-C-CHZ C"0' H 7 
'14 
wo 1 
Hydrolase CH3 CH3 
;ý 
(Tracy and Hall, 1991; Knihinicki et at _ 
1991). The reaction was oriL, )nall\ thought 
to be spontaneous in nature but current c% idence suý_/7ests it to be enzyme mediated 
(Mayer ef a!., 1988, Chen cl ul., 1990). An epimerase enz\ me has recentl\ been 
isolated and purified but its actual physiological function is as vet unknown (ýhieh 
and Chen, 1993). From these in-tivifro experiments, it ienerally accepted that 
inversion occurs mainly in the liver, although inversion has been observed in kidney 
preparations (Knihinicki el al., 1989). It has also been suggested that intestinal pre- 
systemic inversion may occur from evidence provided by in-vi/ro experiments using 
animal tissue preparations (Simmonds et al., 1980; Berry and Jamali. 1991. Jeffery 
ei al., 1991; Sattari and Jamali, 1994) and indirect evidence in man (Jamali ci al., 
1988; Mevhar and Jamali, 1988). However, direct comparison of the extent of 
inversion after oral and intravenous dosing of ibuprofen in man did not show any 
significant differences (Hall ct a!., 1993). thus refuting the view put forward by 
Jamali and co-workers. Chiral inversion has also been demonstrated for ibuprofen 
using the isolated perfused lung preparations (Hall ct al.. 1992) but is unlikely to be 
significant ire-rrivo due to the large extent of protein binding. 
The acyl-CoA thioester is a highly reactive species and is the intermediate 
form of all fatty acids prior to lipid synthesis or catabolism e. g incorporation of fatty 
acids into triulvicerides, transport of long chain fatty acids across membranes, and 
for the 13-oxidation of fatty acids. Thus, the formation of the (1R)-? -APA-CoA 
thioesters is thought to have toxicological consequences. Fears ei al., (1978) haa' c 
demonstrated that fenoprofen, ibuprofen and ketoprofen following administration to 
rats could displace endogenous tatty acids and form h%brid triglycerides. On 
administration of (1R)-ibuprofen and racemic ibuprofen to rats, both enantiomers 
were found on hydrolysis of triacvlglycerols isolated from perinephric fat, but when 
(. ti)-ibuprofen was administered, negligible amounts of the drug were recovered. in 
fat (Williams ei (jl., 1986). Thus, the formation of the thioester intermediates by the 
2-APAs also paved a way for their involvement in fatty acid metabolism. It was 
postulated that in this manner the 2-. \PAs may perturb normal fatty acid synthesis 
and metabolism. It has also been suggested that these thioesters may ac\late the 
amino groups of proteins resulting in formation of immunogens (Williams ei at.. 
fin 
1993). Thus physiological or pathological conditions that increase exposure to the 
thioester may, enhance toxicit\ e. g. enhancement of 2-. 'SPA-CoA thioester formation 
by clofibrate (Knights et u/., 1991). These hypothesised consequences ha\ eý et to 
be conclusively proven to date, and it is worthwhile noting- that there is no e% idence 
as yet to prove that naproxen (marketed and used as the single S-enantiomer i is less 
toxic than the other 2-APAs administered as racemates (Williams and Day, 1988). 
1.8.4 Other metabolic reactions 
In addition to chiral inversion, the 2-APAs also undergo metabolic oxidation 
and conjugation reactions with amino acids and glucuronic acid. Glucuronidation is 
the predominant metabolic route for most of the ? -APAs, although functional 
oxidation is also important with some congeners. For example_ ibuprofen is 
oxidised to form two major metabolites, hvdroxv and carboxvibuprofen in man, 
forming 26 and 35 °o of administered dose excreted in urine (Figure 1.21, Mills of 
u/., 1973). Irrespective of the nature of the form administered i. e. whether racernate 
or individual enantiorners, the optical rotation of both metabolites recovered in urine 
is dextrorotator}' indicating possible stereoselecti, itv in the oxidation reaction. 
Interpretation of these results are complicated by the fact that the obser,, ation may- 
be a result of extensive chiral inversion of ibuprofen and possibly of the metabolites 
(Caldwell ci ca/., 1988). With carboxyibuprofen, a second chiral centre is introduced, 
and thus it can exist as four stereoisomeric forms. Interpretation of the data to date 
is hampered by the methodological problems, i. e. the lack of resolution of all the 
four stereoisorneric forms (Kaiser e/ al., 1976) and the assignment of the absolute 
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Figure 1.21: Metabolism of ibuprofen to yield the two major oxidation 
products hydroxyibuprofen and carboxvibuprofen. 
In man, fenoprofen undergoes aromatic oxidation to form 4'- 
hydroxyfenoprofen which is subsequently excreted as the glucuronide. The 
majority of the metabolite recovered in urine has the . ti'-configuration. As with 
ibuprofen, the stereoselectivity of the oxidation reaction is confounded by chiral 
inversion., which is extremely rapid in man (Rubin ct al.. 1985). Flurbiprofen. 
\, hich does not undergo chiral inversion in man, also undergoes aromatic 
hydroxylation to form the 4'-hydroxy and the '), 4'-dihydrox\v metabolites, 4'- 
hydroxyflurbiprofen being the major metabolite. The ')", 4'-dihydroxy metabolite 
undergoes further methvlation to form the 3'-hydroxv-4'-methoxy product (Da\ ies, 
1995). Mean urinary recovery studies of (S)- and (R)-flurbiprofen and the 4'- 
hvdroxy-metabolite reveal SIR ratios of 0.89 and 0.80 respectively, suggesting a 
lack of stereoselectivity of the oxidation reaction (Small ei al., 1990). However, 
another investigation revealed that the major urinary flurbiprofen metabolites had 
an SR ratio of 0.80, which prompted the authors to suggest that enantioselecti", it\ 
exists in the oxidation and conjugative reactions (Knadler and Hall, 1989). Se\ eral 
other NSAIDs also undergo oxidative metabolism e. g. loxaprofen, indoprofen, 
pirprofen and cicloprofen (Rucker ci al., 1980). 
iý 
The 2-APAs and their principal metabolites undergo \ ar\ ing degrees of 
phase 11 conjugation reaction ýýith glucuronic acid. The ac%l --, lucuronides formed 
are relativer' unstable and under physiological conditions nia\ hydrokse and release 
the parent molecule into the systemic circulation, a process termed futile recycling 
(Meffin et al., 1983). With a decrease in renal function or renal impairment, 
accumulation of these glucuronides occurs and the effect of futile recycling is an 
increased plasma accumulation of these drugs (Meffin el al.. 1986). This problem is 
of great importance with elderly patients who frequently require these drugs 
(Williams et al., 1993). The acyl glucuronides may also undergo acyl migration to 
yield positional isomers which are resistant to enzymatic hydrolysis by ß- 
glucuronidase (Sinclair and Caldwell. 1981 )_ 
As glucuronic acid itself is chiral, the acvl y-, lucuronides of the '--APAs are 
diastereorners and as such, stereoselectivity may, exist in their synthesis, renal 
clearance or hydrolysis. Evidence from in-i'iIrr, experiments have pros ided 
evidence that clearance by glucuronidation is indeed stereoselective (Caldwell el of., 
1988). With rnicrosomes from rabbit. rhesus monkeys and human livers, 
enantioselectivity was evident in the glucuronidation of ibuprofen, benoxaprofen 
and naproxen, favouring the S- enantionmer in each case (El-Mouelhi ei al., 1987). 
In the case of ibuprofen, partial metabolic clearance by glucuronidation in humans 
was higher for the S- enantiorner (Lee et cal.. 1985), indicating stereoselectivity in 
either one or more than one of the processes of formation, hydrolysis and renal 
clearance of the acyl glucuronide. 
The acv-l glucuronides are often considered to be reactive metabolites as they 
can irreversibly bind to protein macromolecules via covalent bonding (Hayball ei 
al., 1995, Stogniew and Fenselau, 1982 Hyneck el al., 1988), forming complexes 
which are potentially immunogenic and suspected to cause anaphylactic reactions 
(Spahn-Langguth and Benet, 1992). Formation of such complexes have been 
observed iii-v"dro for henoxaprofen (Van Breenan and Fenselau, 1985), ketoprofen 
(Hayybal l cr al., 1991, Dubois et al., 1994), carprofen (I w akaw a ei ul., 1990) and 
fenoprofen (Volland L 'i aal., 19O1), and in-viva with fenoprofen (Volland Lc< al., 
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1991). Thus; the profens that are principally cleared via glucuronidation e. g. 
ketoprofen, are potentially more likely to cause immunogenic responses in patients 
with impaired renal function. Ho\ýe%er. these toxic effects hake het to be 
conclusively proven and this is an area that deserves further investigation. 
Many xenobiotics containing the carboxylic acid group are metabolised to 
conjugates with amino acids, principally glycine, glutamine and taurine (Hutt and 
Caldwell, 1990). The mechanism of this conjugation is thought to proceed via the 
formation of respective CoA thioesters. It is thus reasonable to expect that the 
2-APAs that undergo extensive chiral inversion may also form amino acid 
conjugates. In dogs, glycine conjugates of 2-phenvipropionic acid (Tanaka c'I ul., 
1992) and taurine conjugates of loxoprofen (Tanaka c'I al., 1983) have been 
reported. In man taurine conjugates of (I? )- and (S)-ibuprofen have recently been 
discovered accounting for about 1.5 % of the dose (Shirley- ci at., 1994), a Llv, cine 
conjugate was however not detected. 
1.8.5 Renal excretion 
Generally, renal excretion of unchanged 2-APAs is of little importance and 
accounts for small percentage of eliminated drug, reflecting their high lipophilicity 
(Williams L'/ al., 1993). Studies reporting significant excretion of unchanged drug, 
are probably due to the hydrolysis of the labile acyl glucuronides in the bladder or 
. '. v-vivo. (Upton er al., 
1984, Faed, 1984). 
1.9 Aims and objectives of the present investigation 
As is apparent from the above discussion, the enantioselective 
pharmacokinetics and disposition of the 2-APAs are complicated by the following: 
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i) they are highly and enantioselectively bound to plasma proteins, which in the 
case of some of the analogues appears to be concentration and dose 
dependent, and give rise to enantiomer-enantiorner interactions: 
ii) many of these agents undergo metabolic chiral inversion from the inacti\ e /R- 
enantiomers to the active S- antipodes in man, 
iii) they also undergo stereoselective oxidation and conjugation reactions. 
Various aspects of the stereoselective disposition of the 2-APAs have been 
subject to much research interest in an effort to understand the mechanisms involved 
and their relationship to one another, and on the influence of physiological and 
pathological conditions. These studies are quite % aried with regards to 
experimental design and are often limited in usefulness as they address only specific 
aspects of the whole dispositional process. Other than naproxen, the profens are 
marketed and administered as racemates, and because of the occurrence of 
enantiomer-enantiomer interactions, studies involving administration of the racemic 
drug are important as they are a closer representation of the actual therapeutic 
situation. It is also important that unbound drug enantiomer concentrations are 
determined as plasma protein binding plays such a central role in influencing the 
disposition of these agents, and without which the interpretation of the 
enantioselectivity in hepatic and renal clearance mechanisms is impossible. 
(li', S')- Ibuprofen is an important NSAID of the 2-APA group ýxidely used in 
the treatment of a variety of inflammatory disorders and has recently become widely 
available in the U. K. as a result of a change in its legal status. As a result of the 
interest in the stereochemical aspects of the disposition of the 2-APAs, ibuprofen 
disposition has been of extensively investigated both in-viva and in-vitro (Caldwell 
ei u1., 1988, Williams el ul., 1993; Evans, 1992). However, few of the in-vivo 
investigations have presented a total picture of ibuprofen disposition following the 
administration of the racernate as a result of methodological difficulties associated 
with the determination of the enantiorneric composition of the free drug in plasma 
J8 
and the determination of the stereochemical composition of the two major 
metabolites in urine (Kaiser et al.. 1976: Baillie «r a!. _ 
1989. E%ans er at. 1990: 
Rudy ei a/., 1990). An additional problem with the data presented in the literature 
is that the majority of the studies are carried out on relati\ clv young healthy 
volunteers, only during the course of these in\estigations described in this thesis 
have reports appeared which examine the effect of disease state on enantiomeric 
disposition (Li ei al., 1993; Chen and Chen, 1994). The pharmacokinetics of the 
drug in the intended target population should also be thoroughly studied. 
Epidemiological studies have shown that the elderly are the most frequent users of 
the NSAIDs and the most at risk of adverse effects (Day ct al., 1988a, Carson and 
Wil let, 1993)). To date only a few studies have focused on the effects of age on the 
disposition of the 2-APAs (Advenier ei al., 1983. Upton el al. _ 
1984), 
The main objectives of the present in\ estigation are to examine the 
enantiorneric disposition and pharmacol: inetics of ibuprofen follo%\ ing the 
administration of the racemate to healthy young volunteers and to compare the data 
obtained with a similar study carried out in healthy elderly subjects. The aim being 
to establish if age has an influence on the stereoselectiv e disposition of the drug as 
has been reported for other chiral drugs administered as racernates (Chandler ct ul., 
1988; 1 looper and Qing, 1990). 
In order to present a complete study on the stereoselectivity of ibuprofen 
disposition, it is intended to de\elop stereospecific anak-tical methodologies for the 
determination of both unbound and total drug in serum and also the free and 
conjugated drug in urine. In addition, relati\ ely few methods has e been published 
which describe the analysis of the hvdrox\' and carboxy metabolites of ibuprofen in 
urine and the determination of the stereochemical composition of the carboxv 
metabolites. The stereochemical composition of carboxvibuprofen following the 
administration of the racemic drug or R- ibuprofen has to date been problematical 
(Kaiser ei al., 1976, Young ci a!., 1986, Baillic ct a!., 1989; Rudy et al., 1990). It is 
therefore intended to examine appropriate methodologies for the determination of 
total metabolite content in urine following administration of the racemic drug and 
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also their stereochemical composition. As authentic reference samples of the four 
stereoisomers of carboxyibuprofen are not available, an attempt will be made to 




Stereospecific Analysis of Ibuprofen Enantiomers 
in Serum and Urine 
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2.1 Introduction 
The recent surge in interest in the actions and disposition of drug 
enantiomers has been due, in part, to the advances made in analytical techniques 
(Hutt, 1990). The separation and analysis of enantiomers pose an additional 
challenge over conventional drug analysis as enantiomers have almost identical 
physicochemical properties, such as melting and boiling points, lipid solubility and 
chromatographic mobility. However, when placed in a suitable chiral environment 
such as plane polarised light or the presence of another chiral compound. 
differences can be discerned. Some of the more common techniques for 
enantiomeric analysis are presented in Table 2.1 below: 
Table 2.1 Common enantiospecific analytical methodologies 
Physical Methods 
polarimetry, circular dichroism 
pseudoracemic mixtures of enantiomers labelled «ith either stable or 
radio isotopes 
NMR spectroscopy in the presence of chiral shift reagents, solvating 
or derivatising reagents 






(Adapted from Hutt c'i al., 1994) 
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Bioanalysis involves analysing small quantities of analvtes in a complex 
matrix, the exact composition of which is often unknown. Enantiospccific 
bioanalysis adds another dimension of difficulty as the biological media is 
invariably chiral in nature (Camillieri ei at., 1994). Therefore, it is not surprising 
that chromatographic techniques are most commonly used as these can distinguish 
between the individual enantiomers and the matrix, while providing excellent 
sensitivity to quantitate trace concentrations. As such the relevance of these 
techniques will be reviewed below. 
2.1.1 Chromatographic resolution of enantiomers 
Two major approaches are available in enantiospecific chromatography. the 
indirect and direct approach, each of which will be briefly examined. 
a) Indirect approach 
Using this approach, enantiomers are derivatized with optically pure chiral 
derivatizing reagents (CDAs) to form stable covalent diastereomers. As a result of 
their different physical and chemical properties, such diastereomers can be 
separated by conventional chromatographic techniques. The advantage of this 
approach is that achiral stationary phases are used and these are often more robust, 
stable, efficient and economical than chiral stationary phases (CSPs). In addition 
the derivatization reaction provides an opportunity to increase detection sensitivity 
by coupling enantiomers with suitable chromophores. However, this apparently 
simple approach has its pitfalls and these are summarised in Table 2 .? 
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Table 2.2 Potential problems of indirect enantiomeric analysis 
Enantiomeric purity of the CDA 
Racemization of the CDA or analyte during derivatization 
Stereoselective derivatization 
Differential detector responses to the two diastereomers 
(Adapted from Hutt et ul., 1994) 
Of utmost importance is a knowledge of the purity of the CDA used. Only if 
the CDA is 100% optically pure is the diastereomer ratio representative of the 
enantiomeric composition in the original analytical sample. Otherwise, the optical 
purity of the CDA has to be taken into consideration to avoid errors in the 
determined values. This problem has been examined in greater detail by Allenmark 
(1988), Wozniak el al., (1991) and Hutt el ul., (1994). 
b) Direct approach 
In the direct approach, enantiorners are separated on chiral stationary phases 
(CSPs) by in . eint 
formation of diastereomeric complexes. For chiral recognition to 
occur, it has been proposed that a minimum of three complementary interactions, 
one of which must be sterically determined, are required between an analyte 
enantiorner and the CSP (Dalgleish , 
1952), the antipode interacting at two sites 
only. Thus, the enantiomer that forms the more stable complex will be more 
strongly retained on the CSP and hence eluted later. The types of interactions 
involved depend on the CSP and may include hydrogen bonding, hydrophobic and 
dipole interaction, inclusion complex formation, charge transfer complexes and 
steric repulsion (Wainer, 1987). The interaction forces need not necessarily be 
attractive in nature. Repulsive interactions may also be involved in which case the 
enantiomer interacting at three points will be eluted first (Wainer, 1987; Hutt e/ a/., 
1994). 
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One of the earliest reports of chiral separation i n% ok ing CSPs w ere those of 
Danakov's on ligand exchange column chromatography (Armstrong. 1987). Since 
the first commercially available CSP for HPLC. de%eloped by Pirkle i't (, I., i 1981 ). 
the number of available CSPs has increased significantly. A classification s%stem 
was suggested by Wainer (1987) based on their proposed modes of chiral 
recognition (Table 2.3). Recently multimodal CSPs . 
involving two or more modes 
of chiral recognition have been developed (Wallworth el a!., 1992). 
The advantage of using the direct approach is that, in most cases. 
derivatization is not required. Where derivatization is required, the derivatizing 
reagent is usually achiral, and this avoids the problems of enantiomeric purit`, 
racernization and differential detector responses that plague the indirect approach 
(Hutt, 1990). 
Using the direct approach, quantitation of enantiomeric ratios and purity can 
be determined directly from peak areas and the quantitative properties are 
maintained as long as there is baseline resolution. However, in comparison mth 
indirect methods, sensitivity is often poorer, due to peak asymmetry. Also, 
chromatographic selectivity is usually., good bet«een enantiomers but not so between 
enantiomers and achiral impurities. The choice of mobile phases which may be 
employed with CSPs are often limited and this may cause sample solubility 
problems. Last but not least- the presence of endogenous contaminants in 
bioanalysis, even in trace amounts may have marked effects on resolution and 
column stability (Wozniak ei erl., 1991 , Hutt el Lii., 1994). 
When using) HPLC, chiral mobile phase additives may be also be used for 
enantiomeric resolution with achiral phases. The mechanism involved here is the 
formation of transient diastereomeric complexes between the analstes and additive. 
More commonly used additiv is used include the cv clodextrins and )- 
camphorsulphonic acid. The stability of the achiral phases and inexpensi%e 
additives are the main advantages of this approach. Chiral additiNes can he eluted 
and changed, and good selectivities can be achic\ ed with the wide vvariet\' of 
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additives available. However, some of the additi,, es ha\ c chromophores and thus, 
impose a limitation on their usefulness (Armstronýg, 1987). 
Table 2.3 Classification of chiral stationary phases 
Type I: Donor-acceptor CSPs 
examples: (R)-N-(3,5-dinitrobenzov, l )phenylglv, cine 
(R)-N-(3,5-di nitrobenxovl )valine 
(S)-N-(2-naphthyl )alanine 
interactions: hydrogen bonding, n -donor, acceptor. dipole-dipole 
stacking. steric 
Type 11: Derivatised cellulose and arnylose CSPs 
examples: synthetic ether, ester or carbarnate deri\atives of cellulose 
or amylose (e. (,,. Chiracel OD) 
interactions: hydrogen bonding- z -donor/acceptor, dipole-dipole 
stacking, partial inclusion complex formation 
Type III: Inclusion complex CSPs 
examples: a., P. y-cvclodextrins 
interactions: hydrogen bonding, inclusion complex formation 
Type IV: Chiral ligand exchange CSPs 
examples: amino acids bound to silica is 3-glvcvcloxvprop\ l 
spacer group. 
interactions: reversible complex formation between metal ions and 
chiral complexing agents. 
Ty pc V. Affinity or protein CSPs 
examples: a, -acid glycoprotein, bovine, human serum albumin. 
ovomucoid 
interactions- hydrophobic. polar, steric. 
(adapted from Wainer, 1987) 
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The use of HPLC techniques in chiral separations has o%ershadov ed that of 
GC. The usefulness of GC is limited for a number of reasons. High column 
temperatures are usually involved and this may cause racemization of the chiral 
phase or analyte. When indirect methods are involved, apart from all the constraints 
discussed in section 2.1.1, the diastereomers formed must be sufficiently' , olatile. 
The stability differences between diastereomeric complexes may be very small at 
high temperatures, with subsequent poorer chromatographic resolution. Also, large 
scale preparative separations are generally not feasible in GC. Last but not least, 
there is a wider choice of stationary phases and mobile phase additives in LC 
(Allenmark, 1988; Armstrong, 1987). 
Recent developments in electrophoresis and supercritical fluid 
chromatography have seen application in chiral separations (Lynam and Nicolas, 
1993; Rawjee et ul., 1993, Terabe gei cr/., 1994). FHowev, er, these techniques have vet 
to find wide acceptance in bioanalysis. 
2.1.2 Enantiospecific analysis of ibuprofen and related 2-arylpropionic acids 
in biological fluids 
Published methods for the enantiospecitic analysis of the profens involve 
both direct and indirect approaches and in the majority of cases, these are based on 
HPLC methodologies. 
a) Direct method of enantiomeric analysis of 2-arylpropionic acids 
One of the first direct methods for the resolution of the enantiomers of a 
profen used a Pirkle type column with a (R)-N-(3,5-dinitrobenzoyl)phenylglycine 
chiral selector (Wainer and Doyle, 1984). The acids were derivatized into both 
esters and amides forms and the best resolution was obtained with 
l -naphthalenemethylamide derivatives. Based on these experiments, a model was 
proposed for the molecular interaction between the analyte derivatives and the CSP 
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to account for the elution order. The model involves the stacking of amide dipoles 
with supplementary it - it interaction of the aromatic rings and hydrogen bonding. 
An alternative antiparallel interaction model was proposed, using a similar chiral 
phase in which the interactions between the analyte and the CSP are based on an 
antiparallel alignment of the amide dipoles with hydrogen bonding and it - it 
interactions between the aromatic ring of the profen and the unsubsituted phenyl 
ring of the CSP, and it - it interaction between the aromatic group of the amide and 
the dinitrophenyl ring of the CSP (Nicoll-Griffith, 1987). Subsequent work on 
flurbiprofen (McDaniel and Snider, 1987) seemed to support Wainer's hypothesis. 
New Pirkle type phases that were developed were used to separate ibuprofen 
enantiomers as 3,5-dinitroanilide derivatives (Pirkle el al., 1986). The use of Pirkle 
type phases for the bioanalysis of the 2-APAs were published by Crowther ei a!., 
(1984), Sioufi etul., (1987) and Nicoll-Griffith el ul., (1988). In all these methods, 
derivatization was required before satisfactory resolution was obtained. 
A CSP based on a human a, -acid glycoprotein (AGP) was developed by 
Hermansson and Eriksson (1986). With the use of dimethyloctylamine as modifier 
in 2% isopropanol in phosphate buffer, enantiomeric separation of ibuprofen, 
ketoprofen and naproxen was achieved without prior derivatization. AGP columns 
have been used in pharmacokinetic and metabolic studies of flurbiprofen 
(Geisslinger el al., 1992), naproxen (Anderson ei ul., 1992) and ibuprofen 
(Geisslinger el a!., 1990; Petterson and Olsson, 1991). The main advantage of this 
CSP is that simple reversed phase solvents are used, and by varying the modifier and 
pH, good baseline resolution can be obtained. However, being based on biological 
proteins, wide batch to batch variations are observed in the stationary phases which 
limits their utility (Petersson and Olsson, 1991). Also, resolution and separation 
power decreases with increasing number of analyses of plasma samples i. e. the 
columns are not robust (Geisslinger et al., 1992). Hutt and Caldwell (1988) 
reported separation of mandelic acid but not those of 2-arylpropionic acids on a 
commercially available bovine serum albumin column. Human serum albumin 
(HSA) protein phases used alone or mixed with AGP have had better success (Aubry 
el al., 1994). Ovomucoid, avidin and flavoprotein columns have also been used 
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with varying success (Haginaka eº ul., 1994; Mano eº ul., 1994). Recently avidin 
(Oda ei u!., 1991) and ovomucoid bonded phases (Haginaka et u/.. 1993), that allow 
direct injection of serum, have been used for the enantioseparation of ketoprofen. 
These columns work on similar principles as the shielded hydrophobic phase 
columns. Proteins, especially glycoproteins have outer hydrophilic and inner 
hydrophobic surfaces. Large molecules such as serum proteins, would be eluted in 
the void volume, while smaller drug molecules can penetrate and interact with the 
shielded internal surface. These columns would be particularly useful for routine 
therapeutic monitoring of enantiomer concentrations should the need arise. 
Apart from proteins, other naturally occurring molecules have also been used 
as chiral selectors, the most common of these being cellulose derivatives. Wainer 
(1987) has classified them as type 11, and it is thought that these CSPs interact with 
the analyte through attractive interactions and form inclusion complexes. 
Stereoselectivity is based upon steric fit of the analyte into the chiral cavities. 
Okamoto el ul., (1989) reported the separation of flurbiprofen, tiaprofenic acid and 
ketoprofen on amylose tris(3,5-di methylcarbamate) phases (Chiralpak'M AD) 
without derivatization. Ibuprofen enantiomers however, could only be resolved 
after derivatization into their methyl esters. The utility of these cellulose phases in 
bioanalysis was demonstrated by the stereospecific analysis of tlurbiprofen in urine 
using a cellulose tris(4-methylbenzoate) (Chiralcel n" OJ) phase, after derivatization 
into their methyl esters (Aboul-Enein el al., 1992). The main disadvantage of these 
phases is the limited choice of mobile phases that may be used, as they are 
incompatible with chlorinated and aqueous solvents. 
Type III CSPs separate enantiomers based on the mechanism of inclusion 
complexation. They are usually synthetic polymers or biopolymers, the most 
common of these being ß-cyclodextrin. They have been successfully used to resolve 
underivatized ibuprofen enantiomers following isolation from biological fluids 
(Geisslinger ei at, 1989). A simple aqueous-organic mobile phase was used but 
moderately elevated temperatures were necessary to improve the chromatography. 
Even then, the separation of the enantiomers was incomplete, with relatively long 
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retention times and significant batch to hatch differences between the CSI',, were 
also reported. 
Chiral mobile phase additives have also been used in the separation of 
naproxen and other 2-APAs. Separation was achieved by use of cinchona alkaloids 
in the mobile phase (Petersson, 1984). Normal phase columns were used. the 
separation efficiency depended on the type of stationary phase i. e whether silica- 
diol or cyano bonded columns were used. The usefulness of this method is limited 
by the fact that these alkaloids are strong UV chromophores which would adversely 
affect analytical sensitivity. Hutt and Caldwell (1988) attempted to resolve 
2-phenylpropionic acid, ibuprofen and pirprofen using ß-c`elodextrin as a mobile 
phase additive but reported unsatisfactory results. 
b) Indirect methods of enantiomeric analysis of 2-arg Ipropionic acids 
For a drug to be analysed using indirect methods. it must possess a suitable 
functional group(s) that can be derivatized. The 2-arvlpropionic acids possess a 
carboxyl group that can be easily transformed into an ester or amide moiety. Lee cl 
cal., (1984) and Johnson cI al., (1979) used (S)--'-octanol to derivatize ibuprofen and 
naproxen to form their respective esters. This approach is generally not favoured 
due to the relative instability of esters (Testa, 1986) and the poorer resolution of 
esters compared to amides on silica and alumina columns. Generally, the 2-APAs 
are converted to amides by reaction with an optically pure amine prior to analysis by 
either normal or re\ ersed phase chromatography 
Deriv atisation of the 2-APAs to amides is usually carried out by chemical 
activation of the carbow group followed by reaction with a chiral amine. This 
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Reaction with thionyl chloride, to convert the carbonyl group of the profens 
to the corresponding acvl chloride. followed by reaction with either (1? )- or 
(, '')-1- phenethylamine was used in the early GC assays of ibuprofen i Brooks ei al., 
1974) and indoprofen (Tosolini et al., 1974). Due to undesired side reactions 
(Kaiser ei ul., 1976) this activating reagent has been largely abandoned in favour of 
others. Among the more commonly used coupling reagents is 1, V- 
carbonyldiimidazole which converts the carboxvl group into the corresponding 
imidazolide derivative (Maitre el al., 1984; Young et ul., 1989; Rudy ei al., 1990; ). 
However, various problems have been reported including the formation of 
disubstituted urea derivatives and uncertainty over conditions and concentrations 
that are considered as optimal (Hutt, 1990). Initially developed by Bjorkman (1985 ) 
for use with L-leucinarnide as CDA, ethylchloroformate in the presence of 
triethylarnine (TEA), has been widely applied for coupling 2-ard lpropionic acids to a 
variety of amines (Spahn, 1987; Palvlv'k and Jarnali, 1991: Wright et al., 1992: 
Lemko et ul., 1993). The reaction involves formation of a mixed anhydride which 
is subsequently reacted with an amine CDA to yield the required diastereoisomeric 
derivatives. The main attraction of this approach is a short reaction time of 2-3 
minutes. For the derivatization of tiaprofenic acid, a more reactive analogue, 2,2,1- 
trichloroethylchloroformate was required. Subsequent studies however, revealed 
that racemization occurred with tiaprofenic acid (Hutt el al., 1994), ibuprofen (Ahn 
el ul., 1994), ketoprofen and flurbiprofen (Wright and Jai-nail, 1993). The extent of 
the racemization appears to be influenced by the nature of the base (Hutt et u/., 
1994), solvent (Ahn et al., 1994) and the concentration of chloroformate used 
(Wright and Jamali, 1993). The fourth method of activation involves the use of a 
carbodiimide and has been used for pirprofen, carprofen and 2-phenvlpropionic 
acid, (Hutt cl ul., 1986), and ibuprofen (Avgerinos and Hutt, 1987). Although no 
problems of racemization have so far been reported, the major disadvantage of this 
approach is that long derivatization times of up to 2 hours are required (Hutt ct u/., 
1986). 
A variety of chiral amines have been used as CDAs, the most common of 
which being L-Ieucinamide, (1? ) - and (S )- l -phenethvlamine, (I? )- and (S)-l- 
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1-yl)ethylamine, (I? )- and (S)-amphetamine. These CDAs are easily available 
commercially in verv optically pure forms. The use of pheneth\ lamine affords the 
amide an extra chromophore, thus increasing assay sensitivity. With the use of 
(naphthen-l-yl)ethylamines, this effect would be enhanced, and in addition. 
fluorescence detection can be used (Lemko et al., 199-33). Other detection- 
enhancing CDAs such as 1-(4-dimethylaminonaphthen-l-}, I)ethylamine (Goto ct al., 
1980; Nagashima el ul., 1985), 1-(4-dansylaminoprop\l)-N-(2- 
phenylprop] onyl)ethylamine (Iwaki el al., 1994) and 1-(2-anthryl)ethylami ne (Goto 
et ul., 1986) have also been used and in the latter case, detection limits of 100 fmol 
was reported for naproxen. Unfortunately, these reagents are not commercially 
available, thus limiting their potential usefulness. 
2.1.3 Sample preparation procedures 
As with most bioanalytical procedures, sample clean-up steps are vitally 
important for the enantioseparation of the profens. As the carboxylic moiety of the 
profens has a pKa between 4-5 (Albert and Serjeant, 1984), the biological sample 
is usually acidified or buffered below these values and extracted using an organic 
solvent. Sample clean-up also affords the analyst a pre-concentration step %k-hereby 
the analvte can be concentrated down to a small volume before injection. This 
increases the final sample concentration considerably, thereby increasing analytical 
sensitivity. 
However, sample clean-up procedures in enantiomeric analysis may present 
additional problems. It has been shown that sample clean-up may alter 
enantiorneric ratios or result in enrichment of the sample that is present in excess. 
Thus, it is important that analytical procedures be appropriately validated to ensure 
that non-chiral differentiation does not occur (Hutt, 1990). 
In order to study the stereoselective inversion as well as the stereoselectivity 
of the oxidation and glucuronidation of ibuprofen, proper enantiospecific analytical 
procedures must be de\eloped for its determination in serum and urine. A 
Jý 
knowledge of the extent of protein binding of the enantiomers is also necessary in 
order to determine the stereoselectivity in intrinsic metabolic clearance. The 
following section describes the development and validation of an indirect HPLC 
procedure that fulfils these requirements. 
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2.2 Experimental 
2.2.1 Chemicals and reagents 
Acetonitrile, hexane and ethanol (HPLC) grade were purchased from 
Rathburn (Walkerburn, U. K. ). Sodium dihydrogen phosphate, sodium hydroxide 
diethylether (Analar grade), other solvents (GPR grade) and Merck silica gel GF,; 4 
for TLC were obtained from BDH (Poole, Dorset, U. K. ). Ketoprofen, naproxen, 
ethylchloroformate and triethylamine (TEA) were obtained from Sigma Chemicals 
(Poole, Dorset, U. K. ). (1? )-1-(naphthen-l-)l)eth\lamine (K)-NEA), 1-(3-dimethvl 
aminopropyl)-3-ethylcarbodiimide hydrochloride (CDI) were obtained from Aldrich 
(Gillingham, Dorset, U. K. ), 1-hydroxybenzotriazole (HOBT) \%as obtained from 
Fluka Chemicals (Poole, Dorset, U. K. ). WS)-, (S)- 
. (R )-ibuprofen, and 
(/?. &' )- 
flurbiprofen were a gift from Boots Ltd. (Nottingham, U. K. ). 
2.2.2 Chromatographic columns and supplies 
The C1 column (Waters Resolve C, x), 5 µm, 150 \ 3.9 mm, as obtained 
from Anachern Ltd. (Luton, Beds, U. K. ). Refillable guard columns (10 x 2.1 mm ) 
were packed with pellicular C1, (40 - 63 µm ). both obtained from Alltech 
Associates (Lancs, U. K. ). Merck silica gel (40-6 32 . im) for preparati%e 
chromatography was obtained from BDH (Poole. Dorset, U. K. ) and were used in 
solid phase extraction (SPE) cartridges. Empty Bond-elut SPE cartridges and frits 
were obtained from Anachem Ltd. (Luton, Beds). 
2.2.3 Instrumentation 
Reversed phase HPLC was performed using an LDC Constametric 3000 
pump, LDC Spectromonitor 3100 UV detector. Merck Hitachi spectrotluorometric 
detector (Poole. Dorset, U. K. ), and I DC 04100 computing integrator (Stone. Staffs. 
ýs 
U. K. ). Samples were injected using, a Perkin Elmer ISIS 100 autosampler v 
(Beaconsfield, Bucks, U. K. ) fitted with a 100 pl sample loop. Proton nuclear 
magnetic resonance spectra were recorded using a Perkin Elmer R-32 spectrometer 
(Beaconsfield, Buck, U. K. ) Fluorescence spectra \vere measured using a Hitachi 
Fl 000 spectrofl uorometer (Poole, Dorset, U. K. ). 
2.2.4 Synthesis of (R)-1-(naphthen-1-yl)ethylamides of (R)- and (S)-ibuprofen 
(R,, '; ) -Ibuprofen (0.97 mmol, 200 mg) was dissolved in acetonitrile (5 ml) 
and the solution was cooled in an ice-bath. To this was added 200 µl of TEA (1.47 
mmol) and 140 µl (1.47 mmol) of ethyl chIorofonnate. The mixture was gently 
shaken from time to time. After 15 minutes, 250 mg (1.47 mmol) of (/? )-NEA was 
added and the mixture was left to react at room temperature. After 1 hour, the 
solution was evaporated to dryness in a rotary evaporator. The residue was 
redissolved in 20 ml of diethylether, which was then washed twice with 20 ml of 
1. OM HCI. This was followed by two further washings with distilled \\ater (20 ml). 
The ether layer was removed, dried with anhydrous sodium sulphate, filtered and 
then evaporated to dryness. The dry residue was then spotted on a preparative TLC 
plate (20 x 20 cm; 1 mm thickness) coated with silica gel GF2 4 and developed in a 
solvent of hexane: ethyl acetate (6: 1, v/v). The solvent was allowed to migrate for 18 
cm, after which the plate was dried and viewed under a UV light source. The two 
separate bands observed under the UV light and the silica between 6.5 to 7.2 cm and 
10.7 to 1 1.2 cm were scraped off the plate and separately extracted with 20 in] 
diethvlether. After centrifugation at 10008 for 5 minutes. the ether layer was 
separated, filtered through a filter paper and evaporated using a rotary evaporator. 
The crystals obtained were recrystallized twice from ethanol. The melting points, 
NMR and fluorescence spectra (dissolved in acetonitrile: 0.0 IM phosphate buffer, 
pH 3.5; 50: 50 viv) were recorded. The fluorescence spectra are presented in 
Appendix 1. 
(R, 1? )-Ibuprofen diastereomeric amide derivative: mpt.. 1? -127"C, NMR (90 MHz 
CDCI; ), b. ppm; 0.84 (d, 6H, CH(C}13)z), 1.46 (d. 3H, CH; CHCO). 1.54 (d, 311, 
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CH; CHNH), 1.78 (m, I H, CH, CH(CH3)2), 2.39 (d, 2H, CHhCH(CH; )-_ 3.52 (q, I H. 
CH; CHCO), 5.65 (br. d, I H, CONH), 5.70 (br. q, I H. CH; CHNH). 7.08 (dd, 4H. 
para-subsituted phenyl H), 7.2 - 8.0 (m, 7H, naphthyl H); MS: (EI, 35eV) ni = 
(relative intensity %); 360 (21.3 ), 359 (M. 61.5), 197 (14.9), 162 (22.1), 161 (88.3), 
155 (100), 119 (13.2), 105 (5.4). Elemental analysis: Found (%); C, 83.86; H, 8.21; 
N, 3.86, required for C25H29NO; C, 83.51; H 8.14; N, 3.90. 
(R,, S)-Ibuprofen diastereomeric amide derivative: mpt., 125-126" C; NMR (90 MHz 
CDCl3), S. ppm; 0.85 (d, 6H, CH(CH; )2), 1.45 (d, 3H, CH; CHCO), 1.47 (d, 3H, 
CH3CHNH), 1.81 (m, IH, CH2CH(CH_3)2), 2.41 (d, 2H, CH CH(CHI)2 3.43 (q, 1 H, 
CH; CHCO), 5.67 (br. d, IH, CONH), 5.82 (br. q, IH, CH1CHNH), 7.11 (dd, 4H, 
para-subsituted phenyl H), 7.2 - 8.0 (m, 7H, naphthyl H); MS: (El, 35eV) m: 
(relative intensity %); 360 (32.2), 359 (M. + 80.3), 198 (5.8), 197 (18.5), 162 (29.1), 
161 (100), 156 (37.4), 155 (91.3), 154 (18.6), 153 (15.8), 127 (6.9), 119 (21.4), 118 
(15.7), 1 17 (16.3), 105 (8.3), 91 (8.5). Elennental analysis: Found (%); C, 82.58; H, 
8.67; N, 3.89, required for C,; H29NO; C, 83.51; H, 8.14, N. 3.90. 
2.2.5 Enantiospecific analysis of ibuprofen in serum 
a) Extraction 
To serum samples (0.5 ml) was added I µg (10 pl of a 0.1 mg/ml solution in 
acetonitrile) of (R,. S')-flurbiprofen as internal standard. The samples were then 
acidified by the addition of 1-ICI (1. OM; 100 µl) and then buffered to pH 3.8 with 
sodium phosphate buffer (1.0MpH 3.8; 1.0 ml)). Diethylether (3 ml) was then 
added and the samples mixed on a test-tube rocker for 20 minutes. The samples 
were centrifuged at 1000g for 2 minutes and the supernatant diethylether layer was 




The derivatization procedure was based on the method of Avgerinos and 
Hutt (1987), with minor modifications. To the dried residues of sample 
extracts/standard solutions were added 100 µg each of CDI, HOBT and (R)-NEA 
(100 µl each of aI mg/ml solution in dichloromethane). The tubes were tightly 
capped and then briefly vortex mixed. The reaction was allowed to proceed for 2 
hours at room temperature. SPE silica cartridges (100 mg) were activated by elution 
with methanol (1 ml) and subsequently dried in a hot air oven at 1000 C for 1 hour. 
Before use the cartridges were equilibrated with dichloromethane (1 ml). The 
reaction mixtures were then passed through the cartridges and the eluates collected. 
The cartridges were further eluted twice with I ml dichloromethane: acetonitrile 
(9: 1, v/v) and the eluate pooled. The pooled eluate were then dried under nitrogen 
gas at 40" C in a dry block heater and reconstituted with HPLC mobile phase (100 
µl). All samples were analysed in duplicate. 
In order to determine the reaction yield for the derivatization reaction under 
the conditions described above, (RS)-ibuprofen (2 µg) was derivatised as before and 
subjected to chromatographic analysis. The results obtained were compared to 
those obtained from chromatographic analysis of equivalent molar amounts of the 
synthesized amide derivatives described in section 2.2.4. 
c) Chromatographic conditions 
The mobile phase used was phosphate buffer (pH 3.5,0.01 M): acetonitrile 
(50: 50, v/v) run at a flow rate of 1.5 ml/min. The detector was set at excitation and 
emission wavelengths of 290 and 330 nm respectively. The column used was a 
Waters Resolve C18 (5 µm, 150 x 3.9 mm) protected by a guard column (10 x 2.1 
mm) filled with pellicular C, x. Aliquots of 50 pl of reconstituted extracts/standards 
were injected into the HPLC. The elution order of the diastereomeric amides were 
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determined by dematizing and analysing pure enantiomers of(R)- and (. `')-ibuprofen 
and (1? )- and (S)-flurbiprofen. 
d) Validation of ; analytical Method 
A stock solution of (/?, S')-ibuprofen (l mg 10 ml) as prepared in 
acetonitrile. Into six separate 10 ml volumetric flasks were pipetted 0.02,0.05,0,1, 
0.2,1.0 and 2.0 ml of the stock solution. The solutions were evaporated gently 
under nitrogen gas. and drug free serum added to the q. s. 10 ml to give final 
solutions of 0.1,0.25,0.5,1.0,5 and 10 µg/ml of each enantiorner. Aliquots (0.5 
ml) of these standards were transferred into different tubes and stored at -20( 
'C. On 
each day of analysis one set of these tubes (0.1 - 10 . 1g n 
fl) were analysed together 
with the samples. Calibration curves were constructed by plotting peak area ratios 
(ibuprofen enantiomer: (S)-tlurbiprofen derivatives) against the concentration of 
each enantiorner and subjecting this data to linear regression analysis. The 
concentration of each enantiorner in serum samples were determined by comparing 
their respective peak area ratios to the calibration curve prepared. 
The accuracy and within day variation of the assay was assessed by analysing 
six "spiked" serum samples with the following ibuprofen enantiomer concentrations: 
0.1,1.0 and 10 µ i'mI. The precision and accuracy of the assay ý\as determined for 
each enantiomer by calculation of the coefficient of variation (standard 
de\, iation/mean x 100%) and mean percentage difference (mean concentration - 
actual concentration / actual concentration 100%). The recovery of the 
extraction procedure was determined by comparing peak areas obtained with direct 
injections of standard solutions of equivalent concentrations of the drug. 
The between day variation of the assay was determined by anal} sing 
"spiked" serum samples of 0.1,1.0 and 10 p ; 'm1 enantiomer concentrations for six 
consecutive days. The coefficient of variation and accuracy . fiere calculated as 
described above. 
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In order to determine whether the analytical procedure could produce 
accurate data with respect to enantiomeric composition over a wide range of 
concentrations, a series of "spiked" standards were prepared of varying 
concentration and enantiomeric composition from individual (R)- and (S)-ibuprofen 
standards. "Total" ibuprofen concentrations of 0.5,2.0 and 10.0 µg/ml were 
prepared with the following enantiomeric compositions; R: S; 1: 4; 2: 3; 3: 2 and 4: 1 
for each concentration. Each of the samples were analysed in triplicate and the 
precision and accuracy for each composition at each concentration level were 
determined described above. 
2.2.6 Enantiospecific analysis of ibuprofen in urine 
a) Extraction procedure 
For the enantiomeric determination of unconjugated ibuprofen in urine, 0.5 
ml urine samples were used. To the urine samples were added 1 µg of flurbiprofen 
(10 pl of 0.1 mg/ml solution in acetonitrile), 100 pi of HCl (1. OM) and sodium 
phosphate buffer (pH 3.8; 1. OM; 1.5 ml). Hexane: isopropanol (9: 1, v/v; 5 ml) was 
added as extraction solvent. The tubes were then capped and mixed for 20 minutes 
on a test-tube rocker, followed by centrifugation at 1000g for 5 minutes. The 
supernatant organic layer was separated and transferred into separate tubes and dried 
under nitrogen gas at 40°C on a dry block heater. The residues were reconstituted in 
HPLC mobile phase (100 µl) prior to analysis. 
For the determination of conjugated enantiomer levels, a 0.1 ml urine sample 
was used. To the samples were added I µg of flurbiprofen as internal standard, 
followed by 20 gl of 1.0 NaOH. The hydrolysis reaction was left to proceed for 2 
hours at room temperature, after which time HCl (1. OM, 40 µl), sodium phosphate 
buffer (pH 3.8; 1. OM; 200 I fl) and hexane: isopropanol (9: 1, v/v; 1.0 ml) was added. 
The samples were then extracted as before. 
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In order to determine whether the 2 hour hydrolysis reaction was sufficient 
to completely liberate all the acyl glucuronides, a5 ml urine sample from a 
volunteer who was administered 400 mg of the racemic drug was hydrolysed with 
sodium hydroxide (1.0M, 1.0 ml), as described above. At 30 minutes intervals, a 0.1 
ml sample was pipetted out and analysed as before. 
b) Derivatization procedure and chromatographic procedures 
These were identical to those used for the serum assay. 
c) Validation of the urinary assay procedure 
A stock solution of (R, ')-ibuprofen (1 mg/10 ml) was prepared in 
acetonitrile. Into six separate 10 ml volumetric flasks were pipetted 0.02,0.05,0.1, 
0.2,1.0 and 2.0 ml of the stock solution. The solutions were evaporated gently 
under nitrogen gas. Blank drug free urine was added to the flasks q. s. 10 ml to give 
final solutions of 0.1,0.25,0.5,1.0,5 and 10 gg/ml of each enantiomer. Aliquots 
(0.5 ml) of these standards were transferred into different tubes and stored at -20" C. 
On each day of analysis one set of these tubes (0.1 - 10 gg/ml) were analysed 
together with the samples. Calibration curves were constructed by plotting peak 
area ratios (ibuprofen enantiomer: (S)-flurbiprofen derivatives) against the 
concentration of each enantiomer and subjecting this data to linear regression 
analysis. The concentration of each enantiomer in urine samples were determined 
by comparing their respective peak area ratios to the calibration curve prepared. 
The accuracy and within day variation of the assay was assessed by analysing 
six spiked serum samples with the following enantiomer concentrations: 0.1,1.0 and 
10 µg/ml. The precision and accuracy of the assay was determined for each 
enantiomer by calculating the coefficient of variation (standard deviation/mean x 
100%) and mean percentage difference (mean concentration - actual concentration / 
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actual concentration x 100%). The recovery of the extraction procedure was 
determined by comparing peak areas obtained with direct injections of standard 
solutions of equivalent concentrations. 
The day to day variation of the assay was determined by analysing spiked 
serum samples of 0.1,1.0 and 10 µg/ml enantiomer concentrations for six 
consecutive days. The coefficient of variation and accuracy was calculated as 
before. 
2.3 Results and discussion 
In this present study, an indirect method of enantioseparation for ibuprofen 
was favoured over the use of CSPs for the following reasons: 
i) achiral columns, especially reversed phase columns, are more robust and 
stable compared with CSPs. This is especially important when large 
numbers of biological samples have to be analysed; 
ii) the cost of achiral columns are considerably lower than that of CSPs. This 
factor is inter-related to 0 above; 
iii) to date the resolution achieved by indirect separation of ibuprofen 
enantiomers is much better than those by CSPs. This is obvious when 
comparing published direct methods (Hermansson and Eriksson, 1986; 
Geisslinger et at, 1992; Nicoll-Griffith et at, 1988 and Petersson ei at, 
1991) with indirect methods (Avgerinos and Hutt, 1987; Rudy et at, 1990). 
Moreover, while CSPs are relatively efficient at separating enantiomers, they 
are less efficient at enantiomer resolution from achiral or endogenous 
interferences. Thus for bioanalysis, indirect separations have a distinct 
advantage. 
iv) the CDA used, (R)-NEA, is available in high optically purity (>99%), and to 
date there is no evidence of racemization occurring with the derivatization 
procedure of Hutt el a!., (1986). 
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v) (/? )-NEA, is highly fluorescent and increases assay sensitivity. 
A wide variety of C1 phases were evaluated as to their suitability for use in 
the assay. It was found that the Resolve C IR column gave the best separation 
between the diastereomeric amides of ibuprofen (a i=1.16), flurbiprofen (a1 = 
1.29) as well as between (. 5)-flurbiprofen and (R)-ibuprofen ((XEj = 1.23), as 
compared to columns like Partisil ODS-3 (a., = 1.16 ; ar = 1.28 ; aF1 = 1.03), 
Hypersil C18 (oc, = 1.10; a1. = 1.05; aj. J=1.17 ), Spherisorb ODS-1 (a1= 1.10 ; ()CF= 
1.11; al., = 1.20), Spherisorb ODS-2 (a1 = 1.0 ; (XI: = 1.0 ; aFI = 1.21), and 
Ultracarb C18. ((xi = 1.08 , aF = 1.19 aFi = 1.19) using the same mobile phase. 
The other columns were discarded on the basis that they did not give equally good 
separation between the four diastereorneric peaks. 
2.3.1 Synthesis of (R)-l-(naphthen- I yl)ethylam ides of (R)- and (S)-ibuprofen 
In order to fully characterise and validate an enantiospecific analytical 
method based on the indirect approach, it is advantageous to have available 
synthetic samples of the diastereomeric derivatives for use as reference standards 
The synthesis of the required amide diastereoisomers of ibuprofen was therefore 
carried out by reaction of the racemic drug with (R)-NEA using the mixed anhydride 
method. The two required derivatives were separated and isolated by preparative 
TLC, examination of the TLC plate after development showed two distinct bands 
with R, " values of 0.4 and 0.62 respectively. Comparison of the chromatographic 
characteristics of the prepared derivatives with derivatized standards of pure 
enantiomers of ibuprofen, indicated that the faster running band was due to the (R)- 
1-(naphthen-lyl)ethylamide of (S)-ibuprofen (S- acid: R-amine) and that the slower 
was due to that of the (R)-1-(naphthen- l yl)ethylamide of (R)-ibuprofen (R-acid: R- 
amine). The fluorescence spectra for the diastereomeric amides of ibuprofen are 
summarised in Appendix 1. The fluorescence spectra of both amides are identical 
with an excitation and emission maxima of 290 and 330 nm respectively. These 
values were thus used as detector settings for the HPLC fluorescence detector. 
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2.3.2 Enantiospecific analysis of ibuprofen in serum 
a) Derivatization procedure 
The derivatization procedure adopted in this study is based on that by 
Avgerinos and Hutt (1987). The coupling reaction involves a diimide, 1-(3-dimethyl 
aminopropyl)-3-ethylcarbodiimide hydrochloride (CDI) and I- hydroxybenzotriazole 
(HOBT) acting as both activating and dehydrating agents (Figure 2.1) . 
In the 
amounts used, it was found that the yield was essentially quantitative (Avgerinos 
and Hutt, 1987). In the present study, the derivatization yield was found to be 97.5 
and 97.8% for (R)- and (. S')-ibuprofen respectively. This was determined by 
comparing peak areas obtained for derivatized ibuprofen and comparing with those 
obtained by direct injection of equivalent amounts of the respective amides 
synthesised in section 2.2.5(b). 
Although the reaction times for derivatization were relatively long, the 
amides were found to be relatively clean and free from interferences when analysed 
by HPLC However, excess (R)-NEA reagent eluted as a large resolved peak (R, = 
28.2 mins) after the (ýS')-ibuprofen derivative peak. In order to remove the excess 
amine from the derivatization samples, it was necessary to pass the reaction mixture 
through aI ml SPE silica cartridge which effectively removed the excess reagent 
without retaining the amides. The cartridges were further eluted with 
dichlorornethane: acetonitrile (9: 1, v/v) in an effort to totally elute any retained 
amides. This SPE clean-up step was relatively simple, efficient and more effective 
than back extraction with 1. OM HCI. An added advantage was observed when 
analysing serum and urine samples as it was apparent that the SPE cartridge 
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Figure 2.1: Derivatization of the enantiomers of ibuprofen with (R)-1- 
(naphthen-1-yl)ethylamine in the presence of I-hvdrozvbenzotriazole and 1-(3- 
dimethylaminopropyl)-ethylcarbodiimide to yield a pair of diasterosiomeric 
ibuprofenyl-l-(naphthen-Iyl)ethylamides. 
h) Extraction procedure 
From the chromatograms of authentic and "spiked" serum samples (Figure 
2-2) it can be seen that the peaks corresponding to the deri ý at iv es of (R)- and (. ti )- 
ibuprofen eluted with retention times of 22.2 and 25.6 minutes and were free from 
interfering substances. However, for tlurbiprofen, the peak corresponding to the 
()j 
(R)-flurbiprofen derivative co-eluted with to other peaks. This interference as 
only observed in volunteer samples but not in blank or "spiked" serum samples. On 
further investigation it was found that the interfering peaks \%ere due to the carbox 
metabolite of ibuprofen (see Chapter -33). 
Thus, for quantitative purposes, peak area 
ratios were calculated using the (S)-flurbiprofen derivati\ e peak as internal standard. 
The values for extraction recoveries from serum are shown in Table 2.4. and are 
generally greater than 87% for the three concentration levels studied. 
d) Validation of assay 
The analytical procedure showed good precision and accuracy at all three 
concentration levels (Table 2.4a) with coefficients of variation less than 8 "0. The 
between day variation also showed equally good consistency (Table 14b) 
Typical 
calibration curves for both enantiorners are shown in Figure 2.3. Linear regression 
coefficients are typically better than 0.997. The limit of quantitation was at least 0.1 
pg/ml, although this can be lowered considerably by analysing a larger volume of 
serum or by injecting a larger proportion of the sample on-column. However the 
level of detection here is sufficient for pharmacokinetic studies involving the total 
drug enantiorner serum concentrations. The analytical method was developed 
further for the analysis of unbound serum concentrations (see Chapter 5) 
The assay was further validated by analysing a series of samples "spiked" 
with mixtures of the individual enantiomers at three concentration levels. This 
validation approach is necessary as biological samples from pharmacokinetic and 
metabolic studies will probably contain non-racemic mixtures of enantiomers due to 
stereoselectivity in drug metabolism and disposition (Hutt. 1991). The precision and 
accuracy values calculated for these analyses are shown in Table 2.5. The 
measured enantiomeric compositions were in good agreement with the expected 









Figure 2.2: Chromatograms of a) standard solutions of racemic ibuprofen (5 
pg/ml) derivatized with (R)-NE: A, b) blank serum sample, c) serum sample of a 
volunteer 0.75 hr following oral administration of 400 mg of the racemic drug. 
Retention times peak 1: (R)-flurbiprofen, 14.5 min; peak 2: (S)-flurbiprofen, 17.8 
min (a=1.29, R, = 1.8); peak 3: (R)-ibuprofen, 22.2 min ((x=1.23, It, = 1.6); peak 
4: (S)-ibuprofen, 25.6 min (a=1.16, R, =1.3). 
67 
Table 2.4: (a) Within day variation, accuracy and extraction recoveries of 
ibuprofen enantiomers in "spiked" serum samples (n=6) and (b) between day 

















0.1 R 0.090+0.005 5.60 -10.0 88.9+ 5.0 
s 0.091 + 0.006 6.23 -0.9 88.5 - 5.5 
1.0 1? 1.04+0.04 3.40 4.0 89.8 +; 1 
S 1.09+0.05 4.63 9.0 89.3+4.1 
10 R 9.93+0.12 1.12 -0.7 87.5+ 1.1 










0.1 R 0.091 + 0.008 8.34 -9.0 
S 0.090 + 0.007 7.80 -10.0 
1.0 1? 0.98±0.06 6.52 -2.0 
S 0.96+0.05 5.65 -4.0 
10 R 10.01 +0.14 3.41 0.1 














Figure 2.3: Typical calibration curves prepared for the quantitation of 
ibuprofen enantiomers as their (R)-1-(naphthen-l-yl)ethylamides following 
extraction of the drug from serum. 
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Table 2.5: Precision and accuracy data for the determination of a series of 
different enantiomeric compositions of ibuprofen in serum at three different 
"total" concentrations (n = 6). 













R 0.1 0.102 2.0 4.9 
5' 0.4 0.387 4.1 
R 0.2 0.195 5.9 
.ý 0.3 0.303 1.0 8.4 
1? 0.3 0.301 5.8 
S 0.2 0.196 -?. 0 6.2 
0.4 0.405 1.3 4.9 
.' 0.1 0.090 10.0 6.8 
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Table 2.5 (cont'd) 
b) Medium concentration (2.0 µg/ml) 
Theoretical Measured 
Enantiomer Composition Composition Mean Percent Coefficient of 
(µg/m1) (pg/m1) Difference Variation 1°oº 
R 0.4 0.42 5.8 I ?.? 3 
S 1.6 1.55 - 3.1 4.92 
1? 0.8 0.82 ?13.07 
1.2 1.23 4.45 
1.2 1.20 
S 0.8 0.79 -0.1 4.83 
1.6 1.58 -1.1 2.89 
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Table 2.6: (a) Within day variation, accuracy and extraction recoveries of 
ibuprofen enantiomers in "spiked" urine samples (n=6) and (b) between day 

















0.1 1? 0.092 + 0.004 4.31 -8.0 92.7 t- 4.0 
5' 0.094 + 0.004 4.54 -6.0 94.1 + 4. 
1.0 1? 0.95+0.0) ;. 29 -5.0 92.4 ± 3.0 
s 0.96+0.03 ý. 34 -4.0 9 .143.1 
10 1? 10.02 + 0.30 2.96 0.2 95.7+-1.8 











0.1 1? 0.095 ± 0.006 6.67 -5.0 
S' 0.091 + 0.005 5.96 -9.0 
1.0 1? 0.96+0.04 4.47 -4.0 
0.94+0.05 5.01 -6.0 
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Figure 2.5: Effect of hydrolysis reaction time on the enantiomer concentration 
and ratios (S/R) of ibuprofen in a urine sample of a volunteer (2-4 hr) following 
the oral administration of 400 mg of the racemic drug (mean ± sd; n= 3). 
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0.0 0.5 1.0 1.5 2.0 2.5 
Time (hr) 
peaks were observed in the chromatoLTrams of blank and alkali treated urine samples 
at the retention times of the deriv ames of (1? )- and (. S)-ibuprofen and (S)- 
flurbiprofen (22.5,25.6. and 17.8 minutes respectively, ). Ho\ e\ er, as ý% ith the 
serum samples, the (R)-flurbiprofen derivative co-eluted 'pith the carboxv' 
metabolite peaks and as such (S)-flurbiprofen was used as internal standard. 
b) Validation of urinary assay 
The extraction recoveries for both enantiomers of ibuprofen in urine was 
approximately 90% while the within day precision and accuracy are generally good 
and comparable to the serum assay (Table The between daffy variation 
experiments also showed good consistencies (Table 2.6b), and daily calibration 
curves have regression coefficients of better than 0.997 for both enantiomers (Figure 
2.6). 
2.5 Summary 
In summnar ,a reliable and accurate 
indirect stereospecific assay for 
ibuprofen enantiorners in serum and urine was developed and validated. There was 
no evidence of racernization or non-chiral differentiation in the analytical 
procedure. The use of fluorescent detection was possible by using (/? )-NEA as 
CDA, which enhanced analytical sensitivity and selectivity. The application of the 
analytical methodology to human pharmacokinetic studies following the oral 













Figure 2.6: Typical calibration curves prepared for the quantitation of 
ibuprofen enantiomers as their (R)-1-(naphthen-1-v I)ethylam ides following 
extraction of the drug from urine. 
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CHAPTER 3 
Chromatographic Resolution, Isolation and 




Ibuprofen undergoes metabolic oxidation of its isobutvl side-chain to fonni 
hydroxyibuprofen and carboxyibuprofen as major metabolites in both animals and 
man (Mills el ul., 1973). Following the administration of (11.. x'-)-ibuprofen to 
humans, both enantiomers of hydroxyibuprofen are formed, the *, '-cnantiomer being 
predominant (Baillie et al., 1989; Kaiser el ul., 1976). The formation of 
carboxyibuprofen introduces a second chiral centre into the molecule, with the 
result that following administration of the racemic drug, four stereoisomers may be 
found in urine (Kaiser et al., 1976). The determination of the stereochemical 
composition of the carboxy metabolite in urine following the administration of (16')- 
ibuprofen has proved to be problematic due to the difficulties associated with 
chromatographic resolution of the four stereoisomers, as described belo\\, together 
with the lack of readily available analytical standards. 
One of the earliest attempts to resolve the stereoisomers of the two 
metabolites was published by Kaiser cl at., (1976). In this method, urine samples 
were extracted by successive column chromatography prior to separation using 
GLC as (Y')- l -phenylethylamide derivatives. The R- and the S- enantiomers of the 
hydroxy metabolite were well resolved but only three peaks \ýere obtained out of a 
possible four for the carboxy metabolite. Peak assignment for the hydroxy 
metabolite enantiomers was carried out by analysing urine samples from volunteers 
following administration of with (S)-ibuprofen where only (S)-hydro-\\ ibuprofen 
would be present. On the same basis, the two chromatographic peaks corresponding 
to the diastereoisomers of carboxyibuprofen with the s-absolute configuration in the 
propionic acid side-chain of the molecule were also identified. However, the 
absolute configuration at the new chiral centre resulting from oxidation of the 
isobuty l side chain of the molecule were assigned empirically . on the 
basis that 
S- enantiomers of ibuprofen and by dro\v ibuprofen alvýa` s elute before their 11 
antipodes on the GLC system. Thus, in this method, the elution of the 
carboxvibuprofen diastereomers were in the order R,. `-, , '. R-, and Il, R-, and 
there \\ as co-elution of the S', ll- and 1?,,,; - isomers. 
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Subsequent assays by Young et a!., (1986) and Baillie ei a!., (1989) utilised 
capillary GC-MS and derivatization with (-)-(S)- and (+)-(K)-phenethylamine 
respectively. In the study by Baillie et a!., (1989), the assignment of the peaks were 
made with reference to the order of elution suggested by Kaiser et a!., (1976), while 
in that by Young et a!., (1986), the order of peak elution was stated to be the same 
although there was no mention of how this conclusion was arrived at. In both cases, 
again both the R,. S- and SR- isomers could not be resolved. 
An HPLC method utilising a Pirkle-type chiral stationary phase (CSP) with a 
covalently bonded (R)-N-(3,5-din itrobenzoyl)phenylglycine chiral selector was 
published by Nicoll-Griffith et a!., (1988), in which ibuprofen and its two 
metabolites were derivatized to form their corresponding 4-methoxyanilide 
derivatives. Although the enantiomers of ibuprofen were fully resolved, the 
enantiomers of hydroxyibuprofen were only partially resolved, while those of 
carboxyibuprofen were separated only into two separate peaks and the elution order 
of the stereoisomers could not be assigned. The most successful attempt to date is 
that of Rudy e> al., (1990), where hydroxy and carboxyibuprofen were successfully 
separated on a reversed-phase HPLC column as their (S)-l-phenylethylamide 
derivatives. Again, due to the lack of authentic standards for the individual 
carboxyibuprofen diastereomers, the absolute configuration of the material in the 
individual chromatographic peaks could not be assigned unequivocally and was 
made by comparison to the original method of Kaiser er a!., (1976). 
From the publications cited above, it is clear that there are no methods that 
assign the stereochemistry of the carboxy metabolite to the chromatographic elution 
order using specific procedures. As the stereochemical composition of this 
metabolite is important for the examination of the stereoselectivity of ibuprofen 
disposition, it was considered essential to investigate methods for the 
chromatographic resolution of the four stereoisomers and investigate possible 
methodologies for assigning their absolute configuration. 
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3.2 Experimental 
Note on the nomenclature of the stereoisomers of carboxvibuprofen 
Chemically, carboxyibuprofen may be designated as 2-[4- 
(carboxypropyl)phenyl]propionic acid which results in both chiral centres recei\ ing 
the numerical designation 2. In order to avoid ambiguities in this thesis, the chiral 
centre in the 2-carboxypropyl side chain, i. e. the chiral centre introduced by 
metabolism will be referred to as 2', whereas the original chiral centre in the 
propionic acid moiety will be designated as 2. The trivial name \vill be used 
throughout and a particular stereoisomer indicated as, for example, (2'12,2S)- 
carboxyibuprofen. 
3.2.1 Chemicals and reagents 
I-Iexane, ethanol, methanol, isopropyl alcohol and acetonitrile 'sere obtained 
from Rathburn (Walkerburn, U. K. ). Hydrogen chloride gas, diethyl ether, 
trifluoroacetic acid (TFA) and all other chemicals (GPR grade) \wre obtained from 
BDH (Poole, Dorset, U. K. ). 
3.2.2 Chromatographic Columns and Supplies 
The Partisil silica column (250 x 4.6 mm, 5 µm) and Partisil semi- 
preparative Cix column (100 x9 mm, Sµm) were obtained from Whatman 
(Maidstone, Kent, U. K. ). Refillable guard columns (10 x 2.1 mm) were packed with 
pellicular silica (40-63 µm), both obtained from Alltech (Lancs, U. K. ). The 
Spherisorb ODS-1 C1 column (150 x 4.6 mm, 5 µm) was obtained from LDC 
(Stone, Staffs., U. K. ). The chiral column was a Chiralpak AD (amy lose tris (3,5- 
dimethylphenylcarbamate)) column (250 x 4.6 mm, 10 µm) used x0h a matching 
guard column (5 x 4.6 mm, 10 pm), and was supplied by HPI C Technologe Ltd 
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(Macclesfield, U. K. ). The Merck GF254 TLC plates were obtained from BDH (Poole, 
Dorset, U. K. ). 
3.2.3 Instrumentation 
Chiral HPLC was performed using a LDC Constametric 3000 pump, a LDC 
Spectrornonitor 3100 UV detector-, a LDC Cl 4100 computing integrator (Stone, 
Staffs) and a Perkin Elmer ISIS 100 autosampler (Beaconsfield, Bucks, U. K. ) or a 
Perkin Elmer Integral 4000 system. Circular Dichroism (CD) measurements were 
made on a Jasco J600 spectrometer (Halstead, Essex). Proton nuclear magnetic 
resonance spectra were obtained using a Perkin Elmer R-32 spectrometer 
(Beaconsfield, Bucks., U. K. ) at 90 MHz using tetramethylsilane as internal standard. 
3.2.4 Synthesis of carboxyibuprofen diastereomers 
A "racemic" mixture of the four diastereoisomers of carboxvibuprofen were 
synthesised by Dr. J. A. Baker of the Department of Pharmacy, University of 
Brighton, using the procedure outlined in Appendix 2, and these were used as 
analytical standards in this study. Mixtures of two diastereolsomers i. e. 2'. ß', 2R-, 
2'1'', 2S- and 2'R, 2R-, 2'R, 2S- carboxyibuprofen were synthesised by Dr. K. Afarinkia 
of the Chemistry Department of King's College London following a scheme of 
stereoselective reactions, outlined in Appendix 3. The mixtures were purified by 
semi-preparative reversed-phase 1-IPLC using the Partisil ODS-3 column (5 p. m, 100 
x9 mm) with a mobile phase of acetonitrile:! water (25: 75, v; 'v) adjusted to pH 3.0 
with HCI. The flow rate used was 2.5 ml/min and detection was by UV, 220 nm. 
The samples were dissolved in mobile phase to a concentration of 10mg/ml and 
aliquots (50 µ1) were injected onto the HPLC. The eluate containing the peaks of 
interest were collected from the outlet of the detector and freeze-dried oý ernight. 
The purity of the samples before and after semi-preparative chromatography were 
monitored by reversed-phase HPLC analysis using the Spherisorb ODS-1 column (5 
µm, 150 x 4.6 mm) with a mobile phase of acetonitrile: water (75: 25, \, v) adjusted to 
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pH 3.0 with HC1. The flow rate used was 1.0 ml min and detection was by UV. 22V 
nm. 
(1? )-2-Methyl-3-phenylpropionic acid was also stereoselecti% elv synthesised 
by Dr. K. Afarinkia using the first stages of the reaction scheme outlined in 
Appendix 3(b), but with benzyl bromide as starting material, and was used as such. 
3.2.5 Synthesis of the dimethyl, diethyl and diisopropyl esters of 
ca rboxyibuprofen. 
Into a 250 ml ground-glass stoppered flask as transferred 100 ml of 
methanol. The flask was weighed and HCl gas was bubbled through until an 
increase in weight of about 3.6 g was recorded. "Racemic" carboxv ibuprol n (2 S0 
mg) was transferred into a 50 ml round bottom flask and 10 ml of the acidified 
methanol was added and the mixture refluxed for about two hours. The reaction 
was monitored by sampling small aliquots of the mixture using a microcapillary 
tube every 30 minutes. The samples were spotted on a 2.0 cm x 10 cm strip of an 
aluminium backed silica gel TLC plate, developed using a sol%ent system of 
hexane-ethyl acetate (4: 1, v/v) and the spots located by short wa\ elengTth UV (254 
nm ). Under these conditions, carboxyibuprofen did not migrate while the 
corresponding methyl ester was identified by an extra spot «ith an R, - of 0.4. After 
the reaction, the contents of the flask was transferred into a 100 ml separating 
funnel, distilled water (10 ml) was added and the esters were extracted with 
3x 10 nil of diethylether. The ether extracts were combined and dried oxer 
Na-2SO,: NaHCO., (4: 1, w/w), filtered and evaporated to dryness in a rotary 
evaporator. A colourless oily residue was obtained and the NMR spectra recorded. 
The same procedure was repeated using ethanol and isopropanol for the 
synthesis of the ethyl and isopropyl esters of carbo\yibuprofen respecti\ ely. 
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Dimethyl carboxyibuprofen 
NMR (90 MHz. CDC13) b ppm. 1.13 (d. 3H. CH2CHCH, ). 1.45 (d. H. CHCH; º_ 
2.67 (m, 2H, CH2CHCH3), 2.90 (m, 1 H, CH, CHCH? ). 3.61 (s. 6H. COOCHi; ). 3.68 
(q, I H, CHCH, ), 7.17 (dd, 4H, para-substituted phenyl H). 
Diethyl carboxyibuprofen 
NMR (90 MHz, CDCI3) 8 ppm. 1.17 (d, dt, 9H, CHtCHCH,; CH, C1{, O). 1.4 (d, 3H, 
CH1CHCO), 2.75 (m, 3H, CH3CHCH, ), 3.65 (q, IH, CH3CHCO), 4.18 (dq. 4H, 
CH, CH3), 7.17 (dd, 4H, para-substituted phenyl H). 
Diisopropyl carboxyibuprofen 
NMR (90 MHz, CDCI3) b pprn. 1.13 (d, I 5H, CH; CHCH,; 4d, (Cl1; ), CHO). 1.44 (d, 
3H, CH-CH ), 2.6 - 3.0 (complex m, 3H, CH-CHCHH, ), 3.62 (y. 1 H. Cl 1-, ('l IC(> ), -1.9S 
(m, 2H, (CH3)2CHO), 7.17 (dd, 411, para-subsituted phenyl H). 
3.2.6 Chromatographic resolution of carboxyibuprofen diastereoisomers as 
the dimethyl, diethyl and diisopropyl esters. 
Chromatography was carried out using a Chiralpak AD column (10 µm. 250 
x 4.6 mm) with a mobile phase of hexane-. ethanol (99.5: 0.5, V s'), at a flow rate of 
1 ml. /min. Detection was by UV, 220 nm. The esters were dissol%cd in mobile phase 
to obtain a concentration of 0.5 mg/ml and 40 µl aliquots were injected into the 
HPLC. 
3.2.7 Chromatographic resolution of carboxyibuprofen diastereoisomers after 
derivatization as their (R)-1-(naphthen- l-yI)ethylamides. 
The derivatization procedure is similar to that described for ibuprofen in 
section 2.2.5 b). A standard solution of the "racemic" carboxvibuprofen was 
ýý 
prepared in dichoromethane (I mg/10 ml). To a 10 pl aliquot of the standard 
solution was added 100 pg each of CDI, HOBT and (R)-NEA (100 pl each of a1 
mg/ml solution in dichloromethane). The tubes were tightly capped and the 
derivatization procedure carried out as before. Reversed phase chromatography was 
carried out as described in section 2.2.5(c). 
The stereochemical purity of the synthesised (R)-2-methyl-3-phenylpropionic 
acid was also determined by converting it into the corresponding amide and 
subjecting the derivatives to chromatographic analysis as described above. 
3.2.8 Chromatographic resolution of carboxyibuprofen diastereoisomers as 
their free acids. 
Chromatography was carried out using a Chiralpak AD column (10 µm, 250 
x 4.6 mm). The mobile phase used was hexane: ethanol (92: 8, v/v) containing 
trifluoroacetic acid (0.05% v/v) at a flow rate of 1.0 ml/min. Detection was by UV 
at 220 nm. A standard solution of carboxyibuprofen (10mg/ml) was prepared in 
mobile phase and aliquots (20 µl) injected into the HPLC. The (2'. S, 2R)-, (2'K, 211)- 
and (2'R, 2S)-, (2'S, 2S)- pairs of diastereoisomers that were synthesised and purified 
as described in section 3.2.4 were also injected and the chromatograms compared. 
3.2.9 Chromatographic isolation of the individual carboxyibuprofen 
diastereoisomers. 
Semi-preparative purification of carboxyibuprofen was carried out to isolate 
the individual diastereoisomers using the same CSP used in section 3.2.8. The 
mobile phase used was hexane: methanol: ethanol (95: 3.5: 1.5, v/v) containing 0.05% 
v/v trifluoroacetic acid. The flow rate used was maintained at 1.0 ml/min and UV 
detection was set at 220 nm. Carboxyibuprofen standard solutions (25 mg/ml) were 
prepared in mobile phase and 20 µl aliquots of this solution was injected into the 
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HPLC*. The eluate containing the indiý idual isomers was collected as they eluted 
from the detector outlet. The eluate was then evaporated gently under nitrogen gas. 
The stereochemical purity of the isolated carbox ibuprofen isomers as confirmed 
by re-examination using the CSP. 
3.2.10 Circular dichroism spectroscopy of carboxvibuprofen, hydroxyibuprofen 
and ibuprofen. 
Solutions of (R)- and (. S`)-ibuprofen, (I? )- and (S)-hydroxvibuprofen, the pure 
isomers of carboxyibuprofen collected as described in section 3.2.9 and 
mnethyl-3-phenylpropionic acid were prepared in acetonitrile (I mg inl) and 
examined by circular dichroism. A bandwidth of I nm and sensiti\ity of -S0 mdeg 
was used and the operating temperatures maintained at 25"C. Measurements were 
made from 185 to 320 nm. For measurements from 185 to 260 nrn, a concentration 
of 0.3 mg/ml and a cell of 0.02 cm pathlength were used. For measurements 
between 230 to 320 nm, 1 mg/ml solutions and a cell of 1 can pathlength were used. 
The CD spectra \vere normalised for concentration and cell pathlength, and baseline 
subtraction was carried out for each indk idual spectrum. 
3.2.11 Urinary excretion study following administration of (S)-ibuprofen. 
(. ' )-Ibuprofen (50 mg) was weighed and filled into an empt` size 5 gelatin 
capsule. The capsule was administered to a healthy young volunteer after an 
overnight fast and urine excreted over six hours was collected. The urine sample 
was analysed using the procedures described in section 4.2.5,4.2.7 and 4.2.8., to 
determine the chromatographic characteristics of the carboxv metabolites excreted. 
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3.3 Results and Discussion 
Due to the lack of authentic chemical standards of the individual isomers of 
carboxyibuprofen, these had to be isolated chromatographically. These standards 
are necessary if the stereoselectivity of the metabolic oxidation processes are to be 
elucidated. The carboxyibuprofen used as chromatographic standards in the 
development of separation methods and in the pharmacokinetic studies (Chapters 0 
and 7) were synthesised as described in Appendix 2. The syntheses of the pairs of 
diastereoisomers 2'R, 2R-, 2'R, 2. ß- and 2'S, 2R-, 2'5,2S- were used to assist in the 
stereochemical assignment of the isomers. 
3.3.1 Chromatographic resolution of carboxvibuprofen diastereoisomers as 
their (R)-1-(naphthen-l -yI)ethylamides. 
A chromatogram of the indirect separation of the carboxvibuprofen isomers 
after derivatization with (R)-1-(naphthen-l-yl)ethylamine, using similar 
derivatisation and chromatographic conditions as with ibuprofen (Chapter 2) is 
shown in Figure 3.1(a). Due to the poor resolution obtained for peaks 2 and 3, an 
observation consistent with previous data (see introduction and references therein), 
this approach was not pursued further as complete separation would involve 
impractically long retention times and would therefore be unsuitable for routine 
analysis. It was therefore decided to examine possible chiral-phase separation of the 
four stereoisomers. The elution order of the four (R)-l-(naphthen-l-yl)eth`'lamides 






Figure 3.1: Reversed phase chromatographic separation of (a) carboxyibuprofen 
isomers following derivatization with (R)-1-(naphthen- l-yl)ethylamine. Retention 
times of the diastereoisomers: peak 1: 2'R, 2R- = 13.2 min; peak 2: 2'S, 2R- =15.1 min 
(a = 1.25, R, = 1); peak 3: 2'R, 2S- = 15.6 min ((x = 1.04, R, = 0.17); peak 4: 2'. S, 2. S'- _ 
17.9 min (a = 1.17, R, = 0.9) (see text for the determination of the absolute 
configurations of the individual stereoisomers) (b) (R)-2-methyl-3-phenylpropionic 
acid. Retention time of the R- derivative, 17.3 min, retention time of the . S'- derivative, 
20.5 min (a = 1.19, R, = 2.14) (Stationary phase, Resolve C18,150 x 3.9 mm, 5µm; 
Mobile phase, acetonitrile: phosphate buffer (0.01 NI, pH 3.5) (50: 50, v/v); Flow rate, 1.5 
ml/min, - Detection, IN X= 254 nmI. 
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3.3.2 Synthesis and chromatographic resolution of carboxyibuprofen 
diastereoisomers as their methyl, ethyl and isopropyl esters. 
he successful resolution of enantiomers of carboxý-lic acids followti-inL, their 
conversion into the corresponding neutral esters or amide derivati\ es using 
polysaccharide CSPs have been reported in the literature (Shibata et al., 1989). 
Following this approach, carboxyibuprofen was converted into methyl, ethyl and 
isopropyl esters following reflux with the appropriate alcohol treated with HCl gas. 
The structures were confirmed by NMR spectroscopy and their purity determined by 
TLC analysis using a silica gel GF254 a mobile phase of hexane ethyl acetate (4: 1, 
v/v). These derivatives were analysed using a derivatized am}lose CSP (Chiralpak 
AD). With a solvent system of hexane: eth\'l alcohol (99.5: 0.5, ' v), the methyl ester 
derivatives were resolved with baseline resolution (Figure 3.2(a)). 11owe\er, with 
the increasing size of the alkyl group, resolution became progressi\ely poorer, 
accompanied by decreased retention (Figure 3.2 (b and c)). In the case of the 
isopropyl derivatives, only three peaks were observed. Thus, it is apparent that 
increasing the hydrophobicity and steric bulk of the ester group led to a decrease in 
both retention and chiral discrimination. 
3.3.3 Chromatographic resolution of carboxyibuprofen as their free acids 
Resolution of the carboxvibuprofen isomers in their free acid form was also 
attempted using the Chiralpak AD column. The mobile phase was modified with 
the addition of TFA to improve peak symmetry and to reduce retention. The mobile 
phase composition was adjusted to give adequate separation. With a mobile phase 
composition of hexane: eth\-l alcohol (92: 8, v, v) containing 0.05% v/v TFA, baseline 
separation was achieved at a relatively short run time of 21.5 minutes (Figure 3.3). 
As these analytical conditions gave the most satisfactory resolution and did not 
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Figure 3.3: Chromatographic resolution of carboxyibuprofen isomers as the 
free acids using a Chiralpak AD CSP. Retention times peak 1: 11.0 min; peak 
2: 12.1 min ((x = 1.20, R, = 1.3); peak 3: 16.9 min ((x = 1.5, R, = 3.3); peak 4: 20.1 
min ((x =1.3, R, =2.4). For peaks I and 3: a=1.85, R, = 4.25; peaks 2 and 4: a 
= 1.84, R, = 4.55.1 Mobile phase, hexane: ethanol (92: 8, v /v) with TF. k (0.05%, 
v/v); Flow rate, 1.0 ml/min; Detection, t1V' X= 220 nmj. 
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of carbox, ibuprofen diastereoisomers in the pharmacokinetic studies (Chapters 6 
and 7). For the semi-preparative isolation of the diastereoisomers the mobile phase 
was modified to hexane: methanol : ethanol (95: 33.5-1 5, viva with TFA (0.05%, . v) in 
order to improve the resolution further, especially between the first two peaks 
(Figure 3.4). With this improved separation, the amount of substance injected on- 
column could be increased to 0.5 mg. Following repeated injections (n=30) of the 
"racemic" mixture of carboxyibuprofen, approximately 3 mg of each stereoisomer 
were isolated. The stereochemical purity of each isomer was determined by re- 
injection onto the HPLC. In each case, these were found to be greater than 9Q0 
based on peak area measurements (see for example Figure `3.4(b)). The materials 
isolated were examined by CD spectroscopy (see below). 
Attempts to determine the stereochemical purity of the synthesised (R)-2- 
methyl-3-phenylpropionic acid using, the CSP were unsucce'sful, only one 
chromatographic peak being obtained. The stereochemical purity was subsequently 
determined by converting the acid into its corresponding (/? -1-inaphthen-l- 
yl)ethylarnide and analysing it by reversed phase HPLC as described in section 
3.2.7. The stereochemical purity was detennined to be 9100 based on peak areas 
(see Figure 3.1 (b)). 
3.3.4 Human urinary excretion study following administration of 
(S)-ibuprofen. 
Following the chromatographic resolution and isolation of the four 
stereoisomers of carboxyibuprofen it was necessary to determine their absolute 
configuration. As the chiral inversion of (k)- to ()-ibuprofen is unidirectional in 
man, administration of (S)-ibuprofen would result in only the urinary excretion of 
(. S')-ibuprofen and metabolites haying the S-configuration in the propionic acid 
moidty. Therefore, analysis of urine samples after administration of (S)-ibuprofen 
would yield valuable information as to the absolute configuration of the metabolites 




Figure 3.4: (a) Semi-preparative resolution of carboxyibuprofen 
diastereoisomers using the Chiralpak AD CSP. Retention times, peak 1: 21.2 
min; peak 2: 26.2 min (a = 1.23, R., = 2.9) ; peak 3: 39.4 min (a = 1.57, R, = 7.6); 
peak 4: 50.20 min ((x = 1.3, R, = 4.7). INlobile phase, hexane: methanol; ethanol 
(95; 3.2: 1.5, v/v) with TFA (0.05%, v/v); Flow rate, 1.0 ml/min; Detection, VA" X 
= 220 nmj (b) Chromatographic analysis of peak 3 after semi-preparative 
isolation. Retention time, 16.9 min (using the system presented in Figure 3.3). 
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the urinary excretion study for carboxvibuprofen diastereoisomers. only peaks with 
retention times corresponding to peaks 3 and 4 were obtained (Figure ,6 (c)). 
Therefore, peaks 3 and 4 has the S absolute configuration at the original chiral 
centre and by logical deduction the other two peaks, i. e. peaks I and 2 have the 1? - 
absolute configuration at the same centre. 
Knowing the absolute configuration at the chiral centre in the propionic acid 
moiety the CD spectra of the four stereoisomers were examined (see below) in the 
hope that the configuration of the second chiral centre in each isomer could be 
deduced. However this proved to be problematical and an alternativ e approach 
based on stereoselective synthesis was adopted. 
3.3.5 Analysis of 2'R, 2R-, 2'R, 2S- and 2'. S, 2R-, 2'S, 2S- pairs of 
carboxyibuprofen diastereoisomers 





21? - pair and 2'S, 21? -, 2'S, 2S- pair was carried out bv Dr. K. Afarinkia 
(Department of Chemistry, King's College London, see Appendix 3). The approach 
involved stereoselective synthesis of the 2-methti lpropionic acid moiety followed by 
the non-stereoselective introduction of the propionic acid moiety. Also during the 
course of the synthesis programme, (R)-2-methyl- 3-phenylpropionic acid was 
stereoselectively prepared (Appendix 3)). Once the synthetic materials \ýere 
obtained, they were examined by reversed phase chromatography and typical 
chromatograms are presented in Figure 3.5. After semi-preparative purification on a 
reversed-phase HPLC system, the samples were then analysed without deriv atization 
using the Chiralpak AD column and the conditions described in section 3,2.8. With 
the sample containing the 2'. ß, 21Z- and 2'S, 2S- pair of diastereoisomers, two major 
peaks were seen, with retention times of 11.0 and 20.1 minutes respectiýely, 
corresponding to peaks I and 4 of the standard "racemic" mixture (Figure 3.6 (a)). 
IFherefore, peaks 1 and 4 both hay e the S-configuration at the newly formed chiral 
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a b 
Figure 3.5: Reversed phase analysis of the synthetic diastereoisomeric 
mixtures of carboxyibuprofen (a) 2'S, 2R /2'S, 2S- and (b) 2'R, 2R /2'R, 2S- 
diastereoisomers, retention time 11.2 minutes. Stationary phase, Resolve C18, 
150 x 3.9 mm, 5 µm; Mobile phase, acetonitrile: water (40: 60, v/v; ); Flow rate, 






a b C 
Figure 3.6: Resolution of the synthetic (a) 2'S, 2R- , 2'S, 2S- and (b) 2'R, 2R-. 
2'R, 2S- carboxyibuprofen diastereoisomers using the Chiralpak AD after semi- 
preparative purification. Retention times, peak 1: 11.0 min; peak 2: 12.1 min; 
peak 3: 16.2 min; peak 4: 20.1 min.: (c) chromatogram of carboxyibuprofen 
following isolation from the urine of a healthy volunteer after the oral 
administration of (S)-ibuprofen (50 mg). Retention times, peak 3,16.3 min; 
peak 4,20.1 min. (Mobile phase conditions as in Figure 3.3). 
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centre in the carboxypropyl moiety. With the 2'R, 2. S- and 2'11,2/x- pair, two major 
peaks with retention times of 12.1 and 16.9 minutes were obtained, corresponding to 
peaks 2 and 3 of the standard "racemic" mixture (Figure 3.6(b)). Therefore, peaks 2 
and 3 have the R- absolute configuration in the carboxypropyl side chain. Thus, 
analysis of these stereoselectively synthesised pairs of diastereoisomers gave 
valuable information on the configuration of the diastereoisomers at the newly 
formed chiral centre in the carboxypropyl moiety. These data, together with those 
obtained in the metabolic study are summarised in Table 3.1 and reveals the 
stereochemical configuration of the isomers with respect to the order of elution from 
the CSP. 
Table 3.1: Stereochemical assignment and chromatographic elution 
order of the four stereoisomers of carboxyibuprofen. 
Stereochemical Configuration 






1 11.0 S Il 
2 12.1 R R 
3 16.9 R S 
4 20.1 S S 
Thus, the chromatographic peaks 1-4 have the absolute configurations of 2'. S', 2/? -, 
2'1R, 2R-, 2'1?, 2S-, and 2'S, 2S- of carboxyibuprofen respectively. 
With reference to the order of elution with the indirect separation using 
reversed phase analysis after derivatization into amides of (R)-1-(naphthen-l- 
yl)ethylamine, the order of elution of the derivatives were 2'R, 2R-, 2'S, 2R-, 2'R, 2S . 
and 2'S, 2,5- respectively. 
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3.3.6 ('hiroptical properties of carboxv ibuprofen diastereoisomers 
The concentrations and pathlengths used to determine the CD spectra of the 
ibuprofen enantiomers were chosen such that the absorbance of the solutions did not 
exceed 1.5 a. u. f. s. and that the HT voltage of the photomultiplier as le,,, -, s than 7/()0V 
to ensure that valid CD data were obtained. 
The CD spectra of (, 'ý)-ibuprofen showed bands in three distinct regions 
(Figures 3.7 to 3.12). The strongest band was observed at 195 nm with a negativ e 
Cotton effect, while a relatively weaker one was observed at ? 25 nm mth a positiv e 
Cotton effect. Several weakly positive bands were also observed at the region 
around 260 nm. A comparison with published literature showed that the bands at 
225 and 260 nm (Figure 3.7 (a)) for (S)-ibuprofen were consistent mth those 
observed with other (L)-a-substituted phenylacetic acid deri\ ati\ is (Barth c'i al., 
1970). The band at 225 mit has been attributed predominantly to n -ý it transition of 
the carbonyl group while that at the 260 nm region is probably due lI., transition of 
the phenyl moiety. With (/? )-ibuprofen equal and opposite Cotton effects were 
obscr\ cd (Figure 3.7(a)). Also, comparison of the CD spectra of (R)-ibuprofen with 
(R)-hydroxyibuprofen and that of (S)-ibuprofen with (S')-hvdrox\: ibuprofen shoý\cd 
almost identical CD spectra (Figure 3.7(b)). The strong hands observed at 195 nm 
have not been investigated in-depth in previously published work and are most 
probably due to transitions of the phenyl ring. 
With the carboxyibuprofen diastereoisomers, the main differences in the 
Cotton effects were seen at the 225 nm region, as would be expected as this region 
is due to the n- it' transition of the carbonyl group (Figures 3.8 to 3.10). With the 
diastereoisorner, the CD spectra in this region were similar to that for (R)- 
ibuprofen although the absorption for (2'1?, i1? -)-carboxyibuprofen was slightly 
stronger . 
It is therefore evident that the stereochemical configuration of the second 
chiral carbon in the carboxvprop\l moiety exhibits a similar Cotton effect to the 
original chiral centre at this wa\ elength region, although the intensity of the Cotton 
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Figure 3.7: CD spectra presented from 185 to 280 nm for (a) (R)-ibuprofen 
and (S)-ibuprofen (b) (R)-hydroxyibuprofen and (S)-hydroxyibuprofen. 
Samples (0.3 mg/ml) dissolved in acetonitrile; pathlength 0.02 cm; spectra 
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Figure 3.8: CD spectra presented from 185 to 260 nm for (2'R, 2R)- 
carboxyibuprofen, (2'S, 2R)-carboxyibuprofen and (R)-ibuprofen. Samples 
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Figure 3.9: CD spectra presented from 185 to 260 nm for (2'S, 2S)- 
carboxyibuprofen, (2'R, 2S)-carboxyibuprofen and (S)-ibuprofen. Samples 




--------- (2'R, 2S)-carboxyibuprofen 


















185 WL(nm) 260 
Figure 3.10: CD spectra presented from 185 to 260 nm for (2'S, 2R)-, (2'R, 2R)-, 
(2'S, 2S)-, and (2'R, 2S)-carboxyibuprofen. Samples dissolved (0.3 mg/ml) 
in 
acetonitrile; pathlength 0.02 cm; spectra recorded at 25°C. 
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the case of the 2'1?, 21? - stereoisomer, the contribution of the two chiral carbons with 
similar stereochemical configuration was additive. yielding a greater negati\e 
absorbance, as compared with (1? )-ibuprofen. In the case of (2'. ti. 3/? )- 
carboxyibuprofen, the contribution of the two chiral centres are opposite. However, 
because the influence of the second chiral centre (2-carboxypropvl moiety) is 
weaker, the negative band is still obtained although the intensity is lower than that 
of (/? )-ibuprofen. The converse is also true with (2'S, 2Y) and (2'K, 2. ý)- 
carboxyibuprofen (Figures 3.9 and 3.10). 
As (R)-2-methyl-3-phenylpropionic acid is structurally similar to the carboxv 
propyl moiety of carboxyibuprofen, examination of its CD spectrum would provide 
information on the relative effects of the two chiral centres on the CD spectrum of 
carboxyihuprofen. The CD spectrum reveals an absorbance band at 221) nm with a 
negative Cotton effect. Comparison of the CD spectra with that of (1? )-ibuprofen 
showed that the Cotton effect observed was quantitatively weaker (1, i Bure 3.1 1). 
Addition of the CD spectrum of this compound with that of (1? )-ibuprofen yields a 
composite CD spectrum similar to that of (2'K, 2R)-carboxyibuprofen (Figure 3.12 ), 
which supports the observation that the relative contribution of the carboxypropyl 
and propionic acid moieties towards the CD spectrum are additive. Similarly, 
spectral addition with that of (S)-ibuprofen yields a composite spectra resembling 
that of (2'K, 2. ß')-carboxyibuprofen (Figure 3.13)). In this case when the absolute 
configurations of the carboxypropyl and the propionic acid moieties are opposite the 
Cotton effects are also of opposite sign and hence give a weaker resultant band. 
The CD spectra at the 260 nm region for (2'R, 2R)- and (2', S, 21R)- 
carboxyibuprofen were similar to that of (R)-ibuprofen and (R)-hydroxyibuprofen, 
reflecting the contribution of the 'Lb transition and the effect of the stereochemical 
configuration arising from the propionic acid moiety and minimal influence of the 
second chiral centre carbon. The converse is also true for (. S')-ibuprofen, 
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Figure 3.11: CD spectra presented from 185 to 280 nm for (R)-2-methyl-3- 
phenylpropionic acid, (R)- and (S)-ibuprofen. Samples dissolved (0.3 mg/ml) in 
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Figure 3.12: Composite CD spectrum presented from 185 to 260 nm after the 
addition of the CD spectrum of (R)-2-methyl-3-phenylpropionic acid and (R)- 
ibuprofen, overlaid with that CD spectrum for (2'R, 2R)-carboxyibuprofen. 
Samples dissolved (0.3 mg/ml) in acetonitrile; pathlength 0.02 cm; spectra 
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Figure 3.13: Composite CD spectrum presented from 185 to 260 nm after the 
addition of the CD spectrum of (R)- 2-methyl-3-propionic acid and (S)- 
ibuprofen, overlaid with that for (2'R, 2S)-carboxyibuprofen. Samples dissolved 
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Figure 3.14: CD spectra presented from 250 to 320 nm for (a) (R)-ibuprofen 
(b) (S)-ibuprofen (c) (R)-hydroxyibuprofen and (d) (S)-hydroxvibuprofen. 
Samples dissolved (1.0 mg/ml) in acetonitrile; pathlength 1.0 cm; spectra 
recorded at 25°C. 
108 







Figure 3.15: CD spectra presented from 250 to 320 nm for (a) (2'S, 2R)- and 
(2'R, 2S)-carboxyi buprofen (b) (2'S, 2S)-carboxyibuprofen (2'R, 2S)- 
carboxyibuprofen. Samples dissolved (1.0 mg/ml) in acetonitrile; pathlength 1.0 
cm; spectra recorded at 25°C. 
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3.4 Conclusions 
The carboxyibuprofen diastereoisomers were successfully resolked using a 
Chiralpak AD CSP and hexane-ethyl alcohol (92: 8, v 'v) containing TEA (0.050o % v) 
as mobile phase. Analysis of the synthesised pairs of diastereoisorners, and urine 
obtained following the oral administration of 50 mg (S)-ibuprofen revealed that the 
elution order of the carboxyibuprofen diastereoisomers was 2'S, 21Z-, 2'l?, 21? -, 2'!?, 25- 
and 2'S, 2S- respectively. The CD spectra of the individual diastereoisomers were 
compared with those of both (Il)- and (5)-ibuprofen, as well as (1? )- and (5)- 
hydroxyibuprofen. Generally the CD spectra for the respective enantiomers of 
ibuprofen and hydroxyibuprofen were similar. With the carboxvibuprofen 
diastereoisomers, major differences were seen only in the 225 nm band. The effect 
of the second chiral centre in the CD spectra \\ere similar, although quantitatively 
weaker in intensity than that of the original chiral centre %\ ith the same 
stereochernical configuration. Thus, with the and 2'S, 2S- diastereoisomers. 
stronger bands were observed at this region as compared with (l? )- and (. S)-ibuprofen 
respectively. When the second chiral centre is of opposite configuration, the 
intensity of this band is attenuated, although the direction is still the same, reflecting 
the weaker contribution of the second chiral centre. Consistent with the above 
observations, the CD spectra of (l? )-2-methyl-3-phenylpropionic acid when 
combined with that of (R)-ibuprofen and (, '; )-ibuprofen yields CD spectra similar to 
that of (2'1?, 2R)-carboxvibuprofen and (2'R, 25)-carboxyibuprofen respectively. 
The chromatographic system employed above is the first to resole e all four 
stereoisorners of carboxyibuprofen. The application of this methodology to the 
dc\ elopment of a sequential chromatographic technique for the determination of the 




Stereospecific Analysis of Carboxyibuprofen and 
Hydroxyibuprofen in Urine 
4.1 Introduction 
Compared with the large number of published methods for the determination 
of ibuprofen enantiomers in biological fluids (see Chapter 2 and references therein), 
there are relatively few methods for the analysis of carboxv ibuprofen and 
hydroxyibuprofen (Lockwood and Wagner, 1982: Shah and Jung. 1986, Chai cli al., 
1988; Geisslinger et ul., 1989), or that of their enantiomers (see below). in urine. 
This is quite surprising considering the significant interest in the stereoselective 
processes of ibuprofen metabolism. The reason for this is probably due to 
methodological difficulties presented as a result of the introduction of a second 
chiral centre in the carboxy metabolite, coupled «ith the lack of authentic standards 
of the individual isomers. An important pre-requisite for such metabolic studies is 
that specific, sensitive and reproducible analytical methods must be developed to 
quantitate the individual isomers of both metabolites in urine. The enantiospecific 
analysis of (1? )- and (S')-hydroxvibuprofen can be easily- achieved by aý ariety of 
methods (Kaiser ci ul., 1976, Young ei al., 1986, Baillie ci at., 1989, Rudy ei al., 
1990; Chen and Chen, 1994). However, it is the separation of the carboxyibuproten 
diastereomers that presents the biggest hurdle. A major problem with the analysis of 
the dicarboxylic acid metabolite being the lack of resolution two of the 
stereoisomeric metabolites (Kaiser ci ul., 1976, Young e/ at., 1986, Nicoll-Griffith 
ei ul., 1988, Baillie ei ul., 1989). Following the stereochemical assignment and 
chromatographic separation of the individual isomers of carboxvibuprofen as 
described in Chapter 3, this methodology is now developed into a sequential 
normal-chiral phase method for the stereospecific determination of hvdrow and 
carboxvibuprofen in urine. The normal-phase assay quantitates the total 
concentration of the individual hydroxy and carboxy metabolites in urine, the eluate 
from the column containing carboxy and hydroxyibuprofen are separately collected, 
dried and injected onto the chiral stationary phase for the determination of the 
stereochemical composition of the metabolites. 
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4.2 Experimental 
4.2.1 Chemicals and Reagents 
Dichloromethane, ethanol, ethyl acetate and hexane (HPLC (Trade) were 
purchased from Rathburn (Walkerburn, U. K. ). Trifluoroacetic acid, sodium 
dihydrogen phosphate and sodium hydroxide (Analar grade) and other organic 
solvents (GPR grade) were obtained from BDH (Poole, Dorset, U. K. ). 
Hexamethyldisilazane and 4-chlorophenoxyacetic acid were obtained from Sigma 
Chemicals (Poole, Dorset, U. K. ). (J?,. ')-, (K)- and (, 9-hydroxyibuprofen were a gift 
from Boots Ltd. (Nottingham, U. K. ). "Racemic" carboxyibuprofen was synthesised 
by Dr. J. A. Baker of University of Brighton, using the procedure outlined in 
Appendix 2. 
4.2.2 Chromatographic Columns and Supplies 
I'he Partisil silica column (250 x 4.6 mm, 5 pm) was obtained from 
Whatman (Maidstone, Kent, U. K. ). Refillable guard columns (10 x ?. 1 mm) were 
packed with pellicular silica (40-63 µm), both obtained from Alltech (Lanes, U. K. ). 
The chiral column a Chiralpak AD (amvlose tris(3,5-dimethvlphcnvlcarbamate)) 
column (250 x 4.6 mm, 10 µrn) was used with a matching guard column (5 x 4.6 
mm, 10 pin), was supplied by HPLC Technology Ltd. (Macclesfield, U. K. ). Merck 
GF,; 4 TLC plates were obtained from BDH (Poole. Dorset, U. K. ). 
4.2.3 Instrumentation 
Normal phase HPLC was performed using a LDC Constametric 3000 pump, 
a LDC Spectromonitor 3100 UV detector and a LDC C14000 computing integrator 
(Stone, Stalls). Samples were injected using a LKB ? 157 autosampler (Pharmacia, 
Ltd, Milton Keynes). Chiral-phase HPLC was performed using a LDC Constametric 
'000 punmp, a LDC Spectromonitor 3 100 UV detector and a LDC C14 100 computing 
H3 
integrator (Stone. Staffs). Samples were injected using a Perkin Elmer ISIS 100 
autosampler (Beaconsfield, Bucks, U. K. ). 
4.2.4 Preliminary Thin Layer Chromatography (TLC) Experiments 
Thin Layer chromatography was used to obtain preliminary solvent 
conditions prior to normal-phase HPLC. Aluminium backed TLC plates xtierc cut 
into 3x 10 cm strips. At a distance of 1.0 cm from the bottom edge of each strip 
were spotted ca. I tg amounts of (R,. ý')-hydroxvibuprofen, racemic 
carboxyibuprofen and blank hydrolysed urine extracted with diethylether (see 
section 2.2.6). The strips were separately developed using the following solvents: 
hexane, toluene, dichloromethane, ethyl acetate, chloroform and isopropyl alcohol, 
to determine the elution strength of the solvents with respect to the analytes. The 
plates were developed for a distance of 8 cm and spots were located under a short- 
wave UV light source. Based on these experiments, various mixtures of organic 
solvents were used in order to obtain R; values of 0.3 to 0.6 for the analytes, and 
trifluoroacetic acid (0.1 %) was added to the solvent mixtures to obtain more defined 
spots and reduce streaking. These `scouting' experiments provided preliminary 
solvent conditions for normal-phase HPLC. 
4.2.5 Development of an extraction method for the 
Carboxyibuprofen and Hydroxyibuprofen in urine. 
a) Silanization of glassware 
analysis of 
All glass tubes used in the extraction procedure were silanized prior to use. 
This was done by rinsing glass tubes with a solution of hexamethvldisilazane (100o, 
ýýiv) in dry toluene. The glass tubes w ere then placed in a hot air oven at 100°C for 
one hour. The tubes were then rinsed with methanol and further dried in the oven. 
The same procedure was also carried out for the glass pasteur pipettes used in 
extraction procedure. 
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b) Solvent Extraction 
For the determination of unconjugated metabolites, 0.5 nil aliquots of urine 
were used. To these samples were added 25 pg (50 tl of a 0.5 rng'ml solution in 
acetonitrile) of p-chlorophenoxyacetic acid as internal standard. The samples were 
then acidified by adding of hydrochloric acid (1.0M; 100µl) and buffered to pH 1.8 
with 1.5 ml of phosphate buffer (pH 3.8.1. OM). Dichloromethane: ethyl acetate 
(14: 1, v/v; 5 ml) was added and the extraction tubes were then tightly capped and 
mixed on a test-tube rocker for 20 minutes. Phase separation was achieved by 
centrifugation for 5 minutes at 1000g. The lower organic layer was then separated 
into a clean glass tube and evaporated under a gentle stream of nitrogen at 40" C on 
a dry heating block. The residue was then reconstituted in 150 t1 mobile phase and 
50µ1 was injected into the achiral HPLC system. 
For the determination of conjugated metabolite concentrations, 0.1 ml 
aliquots of urine were used. To these samples were added 2 µ`g (50 µI of a 0.5 
mg/ml solution in acetonitrile) of p-chlorophenoxyacetic acid and NaOH (1. OM, 
20µl). The hydrolysis reaction was left to proceed for 2 hours at room temperature, 
at the end of which HCl (I. OM, 40 [d), phosphate buffer (pH 3.8,1.0M, 200 µI) and 
dichlromethane: ethyl acetate (14: 1, v/v I ml) as extraction sol\ent were added The 
tubes were mixed and extraction carried out as before. All analysis of urine samples 
were done in duplicate. 
c) Chromatographic conditions 
1-he column used was a Partisil 5 silica column protected by a guard column 
filled with pellicular silica. The mobile phase consisted of hexane-ethanol (98.2: 1.8, 
vA, ) with 0.050o tritluoroacetic acid as modifier, run at a flow rate of 2 mI'min. The 
UV detector was set at 210 nm and the detector output was set at 0.0? a. u. f. s. 
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4.2.6 Validation of the normal-phase HPLC procedure 
Stock solutions of "racemic" carboxyibuprofen and hvdroxvibuprofen 
(1 mg/ml) were prepared in acetonitrile. Into six separate silanized . olumetric 
flasks (10 ml) were pipetted 0.1,0.2,0.4,0.8,1.6 and 3.2 ml of each solution. The 
solutions were evaporated gently under nitrogen gas. Blank drug-free urine was 
added to the flasks q.. sY. to 10 ml to give final solutions of 10,20.40,80,160 and 320 
. tg/ml of each metabolite respectively. On each day of analysis, 0.5 ml of these 
solutions were pipetted out into separate tubes and analysed. Calibration curves 
were constructed by plotting peak area ratios (metabolite: internal standard) against 
concentration of the metabolite concerned and subjecting this data to linear 
regression analysis. The concentration of urine and spiked samples were 
determined by comparing measured peak area ratios to the calibration curve 
prepared. 
The accuracy and within day variation of the assav was assessed by 
analysing six "spiked" samples each of the following calibration samples: 10,80 and 
320 pg/ml. The precision and accuracy of the assay was determined for each 
metabolite by calculation of the percentage coefficient of variation, CV°, o 
(S. D. /mean x 100%) and the mean percentage difference (mean concentration - 
actual concentration / actual concentration x 100%). The recovery of the extraction 
procedure was determined by comparing the peak areas obtained ýLith direct 
injections of standard solutions of the same concentration (n = 6). 
The between day variation of the assay was determined by analysing 
calibration urine samples of 10,80 and 320 µ ml concentration for 6 consecuti%e 
days. The coefficient of variation and accuracy were calculated as before. 
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42.7 Fraction collection 
The eluate from the HPLC containing carbox\ i R,, 12.6 min: traLtion 
collected between 12.2 and 13.0 min) and hydroxvibuprofen (R,, 15.8 min; fraction 
collected between 15.3 and 16.3 min) were separately collected from the detector 
outlet into silanized tubes. The eluent was gently e% aporated under nitrogen gas at 
40" C in a dry block heater and the residue reconstituted in 100 lal mobile phase and 
subjected to chiral analysis. In order to selectively collect the peaks of interest, the 
outlet tube from the detector was shortened as much as possible (10 cm) to reduce 
the lag time between detector response and the actual elution of the analvte from the 
detector outlet. 
4.2.8 Chiral-phase analysis of carboxyibuprofen and hydroxyibuprofen in 
urine. 
Standard metabolite solutions dissolved in mobile phase or eluate collected 
from the normal-phase analysis redissolved in the mobile phase used for chiral 
chromatography were injected in 50 µl aliquots onto the HPLC. The mobile phase 
was hexane-ethanol (92: 8, \/v) with tritluoroacetic acid (0.05°0, as modifier, 
run at a flow rate of 1 rnI/min. The detection wavelength was set at 220 nm. The 
column used was a Chiralpak AD column (250 x 4.6 mm, 10 µm) connected to a 
guard column containing similar material (5 x 4.6 nm nm, lOp m). 
The enantiomeric composition of each enantiomer of h`droxvibuprofen as 
determined as follows: 
Enantiorneric composition = 
Peak area of enantiomer 
Total peak area of both enantiomers 
117 
Individual concentrations of each enantiomer were calculated by multiplying their 
enantiomeric composition by the corresponding metabolite concentrations obtained 
from the normal-phase analysis. 
For carboxyibuprofen, the same approach was used, the total peak area being 
for all four stereoisomers. 
4.2.9 Validation of the chiral assay procedure. 
In order to determine whether the chiral HPLC method could produce 
accurate stereochemical compositions over a wide range of concentrations, the 
HPLC eluate from the validation experiments in section 4.2.6 were collected and 
subjected to chiral phase analysis. Enantiomeric ratios were determined for both 
metabolites and the coefficient of variation and mean percentage difference 
calculated. 
4.3 Results and Discussion 
When CSPs are used in bioanalysis, separation problems are often 
encountered due to the restricted choice of solvent conditions available. Also the 
presence of co-extracted contaminants may cause problems in analvte retention, 
resolution and column stability (Camillieri et at, 1994). Some of these problems 
associated with CSPs can be overcome by using coupled column chromatography, 
where drug concentrations are determined on an achiral phase and the appropriate 
fraction of the eluate transferred to a CSP via a switching valve to determine 
enantiomeric compositions (Oda et al., 1992). In our situation, the use of this 
technique seems relevant as the mobile phases used are compatible. However, a two 
step approach is adopted to obtain a high throughput of samples and to increase 
assay sensitivity in the chiral separation stage by concentrating the collected eluate 
before introduction into the CSP. 
1l .ý 
4.3.1 Normal-phase anal`sis of carboxvibuprofen and hydroxyibuprofen in 
urine 
The choice of normal-phase chromatography over reversed-phase 
chromatography for achiral analysis was based on the fact that the fractions 
collected would be more easily evaporated. Had rev ersed-phase chromatography 
been used, the aqueous solvents would have to be freeze-dried. This would 
probably result in substantial loss in the amount of metabolite recovered, and 
subsequently cause sensitivity problems with the chiral analy sis. Besides, salt 
residues from the buffer used in reversed-phase analysis may affect chiral-phase 
stability. 
The use of TLC as a preliminary method for obtaining initial sole ent 
conditions prior to normal-phase LC proved quite successful. From initial sole ent 
compositions of hexane: ethanol and hexane: isopropanol (9.5.0.5, containing 
trifluoroacetic acid (0.1% v/v), it was apparent that the hexane-ethanol mixture gave 
better separation between carboxyibuprofen and hvdroxvibuprofen. Solvent 
composition was finally optimised at hexane-ethanol (98.2: 1.8, v, v) and the 
proportion of trifluoroacetic acid was fixed at 0.05% v, vv as the percentage of 
modifier did not appear to have much influence on either analvte retention or 
resolution at concentrations of 0.05 to 0.1 °o viv. Under the conditions used, the 
retention times of the internal standard, carboxvibuprofen and hydroxyibuprofen 
were 4.9,12.6 and 15.8 minutes respectively (Figure 4.1). The resolution factor 
between the latter two peaks are calculated to be 1.5. 
UV Detection was set at 220 nm to increase sensitivity as the 
phony lpropionic moiety has low molar absorptivity at higher wa%elengths. Although 
it was realised that the shorter wavelength could potentially cause difficulties when 
measuring extracts from urine due to high background noise from endogenous 
materials, with a careful choice of sample preparation conditions and the relati\ elv, 
high concentrations of analk-tes in urine, these problems were avoided. Also. the 
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major constituents of the mobile phase are hexane and ethanol, both of which have 
relativ elv good UV transmittance at 220 nm. thus increasing assay stnsiti\ it`- . 
4.3.2 Extraction procedure for carboxyibuprofen and hydroxv ibuprofen in 
urine 
A chromatograrn showing the clean chromatographic baselines achie,, ed 
with blank hydrolysed urine following treatment with sodium hydroxide is shown in 
Figure 4.1. No interferences were seen at the retention times of either 
carboxyibuprofen and hydroxyibuprofen at the level of sensitiv itv used. The choice 
of dich loromethane: ethyl acetate (14: 1, was arrked at after much 
experimenting with various solvents. Dichloromethane ga\ c the cleanest extracts 
but recovery was only 40% with a single 5 ml extraction. This is consistent with the 
observation by Rudy el a/., (1990) where a2x7 ml extraction procedure was used. 
Mixtures of dichloromethane and ethyl acetate were experimented with and it as 
found that a proportion of 14: 1 v/v was found to give good recoveries (Tables 4.1 
and 4.2) with low background noise. 
For the hydrolysis of conjugated metabolites, the urine samples are usually 
hydrolysed either by acid (Nicol-Griffith ci ul., 1988; Chai ei al., 1988 and Rudy 
al., 1990) or by base (Lockwood and Wagner. 1983. Baillie el al.. 1989, Geisslinger 
cl al., 1989) under mild conditions in order to avoid racemization. Here the 
procedure of base hydrolysis for the cleavage of the ester glucuronides as 
essentially similar to that used for the determination of ibuprofen in urine. 
4.3.3 Validation of the normal-phase method. 
The analytical procedure showed good precision and accuracy x%hile 
extraction recoveries were generally- better than 900,6 for both metabolites at all 
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"fable 4.1: (a) Within day %ariation, accuracy and extraction recoveries of 
carboxyibuprofen in "spiked" urine samples (n=6) and (b) between day 
variation and accuracy of carboxyibuprofen in spiked urine samples (n=6). 
(a) 
Concentration Concentration Coefficient of Mean Percent Recovery 
(µg/ml) Determined (µg/ml) Variation (CV%) Difference (ooh 
10 10.22+0.33 3.2 2.16 94.2+3.0 
80 79.94+0.46 0.6 -0.08 93.1 +0. 
320 11 322.9 +11.82 3.7 0.93 90.5 + 3. 
(b) 
Concentration Concentration Coefficient of Mean Percent 
(4g/ml) Determined (4g/ml) Variation (CV%) Difference 
10 9.66 +0.68 7.0 -x. 40 
80 82.68+6.67 8.1 3.36 
320 325.7 + 30.9 8.0 1.79 
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Table 4.2: (a) Within day variation, accuracy and extraction recoveries of 
hydroxyibuprofen in "spiked" urine samples (n=6) and (b) between to day 
variation and accuracy of hydroxyibuprofen in spiked "urine" samples (n=6). 
(a) 
Concentration Concentration Coefficient of Mean Recover` 
(µg/mI) Determined (µg/m1) Variation (CV%) Percent (0,0) 
Difference 
10 10.24+0.70 6.8 2.36 96.6+6.6 
80 79.85+2.23 2.8 -0.18 97.1+2.7 
320 320.7+ 16.8 5.2 0.21 93.2 -+4.9 
(b) 
Concentration Concentration Coefficient of Mean Percent 
(pg/m1) Determined (µg/ml) Variation (CV°ö) Difference 
10 9.91 +0.70 7.0 -0.92 
80 80.3 7+4.3? 5.4 0.46 
320 314.5+30.7 9.8 -1.73 
(1ý 
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good consistency and accuracy (Tables 4.1 and 42). Typical calibration curves for 
both metabolites are shown in Figure 4.2. Linear regression analysis showed 
regression coefficients of better than 0.997. The limit of quantitation for the 
procedure was at least 10 jtgi'ml urine. A lower limit of detection can be easily 
achieved by analysing a larger volume of urine or by injecting a larger proportion of 
the extract on-column. However, this is not necessary in this case as the quantity of 
analytes in urine resulting from a typical oral dose of ibuprofen is relatively high. 
4.3.4 Chiral separation of carboxyibuprofen and hydrox3, ibuprofen 
enantiomers 
The HPLC conditions used for the chiral analysis were similar to those used 
in Chapter 3 for the initial resolution of the stereoisomers of carboxvibuprofen. 
Under these conditions the retention times of the 2', x', 21? -, and 
2'S, 2S- isomers of carboxyibuprofen were at 11.0,12.16.9 and 20.1 minutes 
respectively. (Figure 4.3). The resolution factors for the four peaks were 1.3,3.3 
and 2.4 respectively (Figure 4.3), indicating very good baseline separation, when 
compared to work published previously (Kaiser el ul., 1976, Baillie ei al., 1989 and 
Rudy el al., 1990). The same mobile phase conditions were also used for the 
analysis of hydroxyibuprofen. The elution order of the enantiomers was confirmed 
by injection of authentic enantiorners. Here the Iz-enantiomer eluted before its S- 
antipode, with retention times of 13.9 and 16.1 minutes respectively. The separation 
was baseline with a resolution factor of 1.6 (Figure 4.4). 
The sequential normal-chiral phase approach, although tedious, proved to be 
rather successful. As can be seen from the blank urine eluate, the collected fractions 
were generally free from interferences. Had the urinary extracts been injected 
directly into the chiral phase, there would be co-elution of (R)-hydroxyibuprofen 
with (2'!?, 2i? )-carboxyibuprofen and (S)-hydroxyibuprofen with (2'R, ? S)- 
carboxyibuprofen under the conditions used. Although these can eventually be 
separated by using hexane : ethanol: methanol (95: 3.5: 1.5, v v) with trifluoroacetic 
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Figure 4.2: Typical calibration curves prepared from the quantitation of 
(a) carboxý ibuprofen and (b) by droxy ibuprofen using the normal phase HPLC 
assay. 
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Figure 4.5: Chiral-phase chromatogram of a mixture of carboxyibuprofen 
and hydroxyibuprofen analysed %% ith a solvent composition of 
hexane: methanol: ethanol (95: 3.5: 1.5, %/, %) N, ith trifluoroacetic acid (0.05%,, 
N/%). Retention times, peak I (2'S, 2R)-carboxyibuprofen: 20.9 min; peak 2 ((R)- 
hvdroxyibuprofen): 23.0 min; peak 3 ((2'R, 2R)-carboxyibuprofen): 25.4 min; 
peak 4 ((S)-hvdroxvibuprofen): 31.6 min; peak 5 ((2'R, 2S)-carboxvibuprofen): 
38.9 min: peak 6( (2'S, 2S)-carboxyibuprofen): 49.4 min. 
i, 8 
poorer and long retention times would be involved (Figure 4.5). By separately 
analysing the carboxv and hydroxvibuprofen fractions. better resolution was 
achieved and the sum of the retention times were the same. 
Analysis of standard solutions of racernic carboxvibuprofen yielded peak 
areas with stereoisomer ratios of 0.25 each. Similarly, enantiomeric ratios for (1? )- 
and (S)-hydroxyibuprofen enantiomers were 0.5. 
4.3.5 Validation of the chiral analytical method 
The chiral analysis method was validated by assaying the material in the 
eluate collected from the normal-phase validation experiments. These validation 
experiments are essential to determine whether the chiral assay, was able to 
reproduce the expected enantiomeric compositions precisely and accurately 
throughout the entire analytical procedure and over the range of analyte 
concentrations. The precision and accuracy values of the calculated enantiomeric 
ratios for both metabolites are shown in Tables 4.3 and 4.4. The results indicate that 
there was very little variation from the expected stereochemical compositions over 
the wide range of concentrations examined, indicating that metabolite concentration 
does not result in the chiral discrimination using the sequential chromatographic 
approach. Moreover, even at the lowest concentration used (10 pg/mI), the chiral- 
phase procedure was sufficiently sensitive to determine the stereochemical 
composition of the two metabolites in the eluate from the normal-phase system in a 
reproducible manner. The eluate was generally free of interfering substances that 
would have otherwise affected the measured enantiomeric compositions. Thus the 
measurement of enantiomeric ratios using the method described is accurate and 
precise. 
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Table 4.3: (a) Within day variation and accuracy and (b) between day 
variation and accuracy of stereochemical composition determined by the 
analysis of the eluate from normal-phase analysis of urine samples "spiked" 
with carboxyibuprofen (n=6). 
a) 
Concentration Isomer Stereochemical Coefficient of Mean Percent 
(p. g/ml) composition Variation (C V° o) difference 
(mean + sd) 
10 2'S, 21? 25.05+ 1.24 4.99 0.21 
2'1Z, 2R 25.10+ 1.79 7.13 0.41 
2'1?, 2S 25.01 ± 0.51 2.04 0.04 
2'S, 2S 24.84+2.42 9.75 -0.66 
80 2'S, 2/? 24.97+0.71 2.87 -0.13 
211,211 25.05+ 1.52 6.10 0.22) 
2'IZ, 2.1; 24.99+0.97 3.87 -0.05 
2', ß, 2S 24,99+ 1.17 4.68 -0.03 
320 2'S, 2/? 25.04 ± 1.34 5.34 0.1 4 
2'R, 2/? 25.01 ± 1.04 4.16 0.02 
2'1z, 2. ß' 24.99+ 1.20 4.81 -0.03 
2'S, 2S 24.97 + 0.59 2.36 -0.13 
}_; {; 
Table 4.3 (cont'd) 
(b) 
Concentration Isomer Stereoisomeric Coefficient of Mean Percent 
(µg/m1) composition Variation (CV°ö) difference 
(mean + sd) 
10 2'S, 2R 24.99+ 1.05 4.21 -0.06 
2'R, 2R 25.07+ 1.75 6.98 0.26 
2'R, 2S 24.99+ 1.14 4.55 -0.04 
2'S, 2S 24.96+0.47 1.88 -0.17 
8 0 2'S, 2R 24.98 ± 0.35 1.41 -0.07 
2'1?, 2R 25.02 ± 1.02 4.06 0.09 
2'R, 24.98 ± 0.33 1.31 -0.08 
2'S, 2. ß' 25.02+0.47 1.87 0.06 
320 2'S, 21? 25.06 ± 1.66 6.63 0.22 
2'R, 2R 24.97 ± 0.73 2.94 -0.13 
2'1?, 2. ß' 25.02+ 1.66 6.65 0.06 
2', ß', 2, t 24.96 + 0.88 3.52 -0.15 
i"1 
Table 4.4: (a) Within day variation and accuracy and (b) between da,, 
variation and accuracy of stereochemical composition determined by the 
analysis of the eluate from normal-phase analysis of urine samples "spiked" 
with hydroxyibuprofen (n=6). 
(a) 
Concentration Isomer Enantiomeric Coefficient of Mean Percent 
(µg/ml) composition Variation (CV°o) difference 
(mean + sd) 
10 1l 50.00+0.36 0.71 0.00 
S 50.00+0.36 0.71 0.00 
80 K 50.02+ 1.61 21 0.04 
S 49.98+ 1.60 3.21 -0.04 
320 1? 50.00+0.98 1.96 0.01 
S 50.00+0.98 1.96 0.00 
(b) 
Concentration Isomer Enantiomeric Coefficient of Mean Percent 
(pg/mi) composition Variation (CV%) difference 
(mean + sd) 
10 1? 50.05+2.50 5.00 0.09 
49.95+2.50 5.01 -0.09 
80 1? 50.05 + 1.39 2.77 0.10 
S 49.95 + 1.38 2.77 -0.10 
X20 R 50.1? + 1.68 3.35 0.25 




In summary, a reliable normal-phase HPLC assay for the determination of 
carboxyibuprofen and hydroxyibuprofen in urine has been developed and validated. 
The chiral-phase HPLC method developed was also validated and found to he 
suitable for the determination of enantiomeric composition of the metabolites in 
urine. The methodology described above is the first reported method for the 
determination of the stereochemical composition of the two major metabolites of 
ibuprofen in urine involving sequential achiral-chiral chromatography and the first 
method in which the stereoisomers of carboxyibuprofen can be individually 
quantified following the administration of the racemic drug. The previously 
reported methods for the analysis of this metabolite have all resulted in co-elution of 
two of the stereoisomers or their derivatives (Kaiser c'l cil.. 1976, Young cl al., 1986; 
Nicoll-Griffith el at., 1988; Baillie et al., 1989) or involved long retention times (run 
times of greater than 1 hr) (Rudy et al., 1990) and also the chromatographic peaks 
could not be conclusively identified as to their stereochemical configuration, due to 
the lack of available reference compounds. The application of the above 
methodology to the analysis of the metabolites, both free and conjugated with 





Determination of Serum Protein Binding 
of the enantiomers of Ibuprofen 
134 
5.1 Introduction 
When drugs enter the systemic circulation, they are in\ariabl\ reversibl\ 
bound to plasma proteins. Although human plasma contains over 60 different 
proteins, it is mainly albumin and or, -acid glycoprotein which principally act as 
transport proteins for endogenous and exogenous substances. Generally. albumin 
tends to be the principal binding protein for acidic drugs such as the NSAIDs, while 
o!, -acid glycoprotein tends to bind principally to basic drugs like the ß-blockers and 
quinidine (Lin el ul., 1987; Wallace and Veerbeck, 1987). The types of molecular 
interaction involved in drug-plasma protein binding include ionic, hydrogen and 
dipole interactions, and the binding process is assumed to obey the Law of Mass 
Action, i. e. 
drug + protein ý__ý drug - protein complex. 
Thus the drug-protein complex act as a reservoir that releases more drug as free drug 
is metabolised or excreted (Mehta, 1989). 
As only unbound drug is able to diffuse across biological membranes and 
interact with receptor sites to elicit a response, the ability to measure drug-plasma 
protein binding and to understand the effect of this binding on drug disposition is 
therefore important. Moreover, protein binding has been shown to exhibit 
stereoselectivity. For example, the R-enantiorner of ibuprofen and the S- enantiomer 
of warfarin are more strongly bound to plasma proteins than their respective 
antipodes (Toon and Trager, 1984; Evans et al., 1989). Thus, the study of the 
stereoselectivity of plasma protein binding for chiral drugs like ibuprofen, and the 
factors that affect it, are very relevant in a pharmacokinetic study. 
There are two general approaches to the study of plasma protein binding. In 
the first, only the free drug concentration is determined with respect to the total 
plasma concentration, to give a measure of the extent of the binding. The 
techniques involved here include equilibrium dialysis, ultrafiltration, 
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ultracentrifugation and liquid chromatography, and these approaches yield sufficient 
information for pharmacol: inetic studies. In the second approach, the quantitati\ e 
relationship between the ligand and the protein is examined. The bound and free 
drug concentration data are then fitted in various Scatchard t\ pe plots to yield 
information on binding affinity, capacity and the number of binding sites invoked. 
Using these models, the interaction between the ligand and between ligand 
enantiomers can be analysed. For the purpose of the present study, the first 
approach was considered to be most relevant. 
5.1.1 Methods used for measuring plasma protein binding 
A variety of methods can be used to measure plasma protein binding and the 
relative merits of each have been the subject of several reviews (Rowland, l980, I in 
ci ul., 1987; Mehta el al., 1989). Equilibrium dialysis is the most popular method by 
far and is the reference method by ww hich other methods are compared. Plasma 
samples containing both free and bound drug and drug free isotonic buffer are 
placed on either side of a semi-permeable membrane. Unbound drug from plasma 
diffuses through the membrane and at equilibrium, the concentration of the drug in 
the recipient buffer solution and that unbound in the plasma sample are equal. 
Analytical determination of the drug concentration on both sides of the membrane 
will thus enable the free fraction to be calculated. Equilibrium dialysis is relatively 
inexpensive and yields satisfactory results but factors such as temperature, pH of the 
recipient buffer, buffer composition and dialysis time may significantly affect 
results and need to be defined. The major disadvantage of the approach is that of 
volume shifts during dialysis caused by difusion of water from the buffer 
compartment to the "protein" side of the dialysis cell. When volume shifts are 
substantial and unbound concentrations are low, a correction factor must be applied 
(Lockwood and Wagner, 1983; Lima cl (i!., 19833). This problem is aggra\ ated in 
cases where protein binding is concentration dependent and results in such instances 
need to be interpreted \v ith caution (Huang, 1983). 
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Ultrafiltration is another popular technique, which with the recent 
availability of specially designed centrifugal devices is being increasingly used. . =A 
typical device consists of a sample reservoir and filter unit containing a low 
absorption membrane with a molecular weight cut-off of about 30,000 Daltons (D). 
The plasma sample containing drug is placed in the sample reservoir and the unit 
centrifuged at the required g-force for an appropriate time under conditions of 
controlled temperature. The protein free ultrafiltrate collected beyond the 
membrane is analysed to assess the free drug concentration . 
The method is fast, 
easy and reliable, although the filter devices are relatively expensive. The biggest 
setback of this method is that of drug-binding to the membrane, which should be 
investigated before application of the method. This is usually carried out using 
radiolabelled drug (Mehta, 1989). 
Ultracentrifugation, which involves separating free drug from the drug- 
protein complex by high speed centrifugation is theoretically the ideal method as it 
neither disrupts equilibrium or results in sample dilution. Hovvex er, it requires an 
expensive centrifuge, large volumes of sample and long centrifugation times. It is 
also susceptible to variations caused by drug binding to the tubes and low density 
lipoproteins, which rise to the top of the tube during centrifugation (Rowland, 
1980). 
An alternative technique involves gel-filtration or size exclusion 
chromatography, the unbound drug being trapped in the pores of the gel of the 
stationary phase, while large protein molecules pass through the column relatively 
unimpeded. The eluate containing the free drug is collected and then analysed. The 
method is simple but problems arise if on-column dissociation of the drug-protein 
complex occurs. Also, relatively large samples are required and it is generally more 
useful for in-vilro binding studies (Rowland, 1980). 
Other methods such as differential spectrophotometry, circular dichroism, 




drug-protein solutions are less commonly used methods- which are employed for an 
examination of the mechanistic aspects of drug-protein binding, (Lin cI al., 1987). 
5.1.2 Analytical requirements for the determination of unbound drug 
For drugs which are highly protein bound, e. g warfarin, phenvtoin and the 
2-APAs, free drug assays need to be very sensitive as extremely low concentrations 
are encountered. Often this analytical requirement necessitates the use of 
radiolabelled drugs of high specific activity (Rowland, 1980). However, the 
radiolabelled material must be of high purity, both chemical and radiochemical, 
otherwise misleading values will be obtained (Bjornsson el cal, 1981). In the case of 
ibuprofen, previous studies have indicated that protein binding is greater than 99% 
(Gallo et al, 1986) and that the binding is stereoselectiv e for the R-enantiomer 
(Evans c/ a!., 1989). Thus, with total drug enantiomer concentrations cypccted 
between I- 20 pg/ml, free concentrations in the loxv nanogram per mI range for 
both enantiomers of ibuprofen are expected and the analytical method used requires 
a minimal quantifiable limit in this range. 
In order to study the enantioselectiN e disposition of ibuprofen in human 
volunteers, an HPLC method with adequate sensitivity for the direct analysis of the 
free concentrations of ibuprofen enantiomers was developed and is described 
below. This method is a modification of that developed for serum and urine samples 
described in Chapter 2 and determines directly free drug concentrations Nv ithout 
resorting to radiolabelled compounds. During the course of the investigations 
described in this chapter, a sample of radiolabelled [14C]-ibuprofen became 
available and additional validation experiments were carried out by comparison of 
the results obtained using the developed assay with a previously published 
radiochemical procedure (Evans cal al., 1989). Equilibrium dialysis was preferred 
over the other methods of determining free concentrations because of the advantages 




5.2.1 Chemicals and materials 
Sodium dihydrogen phosphate, disodiurn hydrogen phosphate and sodium 
chloride (Analar grade) were obtained from BDH (Poole, Dorset). Dial\ sis 
membranes (Spectrapor 2) were obtained from Pierce and Warriner (Chester, U. K. ). 
Protein Assay reagents based on the Coomasie blue method were obtained from Bio- 
Rad (Herts, U. K. ). Stainless steel Resolve Cis column (150 x 3.9mm, 5 hum) and 
Radialpak Resolve C1R HPLC cartridges (100 x6 mm, 5 pin) \ere obtained from 
Anachern (Luton, Beds., U. K. ). Radiolabelled [14C. ]-ibuprofen ww ith specific acti\ itv 
of 21.6 mCi/g was donated by Knoll Pharmaceuticals (Nottingham). The liquid 
scintillation cocktail used was Quickscint flow 302 (Zinsser Analytical, Berkshire, 
U. K. ). Liquid scintillation determinations were carried out usin an [KB Wallac 
1209 Rackbeta liquid scintillation spectrometer (Milton Keynes, [1K. Dialysis cells 
made of perspex, of internal volume of 1.25 ml and the dimensions of \ý hich are 
given in Appendix 7 were made in the Pharmacy Department workshop of King's 
College London. Other reagents and materials ý\ere similar to those listed in section 
2.2.1 
. 
5.2.2 Purification of '4C1-ibuprofen. 
The radiolabelled ibuprofen was purified by HPLC prior to use. 
Ibuprofen (3 mg) was dissolved in acetonitrile (1 ml) and -50 µI aliquots were 
injected onto a reversed-phase Resolve Ci8 column (150 x 4.6 mm, 5 µm) \ýith a 
mobile phase of acetonitrile: water (40: 60, v; 'v) with the pH adjusted to 3.5 with 
hydrochloric acid (1.0 M) at a flow rate of 1 ml, 'min. Detection was by UV, set at 
220 nm. The eluate containing ibuprofen \vas collected from the detector outlet into 
a 100 ml pear shaped flask. The combined eluate (from 20 injections) was then 
pooled and the solvent evaporated to half its volume under nitrogen gas at 40T. 
Hexane: i sopropanol (9: 1. v: 2S rn I) was added as extraction sole ent and the 
13() 
mixture well shaken. The solvent mixture \-., as allowed to separate and the 
supernatant organic layer was transferred into a 50 ml pear shaped flask and 
evaporated to dryness under nitrogen gas. The chemical purity of the product was 
subsequently determined by redissolving a portion of the residue in mobile phase 
and reinjecting it onto the HPLC system. Purification of the radiolahelled drug' as 
performed immediately prior to use in subsequent equilibrium dialysis experiments. 
5.2.3 Equilibrium dialysis 
Spectrapor 2 dialysis membranes were cut into 3. x 3.5 cm squares and 
soaked overnight in phosphate buffered saline. Prior to use, the membranes were 
carefully placed between the two halves of the dialysis cells and the cells held in 
place using the screws provided. Serum samples ('I xI ml) were carefully 
transferred into three adjacent dialysis cells. Equal volumes of phosphate buffered 
saline were transferred into the opposite sides of the membranes. The ports of the 
cells were then sealed using plastic stoppers and the cells placed in a shaking «ater 
bath set at 37°C and a shaking frequency of 30 strokes per minute. The cells were 
then allowed to equilibrate for a preset equilibrium time of 8 hours (see section 
5.2.5). 
5.2.4 Determination of protein concentration 
The protein concentration of the serum samples before and after dialysis 
were determined using the Coomasie blue procedure (Bio-Rad Protein Assay kit) in 
order to correct for possible volume shifts during the dialysis experiments. Serum 
samples (25 µl) were diluted 1: 40 (v/ý) with phosphate buffered saline. Protein 
standard solutions consisting of 0,0.0875,0.175,0.35,0.7 and 1.4 mg ml bovine 
serum albumin in phosphate buffered saline. The standard solutions or diluted 
serum samples (100 µl) were pipetted into 10 ml dry test-tubes and 5.0 ml of 
CIoomasie dve reagent (> ml) was added to each tube. After gentle mixing, the 
14 0) 
solutions were left to react for five minutes and the absorbance at 595 nm was then 
determined. Standard calibration curves were constructed using the protein standard 
solutions and the protein concentrations of the serum samples were determined 
against this calibration curve. The ratio of the protein concentrations (F) after and 
before dialysis were determined for each serum sample. 
5.2.5 Determination of time to achieve equilibrium 
To determine the time required for drug concentrations to reach equilibrium 
across the membrane, an experiment with radiolabelled drug was carried out. 
Radiolabelled ibuprofen was dissolved in acetonitrile added to phosphate buffered 
saline to obtain a concentration of 15 pg/ml of racemic drug. The solution was then 
dialysed against drug free phosphate buffered saline. Aliquots (25 µI) were taken 
from both sides of the dialysis cells were removed at regular (hourly intervals from 0 
-5 hours, then 2 hourly from 5 to 9 hours) and the radioactivity determined. The 
radioactivity (expressed in dpm) of the donor and recipient samples were plotted 
against time of sampling to determine the time to achieve equilibrium. This 
procedure was repeated twice (n = 3). 
5.2.6 Analysis of ibuprofen enantiomers in equilibrium dialysate 
(a) Column packing procedure 
A semi-microbore (2.1mm i. d. ) column was packed in-house in order to 
achieve an increase in mass detectability of the HPLC procedure. An empty HPLC 
column was constructed out of an empty stainless steel tubing (150 x 2.1 mm), one 
end of which was attached a Swagelok compression fitting with a2 pm stainless 
steel frit. The empty column was attached to I-[PLC column packer set in an upward 
packing configuration. Loose Resolve C iR media was obtained by emptying a 
Resolve CIK radialpak cartridge. A 1.5g portion was transferred into a 100 ml 
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conical flask. The powder was suspended in 10 ml of methanol and sonicated for 5 
minutes. The suspension was then quickly transferred into the resew oir of the HPLC 
column packer and the solvent lines were quickly attached. The column was packed 
at a pressure of 400 bar using isopropanol as sole ent. After about 30 ml of sole ent 
had eluted, the column was then switched to a downward position and packing 
continued until another 30 ml of solvent had eluted. The packing solvent was then 
changed to methanol and packing continued until another 30 ml of sole ent had 
eluted. The column was removed after residual pressure had dissipated and the 
second Swagelok end-fitting attached. The column was then attached to the HPLC 
and equilibrated with acetonitrile at a flow rate of 0.2 ml. 'min overnight. 
(b) Extraction procedure 
To the dialvsate buffer (2.5 ml: the contents of three cells combined) was 
added flurbiprofen internal standard solution (5 tg /ml in acetonitrile, 25 ph, 
followed by 0.5 ml HCl (1. UM) and 2 ml of phosphate buffer (I. OM, pH 3.8). and 
the whole extracted with hexane: isopropanol (9: 1, v/v, 5 ml) as described previously 
(section 2.2.4 (c)). 
(c) Derivatization 
To the dry residues were added 30 µg each of CDI, HOBT and (IR)-NEA 
(30µl of aI rng/ml solution in dichloromethane). The tubes were then tightly 
capped and the derivatization carried out as described in section 2.2.5 (b). The final 
residues were dissolved in 50 µl of HPLC mobile phase and 30 µl was injected into 
the H PLC. 
(d) Chromatography 
The semi-microbore column packed using the procedure described in 
5.2.6(a) was used. The mobile phase was 50.50 (v/v) mixture of phosphate buffer 
(0.01M, pH 3.5): acctonitrile at a flow rate of 0.6 ml'min. Detection was by 
}4? 
fluorescence with excitation and emission wavelengths set at 290 and 330 nm 
respectively . 
Calibration curves were constructed from analysis of dialv'satc 
solutions "spiked" with racemic ibuprofen to obtain concentrations of f, 10,20.40. 
80 and 160 ng/ml of each enantiomer. The concentration of each enantiomer in the 
dialysate samples were determined by comparing their respecti\e peak area ratios 
(ibuprofen enantiomer: (S)-flurbiprofen derivatives) to the calibration cure e 
prepared and the unbound fraction (fu ') determined by comparing the enantiorner 
concentrations with the corresponding total (free and bound) enantiomer 
concentration of the samples determined using the serum assay procedure (Chapter 
2). The unbound fractions were then corrected for volume shifts using the 
following equation (eqn 5.1 ): 
f = f' x F/( 1',, ' xF+1- f') (eqn 5.1) 
where F is the ratio of the serum protein concentration after and before dialysis, and 
f,, is the unbound concentration after volume shift correction (Huang, 1983). 
(e) Validation of the HPLC procedure 
A stock solution of I mg/10 ml of (/?, S)-ibuprofen in acetonitrile was 
prepared and aliquots of 10,20,40,80 , 
160 and 320 il were pipetted into six 100 
ml volumetric flasks. The solvent was evaporated gently under nitrogen and drug 
free dialysate buffer was added q. s. 100 ml to give concentrations of 5,10,20,40 
, 
80 and 160 ng/mI of each enantiorner. On each day of analysis, 2.5 ml of these 
solutions were pipetted out into separated tubes and analysed. Calibration curves 
were constructed based on these data. The accuracy and within day variation of the 
assay was determined by analysing the calibration samples of 5,40 and 160 n, -'ml 
concentrations repeatedly (n=6). The recovery of the extraction procedure was 
determined as before (section 2.2.5(d)), by comparing peak areas obtained with 
direct injections of standard solutions of equivalent concentrations of the drug 
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Between day variation was determined by analysing the same solutions over six 
separate days. 
5.2.7 Validation of HPLC procedure against the radiolabelled method 
The HPLC method described above was compared with a published 
procedure using radiolabelled ibuprofen (Evans et al., 1989). Serum samples 
"spiked" with 5,10 and 20 tg/ml of each ibuprofen enantiomer were used for this 
validation experiment. Aliquots of serum samples (3 xI ml) were transferred into 
three dialysis cells. Into each cell was also added 20 µl of ['4C]-ibuprofen (0.35 
mg/ml) dissolved in human serum albumin solution (4 % w, "vi in water) . 
On the 
opposite side of the cells (recipient) were placed equal volumes of phosphate 
buffered saline. The cells were then incubated as described above (section 5.2.3). 
After incubation, a 400 pi aliquot of serum and buffer were removed from the cells 
and placed in separate scintillation vials along with 12.5 ml scintillation cocktail. 
The radioactivity was then determined using a liquid scintillation spectrometer. The 
ratio of the radioactivity between the donor and recipient sides of the cells 
(expressed in dpm) was then calculated. 
A 2.5 ml portion of the recipient buffer was extracted, derivatized and 
analysed as described in section 5.2.5. The eluate containing the radiolabelled 
diastereoisomeric amides were collected from the detector outlet and transferred 
into separate scintillation vials and the radioactivity determined as before (dpm 1? -B 
and dpm ti' -B). The procedure was repeated using 200 µ1 of equilibrated serum 
(dpm R -P and dpm S -P). The unbound fraction of (R)-ibuprofen was determined as 
dpmB dpmR- B f"R 
dpm P dpmR-B + dpmS-B 
dpmR -P 
dpmR-P + dpmS-P 
(eqn 5.2) 
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and that of (S)-ibuprofen as: 
dpm B 
fU, s = dpm Px 
dpmS -B 
dpm l? - B+ dpm S-B 
dpm. ti' -P 
dprnI? -P+ dpm. ý -P 
(eqn 5. ') 
Free enantiomer concentrations were calculated by multiplying the respective 
unbound fraction values by the total (bound and unbound) enantiomer 
concentration. The results obtained for the free concentrations and unbound 
fractions for the individual enantiomers were compared to those obtained for the 
same serum samples analysed directly by the HPLC procedure. 
5.3 Results and Discussion 
5.3.1 Purification of ß'4C1-ibuprofen 
Based on peak areas, the purity of the radiolabelled ibuprofen before 
chromatographic purification was about 96% and after purification it was estimated 
to be 99%, based on peak areas. The purification process \vas carried out prior to 
use in order to ensure radiochemical purity. A preliminar dialysis experiment as 
carried out to compare the extent of protein binding in spiked serum samples (20 
p. g/m I) of the radiolabelled drug before and after HPLC purification. Based on dpm 
values of the serum and dialysate buffer samples, the unbound fraction for total 
ibuprofen was estimated to be 1.8% before purification and 0.5% after purification. 
This is consistent with previously reported findings (Evans et a/., 1989). Thus, it is 
obvious that purification of the radiolabelled material is essential to obtain an 
accurate estimate of the extent of protein binding and that \ ariations in results from 
previously published findings may depend on the how rigorously this purification 
process is carried out. 
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5.3.2 Determination of time to achieve equilibrium 
A plot of radioactivity versus time for both the donor and recipient 
compartments of the dialysis cells is shown in Figure 5.1. Equilibrium was achie%ed 
after about 8 hours and as such this was used as the incubation time for subsequent 
dialysis experiments. 
5.3.3 HPLC analysis of ibuprofen enantiomers in equilibrium dialysate 
The assay procedures used to determine the free enantiomer concentrations 
are basically similar to those developed for drug enantiomer analysis in serum and 
urine (Chapter 2). Much larger volumes of samples and dialysate buffer were 
required compared to those used previously in order to increase assay sensitivity and 
as a result of this, the volumes of extraction buffer and acid had to he 
proportionately increased in order in ensure sufficient buffering capacity. In 
addition 30 µg each of the derivatizing reagents were used instead of the 100 tg 
normally used in the analysis of serum and urine samples. This proportionate 
decrease was necessary in order to control the background noise in the 
chromatographic analysis, which was critical as only low nanogram amounts were 
injected on-column. The validation experiments in the serum analysis showed 
reliable quantitation down to 100 ngi'ml (see Chapter 2). Further efforts to reduce 
the limit of quantitation revealed a lower limit of 25 ng on column. To achieve a2 
to 3 fold increase in assay sensitivity, a smaller bore column was thought to be the 
best approach, as it would increase mass detectability and assay sensitivity % ithout 
requiring major changes in the analytical procedure. However, smaller bore 
columns with the same C, media are not commercially available, and neither is the 
loose media. Thus, the Cis media of the required chemistry was obtained by 
emptying a 100 x6 mm Radialpak cartridge, which _yielded 
2.5g of material. The 
packed C18 column showed the same selectivity as the C, 8 column used earlier and 
baseline resolution was achieved between the peaks of interest. Due to lower peak 










Figure 5.1: Plot of radioactivity (dpm) versus time of equilibrium of 
'4C)-ibuprofen in the donor and recipient cells filled with phosphate 
buffered saline (mean ± sd, n= 3), 
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diastereomeric amides yielded sufficiently large peaks to enable reliable 
quantitation (see below). Connection tubing of the conventional HPLC were also 
reduced in order to reduce peak dispersion further. Chromatograms of ibuprofen 
derivative standards, blank dialysate and dialysate of a volunteer's serum sample are 
shown in Figure 5.2. Baseline resolution was achieved and no interfering peaks 
were evident. Peak symmetry was not as good as with the regular columns although 
it did not affect the resolution. This was probably due to relatively low packing 
pressure of 400 bar that was employed in the packing procedure, which was the 
maximum tolerable limit of the column packer. 
5.3.4 Validation of the HPLC assay procedure 
The accuracy, extraction recovery and within and between day variability of 
the assay procedure is shown in Table 5.1 and typical calibration curves are 
presented in Figure 5.3. In general the variation is much larger than that seen for the 
urine and serum assay procedure. This is not unexpected as much lower 
concentrations are involved. However, even at the lowest calibration point of 5 
ng/ml the within day variation is about 13 % and the day to day variation was about 
16% 
, which 
is still within acceptable limits, considering the low concentrations 
involved. This is especially true when applied in protein binding studies where 
much larger experimental variations are usually encountered (Huang, 1983). Thus, 
the minimum quantifiable limit of the method is 5 ng/ml of each enantiomer, using 
2.5 ml of protein dialysate. This low limit of quantitation is therefore sufficient for 
the determination of plasma protein binding in serum samples with a total (bound 
and unbound) enantiomer concentration of at least 5 gg/ml, and can thus be used in 





a b C 
Figure 5.2 Chromatograms of a) standard solutions of racemic ibuprofen 160 
ng/ml of each enantiomer, b) dialysate from drug free serum sample, c) 
dialysate from a serum sample of a volunteer 2.0 hr after oral administration of 
400 mg of the racemic drug (see Figure 2.2 for peak identity). 
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Table 5.1: (a) Within day variation, accuracy and extraction recoveries of 
ibuprofen enantiomers in "spiked" protein dialysate samples (n=6) and (b) 
between day variation and accuracy of ibuprofen enantiomers in "spiked" 















5 1? 4.4±0.6 14.3 -12.0 90.1 + 1-1.9 
S 4.6±0.6 12.8 -8.0 92.2 + 11.8 
40 R 38.5 1.6 4.2 -3.8 94.4+ 1.6 
5' 8.2 +2.5 6.6 -4.5 91.7 } 6.2 
160 1? 162.1 +7.0 4.3 +ý. 4 








Variation (CV°, ö) 
Mean Percent 
Difference 
5 R 4.5+0.7 15.1 -10.0 
S 4.6+0.7 16.6 -8.0 
40 R 36.5 + 3.9 10.8 -8.8 
,ý 37.2 +3.7 9.9 -7.0 
160 R 165.7+6.6 4.0 3.6 
154.2+5.7 3.7 -3.6 












Figure 5.3: Typical calibration curves prepared for the quantitation of 
ibuprofen enantiomers as their (R)-1-(naphthen-1-yl)ethylamides following 
extraction of the drug from dialysate buffer after equilibrium dialysis. 
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5.3.5 Validation of HPL, C procedure against radiolabelled method 
In view of the difficulties involved in plasma protein determination 
experiments and the low free drug concentrations involved it was thought necessary 
to validate the chromatographic procedure developed against the previously 
published procedure involving radiolabelled ibuprofen (Evans el al., 1989). The 
procedure used in the radiolabelled method was adopted \Nithout major 
modifications. The free drug concentrations determined for the "spiked" serum 
samples using both the chromatographic and radiolabelled ibuprofen method are 
presented in Figure 5.4. A linear relationship is evident from the two plots (r = 0.94 
and r=0.90 for (1? )- and (S)-ibuprofen respectively) indicating that the two sets of 
values were linearly related. The gradient of the regressed line (m = 0.9 and m=1.1 
for (R)- and (S)-ibuprofen respectively) also show that the results obtained from 
both methods were within 10% of each other, implying a high degree of correlation. 
The unbound fraction of each enantiomer for the serum samples were also 
calculated and the results tabulated in Table 5.2. The mean \alues ýýere not 
statistically different after being subjected to a Student's t-test for paired samples (p 
> 0.05). Thus, it is apparent that the two methods of determination of free drug 
concentration and unbound fractions yield comparable results and the 
chromatographic method can be used xv ith confidence in the determination of the 
extent of plasma protein binding of ibuprofen enantiomers. The chromatographic 
method has the added advantages of being free from the hazards of handling and 
disposal of radiolabelled substances as well as being simpler and less tedious to 
perform. 
Volume shifts in equilibrium dialysis occurs as a result of the movement of 
water from the recipient to the donor cells causing the dilution of the binding 
protein concentration and if uncorrected, will result in an overestimation of the 
unbound fraction. Correction for volume shift is especially important if the 
unbound fraction of the drug is small (Huang, 1983). The volume shifts in the 
validation experiments were typically between 7-10 °ö and the unbound fractions 
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Figure 5.4: Plot of unbound concentrations of a) (R)-ibuprofen and b) (S)- 
ibuprofen determined using HPLC versus that using the radiolabelled 
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routinely corrected for volume shifts based on protein concentration determinations 
before and after dialysis for every serum sample. 
5.4 Summary 
In summary, a reliable and accurate method of determination of free drug 
concentration in serum samples was developed and alidated against a prey iousl} 
published procedure using radiolabelled ibuprofen. The method is relatively- simple 
and easy to perform. The extent of plasma protein binding was determined using 
equilibrium dialysis and volume shifts were typically between 7-10 % during the 
validation experiments. Equilibrium dialysis was easy to perform and did not 
require the use of specialised apparatus. This method of determination was applied 
to serum samples obtained from human pharmacokinetic studies follomng the oral 
administration of 400 mg racemic ibuprofen. as described in Chapters 6 and 7. 
j;; 
CHAPTER 6 
Enantioselective Pharmacokinetics of Ibuprofen 
in Young Volunteers. 
1( ý 
6.1 Introduction 
Human pharmacokinetic studies of (1?, S)-ibuprofen are complicated by three 
factors. Firstly, the drug is mainly used as a racemic mixture and the unidirectional 
chiral inversion from the inactive I? - to the active S-enantiomer represents a form of 
metabolic activation, the extent and variability of which need to be studied in order 
to obtain an estimate of the dose of the active drug that is presented to the body. 
This will allow subsequent determination of clearance via other non-inversion 
processes. Variability in chiral inversion will also affect other stereoselective 
transformations and may well result in marked differences in enantiomeric 
disposition (Caldwell et ul., 1988). 
Secondly, ibuprofen is extensively bound to plasma proteins (Gallo ct at., 
1986, Lin c'l (il., 1987) with unbound fractions of typically less than 0.01. Plasma 
protein binding has also been shown to be enantioselective in in-vier and in-vivo 
studies, with the S- enantiomer having a significantly higher unbound fraction 
(Evans ct iii., 1989; 1990). Like others compounds in the "profen" group, ibuprofen 
is cleared almost exclusively by hepatic metabolism (Williams et ul., 1993) and the 
clearance (CL) of such drugs is given by: 
CL = fu CLu (egn6.1) 
where f is the unbound fraction and CL is the unbound or intrinsic clearance of the 
drug (Rowland and Tozer, 1989). Therefore , stereoselective 
differences in total 
clearance may be due either to differences in unbound clearance or in protein 
binding. Thus, pharmacokinetic studies based on total (bound and unbound) 
determinations alone Nvill not `ield information on the enantioselectivity of the 
underlying dispositional processes. Due to the large extent of protein binding, \er\ 
low unbound concentrations of each enantiomer are encountered and this represents 
a severe analytical challenge. As a result, pharmacokinetic studies of ibuprofen 
enantiomers based on unbound drug concentrations are rare. 
15! 
Thirdly, in addition to chiral inversion, ibuprofen undergoes functional 
oxidative and conjugative metabolism. The excretion of ibuprofen as the ac,, l 
glucuronide accounts for about 10°o of the dose. Although this is quantitatively a 
relatively unimportant pathwaN,, in-vitro experiments reveal the glucuronidation to 
be stereoselective (E1 Mouehli et ul., 1987). The major metabolic pathway is 
oxidation, to yield two principal metabolites, namely hydrox ibuprofen and 
carboxyibuprofen (Figure 6.1). In the case of carboxyibuprofen, a second chiral 
centre is introduced into the molecule and the substrate or product 
enantioselectivity of the process is difficult to determine due to the analytical 
problems discussed previously (Chapters 3 and 4). Thus, the stereoselectivity of the 
oxidative metabolism is difficult to discern without suitable anal`tical methods. 
The first study on the pharmacokinetics of ibuprofen enantiomers in man 
(Van Giessen and Kaiser, 1975) reported a difference in the plasma elimination half- 
lives for the 1? - and S- enantiorners. A gas-liquid chromatographic method 
developed (Kaiser el al., 1976) was utilised to studN, the stereoisomeric composition 
of the hydroxy and carboxy metabolites in urine after administration of the 
individual isomers, as well as the racernate. (. Iý)-Hvdrox 'ibuprofen was formed in 
enantiomeric excess, regardless of the stereochemical form of the administered drug 
i. e. racernate or either single enantiorner. However, it Walas not possible to determine 
whether this indicated stereoselectivity in oxidation or was a result of chiral 
inversion. The gas-liquid chromatographic method used here could not resole e the 
2'/?, 2 '- and 2'. S', 2i? - isomers of carboxvibuprofen and this only permitted limited 
interpretation of the results obtained following administration of either the racemate 
or (K)-ibuprofen. 
Lee ci af., (1985), demonstrated unequivocally the unidirectional nature of 
the chiral in ersion process in man by studying the plasma kinetics of the 
enantiomers after separate administration of both the racernate and the individual 
enantiomers of ibuprofen. The extent of chiral i n's ersion was estimated to be 61 Io 







































































ibuprofen. Comparison of the areas under the plasma-concentration versus time 
curves (AUC) following administration of the racemate showed lower AUCs than 
would be predicted by administration of the enantiomers separately. This was 
proposed to result from enantiomer-enantiomer mutual displacement in protein 
binding, although this was not examined in this study. Partial metabolic clearance 
by glucuronidation was also found to be greater for (S)- ibuprofen but whether this 
was due to inherent stereoselectivity in transformation or as a result of the 
enantioselective plasma protein binding could not be determined as unbound drug 
enantiomer concentrations were not measured (Evans, 1992), although in-yarn 
evidence seems to suggest stereoselective metabolism (El Mouelhi c/ ul., 1987). 
Various other studies have similarly investigated the plasma 
pharmacokinetics of ibuprofen enantiomers either by administration of the racemate 
or the individual enantiomers (Jamali ci of., 1988, Cox ci of., 1988; Avgerinos and 
Hutt, 1990, Geisslinger cl of., 1990). In contrast with the findings of Lee cl al., 
(1985) and Van Giessen and Kaiser (1975), Jamali and co-workers (1988) found that 
elimination half-lives of both enantiomers to be similar and the enantiomeric plasma 
ratio (S 1? ) increased only up to four hours post drug administration, thereafter 
decreasing to a constant value. A pre-systemic site of inversion, notably intestinal 
inversion was postulated to account for this observation. However, this argument 
was not supported by subsequent pharmacokinetic studies (Aývgerinos and Hutt, 
1990, HalI et ul., 1993) or in-vitro studies using animal tissues (Jeffrey et at, 1991). 
As a result of the difficulties in, ý-oly ed in enantiospecific analysis, the 
majority of studies on ibuprofen disposition in the 1970s and 80s were carried out 
on a limited number of subjects. However the interindividual variability in the 
enantioselective pharmacokinetics of ibuprofen following the oral administration of 
400 mg of the racemate to 24 healthy volunteers was reported by A% gerinos and 
Ilutt (1990). Although the extent of inversion could not be calculated v ithout the 
administration of individual enantiomers, examination of the percentage of the total 
AUC due to the S-enantiomer indicated that either the extent of chiral inversion 
showed little variation within the population group, or that the \ ariability, in 
It) i 
inversion was balanced by similar variability in alternati\ e metabolic or excreton 
pathways. Similar lack of 1nterindividual variability was also observed in the other 
determined pharmacokinetic parameters (A'gerinos and Hutt, 1990). 
Being a drug of low hepatic extraction, the plasma protein binding of 
ibuprofen is a primary determinant of total drug clearance. This was clearly 
demonstrated in a human study involving 15 healthy volunteers (Lockwood el (I/., 
1983), where a non-linear relationship was found between AUC of total plasma 
concentration and dose, suggesting a change in plasma clearance. When unbound 
drug concentrations were measured, the AUC of the unbound drug was linearly 
related to dose, indicating dose-independent clearance of unbound drug and the 
cause of the non-linearity to be linked to changes in plasma protein binding. 
Subsequent studies have indicated an increase in the unbound fraction of both 
enantiomers was found to be the cause of the non-linearity between AUC and dose 
over the range of 200 - 1200 mg of the racemate, while intrinsic clearance was 
unchanged for both enantiorners (Evans e/ al., 1990, Paliwal ei ul., , 
1993, Smith ei 
u/., 1994) and emphasised the importance of determining unbound concentrations in 
pharmacokinetic studies of ibuprofen enantiomers. 
As metabolic oxidation forms a major elimination pathway of ibuprofen, the 
stereoselectivity of the oxidative reactions need to be addressed. In one of the 
earliest studies by Kaiser et al (1976), (L )-hydroxyibuprofen was preferentially 
formed after administration of either racemic drug or (I? )-ibuprofen. This could be a 
result of extensive chiral inversion, inherent stereoselectiwy of the oxidation 
reaction (Baillie e> al., 1989) or as a result of stereoselective plasma protein binding 
(Evans, 1992). This question can be resolved if the partial metabolic clearance 
based on unbound concentrations, of each of the enantiomers of hydroxyibuprofen 
were determined. As a consequence of the methodological difficulties in resolving 
the diastereoisomeric forms of carboxyibuprofen, the stereoselectivity of this 
oxidation pathway remains largely answered. Studies based on the analytical 
method of Kaiser e> al., (1976) have suggested the possibility of stereoselecti% e 
clearance of the (. ti)-ibuprofen via this route, although product stereoselecti\ itv at 
IH 
the newly formed chiral centre could not be ascertained (Baillie L'v u!., 1989, Smith 
et u!.. 1994). Ho\\ c% er, there is some evidence that the ,- configuration may 
predominate at this chiral centre, although the stereochemical configuration \wh 
respect to order of elution of the chromatographic peaks were not directly 
determined (Rudy et u!., 1990). 
It is therefore apparent that any study of the enantioselectiý c disposition of 
ibuprofen needs to address, the extent and variability of chiral inversion, 
stereoselectivity in plasma protein binding as well as the stereoselectiv it\ of the 
major metabolic pathways. The majority of the studies discussed abo\ e has e 
addressed some of these issues but a comprehensive study to obtain an o\ oral l 
picture of the relative importance of the various processes involved has not been 
reported in the literature.. With the use of the analytical methods developed in 
Chapters 2,4 and 5, the following section describes a single dose pharmacokinetic 
study in healthy young volunteers that examines the above issues. 
6.2 Experimental 
6.2.1 Clinical Study Protocol 
(a) Inclusion criteria 
Eight healthy young volunteers between the ages of 20 to 35 years (mean a, -, e 
of ? 8.1 ± 5.4, see Appendix 5 for Volunteers' characteristics) were studied. The 
volunteers were required to give written consent before the study and underwent a 
thorough physical examination and routine biochemical tests before being recruited 
into the study. All aspects of the study were conducted according to the Helsinki 
declaration and ethical approval was obtained from the ethical committee of the 
School of Medicine and Dentistry, King's College London. 
162 
(b) Study Design 
The volunteers were required to abstain from any medication, alcohol and 
beverages containing caffeine for 24 hours prior to the study. They were also 
required to fast from midnight of the study day until three hours post drug 
administration. Fluids were allowed up to 6 a. m. on the day of the study. 
Volunteers swallowed a single 400 mg tablet of racemic ibuprofen (BrufenR) \tiith a 
glass of 150 ml water. Blood samples (10 ml) were collected via an indwelling 
cannula at 0,0.25,0.5,0.75,1.0,1.5,2.0,2.5,3.0 3.5.4.6,8,10 and 24 hours post 
drug administration. The blood samples were collected in plain vacutainers and left 
to clot for two hours prior to centrifugation and separation of serum. Serum was 
stored frozen at -20"C until required for analysis. Volunteers were also required to 
empty their bladders prior to drug administration. Sequential urine samples were 
collected over the following time intervals; 0-2,2-4,4-6,6-8,8-10 and 10-24 hr, and 
the individual urine volumes were recorded. A pooled 24 hour sample was prepared 
from the individual samples, and a 50 ml portion of each of the urine samples saved 
and frozen at -20°C until required for analysis. Serum albumin concentrations were 
determined as detailed in Chapter 5 and the individual data is presented in Appendix 
5. 
(c) Drug Analysis 
The enantiomeric composition of ibuprofen in serum and urine as 
determined using the methods described in Chapter 2. Unbound ibuprofen 
enantiomer concentrations were determined using the methodology described in 
Chapter 5 for serum samples obtained at 0.5,1.0,2.0 , 
3.0 and 4.0 hours. The 
urinary enantiomeric and diastereoisomeric composition of hydroxyibuprofen and 
carboxyibuprofen were determined using the methods described in Chapter 4. 
}t 
6.2.2 Pharmacokinetic and data analysis 
Pharmacokinetic anal- sis of the serum concentrations of the enantiomers 
were performed using the non-compartmental approach with the use of the TOPFIT 
curve fitting program (Instruction manual for TOPFIT pharmacokinetic curve fitting 
program). The terminal disposition constant (ku) and elimination half life (tj,, ) for 
each serum concentration-time profile was calculated by linear regression of the log- 
linear portions of the serum concentration versus time profiles. The area under the 
curve (AUC) values from time 0 to co for each serum profile were calculated from 
the time of administration to the last measurable serum concentration by the 
trapezoidal rule and were extrapolated to infinity using the last measurable serum 
concentration and k, (Gibaldi and Perrier, 1982). Extrapolated areas were typically 
less than 2% of total AUC. The 0111 ý and values were determined hw visual 
inspection of the data. Apparent total body clearance (Cl. ) and volume of 
distribution (V(1 ) were calculated according to the following expressions: 
CL/f = Dose, %AUC -- 
(eqn 6.2) 
Vs /f = Dose, /'k,. AUC, _,, 
(eqn 6.3) 
here f is the fraction of the dose reaching the systemic circulation. As the 
bioavailablity of orally administered ibuprofen is essentially unity (Hall ci a/., 
1993), f=1 was assumed to be unity for all calculations. 
The fraction of (R)-ibuprofen undergoing inversion (F,,,, ) was calculated 
from an examination of the stereochemical composition of the drug and both major 
metabolites, (free and conjugated) excreted in urine using the following equation: 
Fim = 
öS metabolites - °'ö S dose eqn 6.4 
Iz dose 
where Oö S dose and the %ö1? dose are the percent of the administered dose in the .1 
and 1? configuration respectively, i. e. 50° o, and "% S metabolites" is the sum of the 
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molar amounts of metabolites excreted with the . ti configuration in the propionic 
acid moiety expressed as a percentage of that recovered. 
Assuming all of a given metabolite formed appears in the urine, the 
formation clearances (CL, -) were calculated as: 
CLI- = Am/AUCparcni (eqn 6.5) 
where Am is the amount of metabolite recovered in urine and AUCruir nt is the AUC 
of the enantiomer from which the metabolite was derived (Rudy et al., 1991) 
The unbound fraction (fu) of each enantiomer was determined as follows: 
fti _ O 
concentration in dialysate 
concentration in serum 
100 (eqn 6. ( 
(Knadler ci ul., 1989). The mean of the five determinations for each indi, idual 
serum profile were calculated and used in subsequent data analysis. The half life 
(t i) and elimination rate constant (k, u) 
for each unbound concentration-time 
profile was calculated using the TOPFIT program based on linear regression of the 
log-linear portions of the unbound enantiomer concentration versus time curves 
profile. The AUC for unbound drug (AUC) was calculated as. 
AUCu _0ö unbound x AUC (eqn 6.7) 
Total body clearance and volume of distribution based on unbound concentrations 
(CL, and Vd,, respectively ) were calculated as before: 
CL,, = Dose/AUCu 
Vd =C L/(k, ) 
(eqn 6.8) 
(eqn 6.9) 
The mean pharmacokinetic parameters derived from the total and unbound 
serum data and urinary excretion data for the enantiomers of ibuprofen and 
lhý 
hydroxyibuprofen and the stereoisomers of carbot, ibuprofen were tested for 
statistical significance using the Student's t-test for paired samples. 
6.3 Results 
6.3.1 Serum level data 
The mean serum concentration versus time curves for both ibuprofen 
enantiomers following the administration of 400 mg of the racemate to eight healthy 
young volunteers are shown in Figure 6.2, and the individual serum level data is 
tabulated in Appendix 6. The pharmacokinetic parameters derived from the serum 
concentrations are presented in Table 6.1. Following administration of 400 in-, of 
the racemate, the serum concentrations of the (, '')-ibuprofen were greater than those 
of the 1? enantiomer after 2 hours post-dose. The (S)-ibuprofen serum lc: els also 
declined more slowly, and this is reflected by the significantly longer ti;, values (p < 
0.001; Table 6.1). These findings are consistent with previously reported data (Van 
Giessen and Kaiser, 1975, Lee et al., 1985, Cox c'f at., 1988, Avgerinos and Hutt, 
1990). The slower decline of the (. S)-ibuprofen levels, results in a gradual 
enrichment of (S)-ibuprofen in serum (Figure 6.2). 
The calculation of the clearance (CL) of (. S')-ibuprofen requires a knowledge 
of the actual dose administered (eqn 6.2) but as a result of chiral inversion, the 
actual "dose" or systemic exposure of an individual to the S enantiomer is not 
known. However, an estimate of the "dose" can be made with the availability of 
F,,, v values calculated from the urinary recovery 
data (see below) and the (S)- 
ibuprofen "dose" is calculated as: 
(. S')-ibuprofen "dose" = (1 f- F,,,,. )200 mg (eqn 6.10) 
The AUC, CL and other pharmacokinetic parameters also reflect differences 
















Figure 6.2: Mean ibuprofen enantiomer concentration-time curves following 
the oral administration of 400 mg of racemic drug to eight healthy young 
volunteers (mean ± sd). 
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Table 6.1 : Pharmacokinetic parameters of ibuprofen enantiomers follo-'s ing the 
oral administration of the racemic drug( 400 mg) to eight healthy young volunteer`. 





t1 2 AUC 






sl 17.7 2.0 1.2 53.0 62.9 6.4 0.65 
s2 13.0 1.5 2.5 57.0 58.5 1?. ý 0.68 
s3 19.5 2.0 1.2 66.9 49.8 5.1 ()6, S 
s4 21.6 2.5 1.5 80.7 41.3 5.4 0.63 
s5 13.6 2.5 1.1 49.0 68.0 6.2 0.6 
s6 21.4 1.0 1.2 69.4 48.0 5.2 0.78 
s7 12.2 2.0 1.6 53.7 6 '. 1 8.8 0.78 




















sl 16.7 2.0 1.7 5?. 3 105.2 15.2 
s2 15.2 1. 3.0 75.3 74.4 19.6 
s l% 14.8 2.0 1.9 58.7 95.4 15.5 
s4 26.2 120.0 45.3 8.2 
sý ? 1.6 ?. 5 ?.? 94.2 56.6 10.7 
s6 ? 1.? 1.0 '. 2 91.0 65.2 1? 
s7 12.6 2.0 1.9 54.9 108.1 17.7 
s8 20.0 1.0 ?. 5 53.6 103.9 22.5 
Mean 18.8 1.8 1.1 75.0 81.7 1 5.? 
SD 4.7 0.6 0.4 24.8 24.5 4.7 
CV00 t ? ý. 1 32.8 19.7 33.0 30.0 31.1 
p\ alue* n. s. n. s. p<0.001 n. s. p 0.05 p 0.01 
" Comparison between the means for the enantiomers of ibuprofen were carried out using Student's t- 





"Table 6.2: Urinary excretion of ibuprofen and hydroxyibuprofen enantiomers and 
and carboxyibuprofen isomers following the administration of the racemic drug 
(400 mg) to eight healthy young volunteers (expressed as a percentage of dose). 
Mean s_d. 
(R) - ibuprofen 







(R) - hydroxyibuprofen free: 
conjugated: 
total 




(2'S, 2R) free: 
conjugated: 
total 
0.06 0.02 0.01 - 0.24 
1.09 0.31 O. 66-1.5') 
1.15 0.37 0.70-1.82 
0.38 0.1 1 0.31 -0.56 
8.07 3.01 4.47 - 11.?? 
8.45 3.19 4.70-13.86 
1.96 0.53 1.22-2.81 
1.61 0.90 1.08- 3.17 
3.57 1.24 2.64 - 5.46 
5.40 1.86 3.41 -7.85 
16.10 3.14 11.40 -? 1.4? 
21.50 3.70 16.99-27.05 
1.83 0.39 1.17-4.11 
0.95 0.80 0.55 - 1.49 
2.79 0.62 1.80-4-99 
(2'R, 2R) free: 2.69 0.61 1.44-4.20 
conjugated: 2.27 0.78 2.35 - 2.80 
total 4.96 0.65 3.75 - 6.36 
(2'R, 2S) free: 8.38 2.34 5.45 - 12.43 
conjugated: 8.07 2.16 5.21 -11.01 
total 16.45 4.17 12.68 -23.45 
(2'S, 2S) free: 10.50 22.14 6.46- 15.96 
conjugated: 9.35 2.53 7.14 -11.88 
total 19.85 4.39 13.36 - 25.85 
Total recovery 78.72 11.82 66.43 - 91.68 
Note. Comparison between the means for the enantioniers of ibuprofen and hydroxyibuprofen and the 
stereoisomers of carboxyibuprofen derived from (R )- and (S )-ibuprofen were carried out using Student's t 
test for paired samples. All means tested were found to be statistically significant(p < 0.01 ). 
Comparison between the means for the individual stereoisomers of carboxyibuprofen derived from (R )- and 
(. V )-ibuprofen respectively were done using a Student's t-test for paired samples. 
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stereoselectiv itv % ith respect to formation of the alcohol and the metabolite appears 
to show substrate selectix. ity, for conjugation. Examination of the formation 
clearances for the sum of the diastereoisomers of carboxyibuprofen arising fron 
oxidation of either enantiomer of the drug indicates substrate stereoselectik itv for 
(S')-ibuprofen (5' 1? = 4.1). However, examination of the corresponding data for the 
formation of the individual stereoisomer indicates a reduced, but significant product 
stereoselectivity for the formation of a particular diastereoisomer. Thus, oxidation 
of ibuprofen to yield carboxyibuprofen shows substrate-product stereoselectivitv 
with the predominantly formed diastereoisomer having the same configuration at the 
metabolically introduced centre as that in the substrate in both cases, i. e oxidation of 
(R)-ibuprofen preferentially yields (2'R, 2R)-carboxyibuprofen, whereas (. I')- 
ibuprofen preferentially yields (2'S, 2.5)-carboxyibuprofen. It is also of interest to 
note that the product selectivity is greater in the case of the R-enantiomer than that 
for (5')-ibuprofen (2'/?, 2/? /2'. ß'_21Z = 1.75; 2'S. 25'. ? '1z; 25 = 1.2?: see Table 6. -1), 
Such 
differences presumably reflect the orientation of the substrates to the active sites of 
the cytochrorne P4;,, mediating the reaction. 
The conjugation of carboxyibuprofen also appears to show some 
stereoselectivity, for example the mean ratios of free-conjugate for the four 
stereoisomers are: 1.9,1.2; 1.0; and 1.1 for the 2'ß', 21z; 2'R?. ti': 2'. S, 2S 
respectively (see Table 6.2) Thus, the 2'/?, 2 - stereoisomer appears to be a poorer 
substrate for conjugation than the other three carboxvibuprofen stereoisomers. The 
ioselectivitv, i. e. the significance of this data is, however limited as at present the reg 
position of conjugation is unknown. 
The extent of chiral inversion, Fin,. is shown in Table 6.1. The mean % alue of 
0.68 agrees well with previously reported values (Lee ci at, 1985, Rudy ci ul.. 1991 
Smith et al., 1994), calculated by either separate administration of the I? - 
enantiomer, by the urinary excretion method. or by administration of a 
pseudoracemate. An interesting observation is the small interindividual variability, 
of Fin% , consistent with the observations made previously 
based on indirect evidence 
(A\ gerinos and Hutt, 1990). 
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6.3.3 Plasma protein binding and pharmacokinetic parameters based on 
unbound concentrations. 
The plasma protein binding for each volunteer (expressed as Oo unbound) 
was determined by taking an average of the values obtained by anale sing the 
equilibrium dialysate from five serum samples selected during the absorption and 
elimination phases of the serum concentration versus time curve (Table 6.4). Mean 
values of 0.25 and 0.51 % were obtained for (R)- and (, ' )-ibuprofen respectively, and 
these compare favourably with values of 0.33 and 0.55 `ö obtained by Evans et al., 
(1990) with a similar dose of racemate but analysed using a methodology based on 
the use the radiolabelled drug. The slight difference may be due to presence of 
radiolabelled impurities experienced when radiolabelled drugs are used in 
equilibrium dialysis (Evans ct ul., 1990). The percentage unbound values between 
the enantiorners are statistically significant (p < 0.0001) using a Student's t-test for 
paired samples, indicating stereoselective binding in favour of the 1z enantiomer. 
The ratio of the unbound SIR concentration is 2.04, and is within the range of values 
of between 1.7 to 2.1 from previously reported in in-vivo studies (Evans et aL, 1990, 
Paliwal et ul., 1993, Smith et al., 1994). 
The pharmacokinetic parameters based on unbound concentrations (Table 
6.5) showed enantioselective differences in AUCH, ,t j/2, and 
CL,, (p < 0.001), with 
the S enantiomer displaying a higher AUCU, longer t,,,,, and lower CL,, The 
unbound metabolic clearance of (k)-ibuprofen is a result of the unbound clearance 
b`' inversion and non-inversion pathways, thus: 
CL JC L',;,, eI L, +CL,, 
(eq n 6.11) 
The inversion clearance CL;,,,., u can be calculated as: 
CLinv. it 
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since a certain proportion of the unbound clearance of (/? )-ibuprotcn constitutes 
chiral inversion 
C Lj 




The results of these clearance values are shown in Table 6.5. The inversion 
clearance for (R)-ibuprofen was predominant, accounting for 680,0 of the total 
unbound clearance for that enantiomer. A comparison of CL,, 111 ,, of (R)-ibuprofen 
and CL for (S)-ibuprofen revealed that CL,, of (S)-ibuprofen was t\'ýice as large, 
indicating that clearance through the oxidative and glucuronidation pathways was 
stereoselective for the S- enantiorner. 
The stereoselectivity in the unbound clearances of the (S)-ibuproten is also 
reflected in the unbound formation clearances of the metabolites (Table 6.6). 
Comparison of the enantiomeric ratios (SR) in the formation clearances based on 
total and unbound drub calculations results in reduced but still significant 
differences between the enantiomers for all metabolic pathways. Thus, the ratio of 
the formation clearances for ibuprofen glucuronides decreased from S 1l = 6.7 to 3.1 
«hen calculated from total and unbound enantiomer concentrations respectively. 
Similarly, the corresponding values for the hydroxy metabolite decreased from 5.3 
to 2.4 and those for the sum of the carboxy diastereoisomers derived from a 
particular ibuprofen enantiomer decreased from 4.1 to 1.9. Ho\N e\ er, the \ alues for 
the diastereoisomers derived from a single enantiomer of ibuprofen remained 
constant at 1.74 and 1.22 for the 2'K, 2Ri2'S? ll and 2'S, 2S'/2'h 2S respectively. This 
latter result is to be expected as the fraction unbound is taken into account in 
comparison of the ratios. Therefore, even though the relative stereoselectiv it` of the 
individual pathways is reduced when based on unbound clearance values, the data 
indicate inherent stereoselectivity of the metabolic pathways involved. Thus, the 
stereochemical composition of the metabolites found in urine arises as a result of 
stereoselectivity in both protein binding and metabolism. In addition, selecti\ itv in 
17-71 
Table 6.5 : Pharmacokinetic parameters based on unbound concentrations of 
ibuprofen enantiomers in following oral administration of the racemic dose (400 mg) 
to eight healthy young volunteers. 
Subject 
No: 















sl 0.22 0.12 1.08 2673.1 28.59 18.58 10.01 
s2 0.35 0.20 2.20 3182.6 16.71 11.36 5.5 
s3 0.29 0.19 0.96 1429.5 17.18 11.68 5 50 
s4 0.19 0.15 1.46 2748.0 21.74 13.70 8.04 
s5 0.23 0.11 1.18 3021.7 29.58 17.75 1 1.8 3 
s6 0.32 0.22 1.28 1663.4 15.01 11.71 > ;0 
s7 0.2 j 0.11 1.34 3600.8 31.04 24.21 6.83 
s8 0.23 0.15 1.17 2301.1 22.7 1 22 7.5O 
mean 0.25 0.16 1.3 3 2577.5 22 82 15.5 3 7.21> 
sd 0.06 0.04 0.38 744.4 6.30 4.47 2.72 
CV (%) 23.17 28.14 28.66 28.9 27.60 28.78 37.26 
(S)-ibuprofen 
_ `_ 
sl 0.54 0.28 2.4 3 4097.2 19.47 
s2 0.5? 0.39 2.73 3380.4 14.30 
s3 0.51 0.30 1.99 31,21 18.71 
s4 0.33 0.40 1.57 1865.0 13.72 
s5 0.34 0.32 3.56 5132.6 16.65 
s6 0.49 0.45 1.65 1900.9 13.31 
s7 0.66 0.36 1.37 1942.3 16.38 
s8 0.69 0.37 1.43 1863.5 15.05 
TI 
mean 0.51 0.36 2.09 2925.6 15.95 
sd 0.13 0.05 0.77 1242.6 2.27 
CV (o%) 25.41 15.29 36.66 42.5 
--14.25 
pvalue p<0001 p<0.001 p<0.05 n. s. p<0.05 
* Comparison between the means of the enantiomers of ibuprofen and hydroxyibuprofen and that of the 
individual stereoisomers of carboxyibuprofen and the stereoisomers of carboxyibuprofen 
derived from (R 
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renal excretion may also contribute to the observed differences, howeý er at present, 
this cannot be determined. 
6.4 Discussion 
As can be seen from the results, the pharmacokinetics of ibuprofen 
enantiomers are complicated by the fact that enantioselectivitv occurs in plasma 
protein binding, metabolic oxidation and glucuronidation, and that chiral ins ersion 
forms a major clearance pathway of the 1? enantiomer. As a result of the reported 
enantiomer-enantiomer displacement and non-linearity in protein binding (Paliwal 
et al., 1993), a comparison of the results obtained above with previously published 
data is difficult. Also a wide range of study designs, based on administration of 
either the racemate or individual enantiomers, and different dosages further 
complicates comparisons. 
Estimation of the extent of chiral inversion can be carried out in a number of 
ways, depending on whether the individual enantiomers, racemate or a 
pseudoracernate are administered. When (R)-ibuprofen is administered, F,,,, can be 
estimated by direct comparison of the AUCs obtained for the Il and . ti enantiomers 
(Baillie ci al., 1989). Alternatively, the R and S enantiomers can be given to the 






where AUC1z.., and AUC, S"., s. are the AUCs of the S- enantiomer after administration of 
the 1? - and S- enantiomers respectively (Lee ci al., 1985). An underlying assumption 
of this method is that the kinetics of (. '') ibuprofen are time independent between 
subsequent study periods, an assumption which needs to be addressed (Rudy ci a1., 
n ; 17 
1991; Smith ci al., 1994). As a result of this. the administration of a 
pseudoracernate involving (S)J)4-ibuprofen was emplo}-ed (Rude c'i . if., 1 Q' l ). Based 
on serum levels of (. ß)J)4-ibuprofen, CL and AUC of (S)- ibuprofen without the 
contribution from chiral inversion can be calculated, and hence IF,, can be 
estimated. This approach is not possible using an unlabelled racemic dose. When 
racemic doses are administered F11.1 can be con eniently calculated by determining 
the stereochemical content of the drug and its metabolites in urine. The results 
obtained in the present study using this method, fall within the range of 0.52) to 0.74 
reported in the literature (Geisslinger et ul., 1990 ; Lee et ul., 1985: Hall L'i (1l., 1991, 
Smith el ul., 1994). 
Because of the limits of sensitivity imposed by the non-radiolabelled method 
for the determination of ibuprofen enantiomers in equilibrium dialysis, the unbound 
concentrations could not be determined for all serum samples. As such five samples 
were chosen along the absorption, at the peak and during the elimination phases of' 
the serum concentration versus time curves. The AU,, was then calculated as 
mean percent unbound x AUC, as shown in equation 6.7 . 
This method of 
calculation is valid as the serum concentrations were within the limits \khcre plasma 
protein binding was constant, i. e. unbound concentrations \\ere linearly related to 
total serum concentrations (Figure 6.3). This approach was adopted in preference 
over that of estimating AUC directly based on only five unbound le\ eis as had been 
done previously (Evans (-'/ ul., 1990) as more errors will be introduced in the 
calculation of unbound AUC based on only five unbound concentrations. 
Although the CL, Vd and formation clearances of the metabolites show 
stereoselective differences between the individual enantiomers, whether these 
changes are a result of the stereoselectivity in protein binding can only be 
ascertained by evaluating the corresponding parameters based on unbound 
concentrations. While the total CL of (ý)-ibuprofen was significantly greater than 
that of the R-enantiorner, the reverse situation was observed when unbound 

























Figure 6.3: Plot of unbound concentrations versus total (bound and unbound) 
serum concentrations of (a) (R)-ibuprofen and (b) (S)-ibuprofen in serum 
samples following the oral administration of racemic drug (400 mg) to eight 
healthy young volunteers. 
180 
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for the S enantiomer was due to higher unbound concentrations. The Cl, of 
(l? )-ibuprofen is mainly due to clearance by in\ ersion (CL, nvu) which is twice as 
large as clearance by alternative pathways (CLther. u) 








The overall picture can be 
(R)-ibuprofen-acy l glucuronide 
(R)-hvdroxv1buprofen 
(? 'ß', 21z)- and 
(2'I?, 21? )-carbo\v ibuprofern 
(S)-ibuprofen-acvl glucuronide 
hydro xvibuprofen 
(2'1?, 2 )- and 
(? 'S, 2 )-carboxyibuprofen 
Figure 6.4 : Schematic representation of the enantioselective clearance of 
ibuprofen. The line thickness of the arrows indicate relative importance of the 
pathway. 
Based on the above model, one would expect that the metabolites with the S- 
configuration in the propionic acid moiety to predominate in urine. This is reflected 
in the amounts of "S metabolites" excreted in urine as well in the higher formation 
clearances of all the "S metabolites". These findings contradict those of Rudy ct al 
IQi 
(1991), «ho reported that the magnitude of CL,,,,, and CLlh, of (R)-ibuprofen to he 
of the same magnitude. Hov, 'e%er en-vibe data using rat hepatocvtcs (\iaotao and 
Hall, 1993) and subsequent reports by the same authors and others (Rudy ei al., 
1995; Smith et al., 1994) support the above finding that CL, n, is the main route of 
clearance for (R)-ibuprofen. The central importance of plasma protein binding is 
again illustrated in the case of the AUC and AUCu values. While there was no 
difference in the AUC for both enantiomers, the AUCu was significantly higher for 
the S-enantiomer (Table 6.5). The mean Vd for the S- enantiomer was also 
significantly higher than that of the IK antipode. That this is again a consequence of 
stereoselective protein binding is apparent from the following expression: 
Vd = Vi, (1+ RrFn) + Vr (f / fr) (eqn 6.1 ) 
where V,, is the plasma volume, R,..,, j is the ratio of plasma binding protein in the 
extracellular fluid to plasma, Vi is the volume of extravascular tissue and f,, and fl 
are the fractions of unbound drug in plasma and tissue respecti\el\ Assigning 
normal physiological values 1.4,3.0L and 30L to RI. V,, and V-r- respectively to 
equation 6.15, then, 
Vd = 7.2+ 30 (f1/f, ) (eqn 6.16) 
(Oie and Tozer, 1979; Lin et al., 1987; Evans, 199? ), As tissue binding is of minor 
importance with ibuprofen, it is therefore clear that the larger V,, of the 
S- enantiomer is most probably a result of the higher unbound fraction. This is 
corroborated by the fact that this enantiomeric difference disappears when ff, is not 
taken into consideration as with the case of Vd,, i. e. the unbound Vd are not 
significantly different between the two enantiomers (Table 6.5). 
The formation clearances of the metabolites of ibuprofen also show 
stereoselectivity for the S-enantiomer. Although this is clearly consistent xý ith 
higher clearances for (S)-ibuprofen, these differences could again be caused by 
stereoselectivit'v in protein binding. However, this was not the case as the unbound 
I- 
I -'__ 
formation clearances were also significantly different- indicating inherent 
enantioselectivity in functional oxidation and ulucuronidation. A comparison 
between the total and unbound formation clearances for the metabolites also reveal 
that the magnitude of the stereoselective differences were smaller with unbound 
formation clearances, again revealing the influence of plasma protein binding on 
disposition, which would be expected for a low hepatic extraction drug (Rowland 
and Tozer, 1989). 
6.5 Conclusion 
Stereoselective differences were observed in the pharmacokinetics of the 
enantiomers of ibuprofen following the administration of the racemic drug to 
healthy young volunteers. Stereoselective protein binding was also evident, with 
higher unbound S- enantiomer concentrations and this stcreoselectiý ity explains the 
differences observed in Vd and AUC,, between the enantiomers. Clearance by 
inversion was the major pathway for (1R)-ibuprofen and the clearance by metabolic 
processes (oxidation and glucuronidation) «was stereoselective for the S-enantiomer, 
being twice as large as the corresponding . alue for the R-enantiomer. The 
formation clearances of the metabolites were also stereoselecti've for (S)-ibuprofen, 
although these processes were inherently stereoselective and did not arise as a result 
of higher unbound S enantiomer concentrations. As regards the clearances of the 
individual carboxyibuprofen isomers, it is clear that the stereochemistrti of the 
substrate influences the stereochemistr<' of the product at the newly formed chiral 
centre. Thus, for (S')-ibuprofen, the preferred product was (2', x. 2. ' )- 
carboxyibuprofen while for (/? )-ibuprofen, the preferred product was (2'k.? k)- 
carboxyibuprofen. The results of this single dose study emphasises the important 
role played by plasma protein binding on the disposition of a highly protein bound 
drug with a low hepatic extraction ratio. 
1; ý 
CHAPTER 7 
Enantioselective Pharmacokinetics of Ibuprofen 
in the Elderly 
1 ý4 
7.1 Introduction 
As a class of compounds, the NSAIDs are extensiv el bound to plasma 
proteins and have low hepatic extraction, i. e_ the intrinsic clearance is low 
compared to hepatic blood flow. As only the unbound fraction is a%ailable for 
clearance, conditions which affect the plasma protein binding of these drugs will 
affect of their pharmacokinetics and disposition (Lin et ul., 1987). As is apparent 
from the results presented in the previous chapter, the unbound fraction of (R)- and 
(S)-ibuprofen are 0.25 and 0.51 % respectively. With such a high extent of binding 
small changes in binding affinity may lead to substantial changes in the unbound 
fraction, and thus significantly affect the pharmacokinetics, disposition and 
pharmacological activity. 
Many physiological and pathophysiological conditions affect plasma protein 
binding. These include ageing, loss of renal function or disease, hepatic disorders, 
stress, surgery, pregnancy, burns and drug interactions (Wallace and Verbeeck, 
1987). Of particular interest here is the effect of ageing, as the NSAIDs are «idely 
used in the elderly population (Walt ei at.. 1986, Johnson er al., 1993). Ageing 
atiects plasma protein binding in two ways: firstly, the serum concentrations of' 
albumin, the major protein to which acidic drugs bind, decreases with aoe. 
Secondly, differences in binding may also be a result of changes in the binding 
characteristics of the albumin (Dawling and Crome, 1989). There is also evidence 
that neonatal albumin differs in biochemical properties from that of adults (Wallace 
ci aal., 1977) and changes in plasma protein binding occur. 
Apart from affecting plasma protein binding, ageing also affects drug 
disposition through other mechanisms. With increasing age, body fat increases with 
a simultaneous decrease in body water (Woodhouse and Wvnne, 1987). Thus highly 
lipid soluble drugs like lignocaine and diazepam tend to have an increased Vd in 
the elderly. Conversely, water soluble drugs like antipyrine would have a reduced 
Vd giving rise to higher plasma concentrations (Vestal ei a, 1., 1975). Of greater 
IS 
importance is the drug metabolising capacity of the liver. The hepatic clearance of a 
drug, CLI,. can be represented as: 
CLh=QxE (egn7.1) 
where Q is the liver blood flow and E is the extraction ratio of the drug. Clearance 
of drugs which have a high hepatic extraction ratio is dependent on hepatic blood 
flow and thus, the decrease in blood flow in the aged affects the clearance of drugs 
like propranolol and morphine (Woodhouse and James, 1990). The intrinsic 
metabolic capacity of Phase I oxidation is also reduced \wh age. Thus, the systemic 
clearance of antipyrine is reduced in elderly subjects, accompanied with a 45 °%o 
decrease in t,, 2 (O'Malley et ul., 1971; Posner ci al., 1987). Compared to other 
physiological functions, renal function undergoes the most significant decrease with 
age, which is , estimated to 
be about 0.62° oa year (Ritschel ei at., 1991). Drugs 
which are principally cleared by renal mechanisms are therefore most affected e. 
digoxin and gentarnicin (Tregaskis and Stevenson, 1990). 
Studies of the influence of age on the phannacokinetics and disposition of 
the 2-APAs are scarce, and do not give a consistent picture. Albert ct ul., (1984 ) 
reported the lack of effect of ageing on the pharmacokinetics on ibuprofen, but the 
clearance of ketoprofen and ibuprofen were reported to be decreased (Greenblatt Ci 
ul., 1984, Advenier el al., 198-33). That these discrepancies in the findings may be as 
a result of measuring only total drug concentrations, rather than both free and bound 
concentrations was highlighted by Upton et ul (1984), who reported that measuring 
only total concentrations masks an increase in the unbound fraction together \ýith a 
concomitant decrease in unbound clearance of naproxen. Clearly, studies in which 
only total drug concentration are measured offer limited information in these 
situations (Rudy eel al., 1995). An additional problem with the above studies on 
ibuprofen and ketoprofen is that the enantiomeric composition of the material in 
plasma was not taken into account. 
186 
The effect of ageing on the stereoselective pharmacokinetics of chiral drugs 
administered as racemates has also been poorly studied. As ageinv affects various 
pharmacokinetic parameters which exhibit stereoselectiv itv e. g. protein binding. 
hepatic metabolism and renal elimination, it is conceivable that the disposition of 
chiral substances will exhibit differences in their stereoselective mechanisms in the 
elderly. In a study of the oral clearance of propranolol enantiomers in young and 
elderly volunteers, the elderly had a lower oral clearance for both enantiomers but 
no stereoselective effects were observed (Zhou et al., 1992). Therefore, the 
decreased ß-adrenergic blocking effect of the drug in the elderly is not due to 
changes in the stereoselective metabolism of the more active (-)-, '-enantiomer. To 
date, differences in stereoselective drug disposition in the aged population have has 
only been reported for hexobarbital and mephobarbital. The clearance of cl- 
hexobarbital was not age-related whereas that of /-hexoharhital was decreased two- 
fold in the elderly. However, as pharmacological activity resides only in the cl- 
enantiomer, the pharmacological response was not affected (Chandler ci ßa1., 1988). 
With mephobarbital, an age and gender-related effect was observed. The (I? )- 
enantiomer was cleared more rapidly than the (L')- antipode in all cases. The oral 
clearance of the R- enantiomer in young men was higher than that observed inboth 
young females and elderly men. However , there were no significant 
differences 
between young and elderly women, or between elderly men and women in 
clearance. Thus the clearance of (R)-mephobarbitone is both age and gender 
related (Hooper and Qing, 1990). The object of the present investigation is to 
examine the pharmacokinetics of ibuprofen enantiomers following the oral 
administration of the racemic drug to healthy elderly volunteers and compare the 
data obtained to that presented in Chapter 6 in a group of young volunteers. During 
the course of these investigations, a report concerning the effect of ageing on the 
enantioselectivity of ibuprofen disposition has been published (Rudy et a!., 1995). 
The results of the present investigation will be compared with those of the stud". by 
Rudy et al., (1995 ). 
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7.2 Experimental 
7.2.1 Clinical Study Protocol 
(a) Inclusion criteria 
Eight healthy elderly volunteers between the ages of 65 to 80 v ears (mean 
age of 69.5 ± 4.4, see Appendix 5 for volunteer characteristics) were studied. The 
volunteers were required to give written informed consent prior to the study and 
underwent a thorough physical examination and routine biochemical tests before 
being recruited into the study. All aspects of the study were conducted according to 
the Helsinki declaration and ethical approval was obtained from the ethical 
committee of School of Medicine and Dentistry, King's College London. 
(b) Study Design 
The volunteers were required to abstain from any medication, alcohol and 
beverages containing caffeine 24 hours prior to the study. They "sere also required 
to starve from midnight prior to the study day until three hours post drug 
administration. Fluids were allowed up to 6 a. m. on the study day. Volunteers 
swallowed a single 400 mg tablet of racemic ibuprofen (Brufen") with a glass of 
150 ml water. Blood samples of 10 ml were collected via an indwelling cannula at 
0,0.2 5,0.5,0.75,1.0,1.5,2.0,2.5,3.0 3.5,4,6,8,10 and 24 hours post drug 
administration. The blood samples were collected in plain vacutainers and left to 
clot for two hours prior to centrifugation and separation of serum. Serum was stored 
frozen at -20°C until required for analysis. Volunteers were also required to empty 
their bladders prior to drug administration. Sequential urine samples were collected 
over the following time intervals, 0-2,2-4,4-6,6-8,8-10 and 10-24 hr, and the 
individual urine volumes were recorded. A pooled 24 hour sample was prepared 
from the individual samples and a 50 ml portion of each of the urine samples saved 
ý' 1 
and frozen at -20°C until required for analysis. Serum albumin concentrations were 
determined as detailed in Chapter 5 and the individual data is presented in Appendix 
5. 
7.2.2 Drug Analysis 
The enantiomeric composition of ibuprofen in serum and urine %%as 
determined using the methods described in Chapter 2. Unbound concentrations of 
ibuprofen enantiomers were determined using the methods described in Chapter 5 
The urinary enantiomeric and diastereoisomeric composition of hvdroxyibuproten 
and carboxyibuprofen were determined using the methods described in Chapter 4. 
7.2.3 Pharmacokinetic and data analysis 
Pharinacokinetic analysis of the serum and urinary concentrations were 
carried out as described for the young volunteers in section 6.2.2. The 
pharmacokinetic parameters derived from the total and unbound serum data and 
urinary excretion data for ibuprofen, carboxyibuprofen and hydroxyibuprofen were 
compared with those obtained for the young volunteers and tested for statistical 
significance using the Student's t-test for independent samples. 
7.3 Results 
7.3.1 Serum level data 
The mean (I? )- and (S)-ibuprofen serum concentration versus time plots are 
shown in Figure 7.1 and the individual serum level data are tabulated in Appendix 


















Figure 7.1 Mean ibuprofen enantiomer serum concentration-time curves 
following the oral administration of the racemic drug (400 mg) to eight healthy 
elderly volunteers (mean ± sd). 
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Table 7.1: Pharmacokinetic parameters of ibuprofen enantiomers following the 
oral administration of the racemic drug (400 mg) to eight healthy elderly volunteers. 












es l 17.7 2.0 1.2 53.0 62.9 6.4 0.65 
es2 20.8 1.5 1.7 80.0 41.7 6.1 0.66 
es3 23.1 1.0 1.6 71.9 46.3 6.6 0.77 
es4 17.8 1.0 2.2 68.6 48.6 9.1 0.60 
es5 15.8 2.0 2.0 68.1 49.0 8.3 0.71 
es6 10.6 0.8 1.5 45.9 72.7 9.5 0.64 
es7 16.8 1.5 1.5 53.4 62.4 8.1 0.57 
es8 20.2 1.0 2.0 73.3 45.5 8.0 0.6 3 
Mean 18.4 1.2 1.7 64.5 5 3.4 7.8 0.64 
SD 4.0 0.4 0.3 1 1.8 10.7 1.2 0.1 
CV% 22 0 33 7 16 8 18 3 20 1 1 15 0 11 . . . . . . . 
Y vs E n. s. n. s. n. s. n. s. n. s. n. s. n. s. 
p value** 
(S)-ibuprofen 
esl 20.2 1.0 ?.? 81.5 63.8 12.3 
es2 18.2 1.5 2.6 77.8 71.2 16.0 
es3 21.4 1.0 2.2 83.4 70.8 13.7 
es4 17.1 2.5 4.1 104.0 51.4 18.0 
es5 13.6 2.0 2.3 61.1 93.4 18.9 
es6 15.4 2.0 2.8 93.5 1 58.4 14.3 
es7 18.0 1.5 2.4 97.4 53.7 11.1 
es8 16.4 1.0 2.4 62.3 87.2 17.9 
Mean 17.5 j 1.6 2.6 82.6 68.7 15.3 
SD 2.5 0.6 0.6 15.6 15.2 2.9 
CV°o 14.3 36.0 ? 3.1 18.8 22.1 18.8 
p value n. s n. s. P<0.005 n. s. n. s p<0.0001 
Y vs E** n. s n. s n. s n. s n. s n. s 
n value 
* Comparison between the means of the enantiomers of ibuprofen were carried out using a Student's t-test 
for paired samples. (n. s. = p>0.05). 
" Comparison between respective means for young and elderly volunteers were carried out using a 
Student's t-test for independent samples (n. s. = p> 0.05). 
IL)l 
Following the oral administration of 400 mg racemic ibuprofen serum 
concentrations of the 1X- and S-enantiorners were similar to those obtained with the 
young volunteers. The difference in tit, values between the enantiomers were also 
statistically different in the elderly (p < 0.005), with the S-enantiomer halving a 
significantly longer t112 . 
Similar differences in CL and Vj were also observed 
between the individual enantiomers. However, the difference in CL did not achieve 
statistical significance in the case of the elderly volunteers. Comparison of the 
values of the various phannacokinetic parameters between the young and elderly 
group did not reveal any age related differences (Table 7.1). 
7.3.2 Urinary excretion data 
The urinary excretion data for ibuprofen and its metabolites for the elderly, 
group are summarised in Table 7.2 and the individual data tabulated in Appendices 
17 to 25. The calculated fractional inversion and formation clearances are tabulated 
in Tables 7.1 and 7.3. The total amount of drug related material recovered in the 0- 
24 hour urine is 84.1 (+ 7.9) %. The hydroxv and carboxv metabolites formed X7.7 
and 46.0 % of the administered dose excreted in urine. Unchanged ibuprofen. 
accounting for 9.7% of the administered dose was excreted mainly as the acyl 
glucuronide (9.2%, Table 7.2). As with the young group, ibuprofen was excreted 
mainly as the S-enantiomer (8.8%) with an . ti/R recovery ratio = 9.4. Stereoselectivc 
clearance was also observed with the hydroxyibuprofen and the carboxv ibuprofen 
metabolites as reflected by the respective formation clearances, ýýhich were 
significantly greater for the metabolites derived from (. S')-ibuprofen compared to 
those of the R- enantiomer (Table 7.3). The urinary recover` of the . S'-hvdroxv 
metabolite showed marked stereoselectivity compared with that of the R-antipode 
(SIR = 5.1) and preferential conjugation of the S-enantiomer was also evident (ratio 
conjugated/ free. S=2.9, R-1.0). Thus, the substrate stereoselectivity for the 
formation of hydroxyibuprofen and preferential stereoselectivity for conjugation 
observed in the young volunteers were also observed in the elderly group. The ratio 
(S R) of the formation clearances of hydroxyibuprofen was found to be 4.2, \%hich 
1,,, 
Table 7.2: Urinary excretion of ibuprofen and hydroxyibuprofen enantiomers and 
carboxyibuprofen stereoisomers following the oral administration of the racemic 
drug (400 mg) to eight healthy elderly volunteers (data expressed as a percentage 
of dose). 
I Mean A. Range 
(R) - ibuprofen 







(R) - hydroxyibuprofen free 
conjugated 
total 




(2'S, 2R) free 
conjugated 
total 
(2'R , 2R) free: 
conjugated: 
total: 
(2'R, 2S) free: 
conjugated: 
total: 
(2'S, 2S) free 
conjugated 
total 
0.04 0.02 0.02 - 0.07 
0.89 0.33 0.68 - 1.44 
0.93 0.34 0.4 3 -1.48 
0.48 0.09 0.31-0.56 
8.32 2.12 5.27-1206 
8.79 2.17 5.66 - 12.5 8 
2.31 1.04 0.99-3.49 
2.24 0.96 1.17 - 3.86 
4.56 1.73 2.17-7.35 
5.86 2. -) 1 3.71 - 9.26 
17.28 5.00 9.53-24. O-3 
23.14 5.54 15.03 - 32 53 
2.30 3.71 0.79 - 3.49 
1.07 0.88 0.25 -2-57 
3.37 0.96 1.53 -4.49 
3.07 4.51 I 1.44-4.20 
?. 55 0.87 0.78 - 3.89 
5.62 1.08 f . 59 - 7.25 
10.41 4.30 6.27 - 15.78 
6.74 3.80 2.51-11.83 
17.15 5.58 14.70 -20.20 
10.45 j 4.39 5.85 - 15.86 
9.38 5.13 2.27-21.49 
19.83 5.65 16.36 - 16.86 
Total recovery 1 84.14 1 7.92 1 69.28 - 96.11 
Comparison between the means for the enantiomers of ibuprofen and hydroxyibuprofen and the 
stereoisomers of carboxyibuprofen derived from (R )- and (S )-ibuprofen were carried out using Student's t- 
test for paired samples and were found to be statistically significant for all species (p >0 005) 
Comparison between the means for the individual stereoisomers of carboxyibuprofen derived from (R )- and 
(. 9-ibuprofen respectively were done using a Student's t-test for paired samples 
The means tested were found to be statistically significant (fp < 0.005) for the stereoisomers 
derived from (R)-ibuprofen but were not significant for those derived from (S)-ibuprofen (p > 0.05) 
Note: Comparison between respective means for youung 
and elderiv volunteers were carried out using 
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was not significantly different from that found in the young volunteers (S 1? 
Tables 6.3 and 7.3 ). 
As with the young, the formation clearances for the carboxv'ibuproten 
diastereoisomers arising from the oxidation of the respecti\ e 1? - and S- enantiomers 
of ibuprofen indicate substrate stereoselectivity for the latter (Si!? = 3. ý ). For the 
formation of the individual stereoisomers, substrate-product stereoselectD. ity \%ith 
the predominantly formed diastereomer having the same absolute configuration at 
the newly formed chiral centre, i. e. oxidation of (R)-ibuprofen preferentially yields 
(2'1?, 211)-carboxyibuprofen while (S)-ibuprofen preferentially forms (2'S, 2. ti)- 
carboxyibuprofen. However, comparison of the product stereoselectiv it\ between 
the young and elderly for the R- enantiomer (2'/?, 21? /2', ß, 21? = 1.75 for the young., 
1.67 for the elderly), and for the (S')-antipode (2'S, 25 2'I?, 2S = 1.22 for the young, 
1.15 for the elderly) showed reduced stereoselectivity, such that the difference for 
the latter did not achieve statistical significance. 
The extent of chiral inversion, F;,,,. is tabulated in Table 7.1. The mean value 
of 0.64 is similar to that of 0.68 obtained with the young group. The small 
interindividual variability of F;,,,. observed in the young volunteers is also evident 
here. 
7.3.3 Plasma protein binding and pharmacokinetic parameters based on 
unbound concentrations. 
The main differences between the young and the elderly groups are with the 
plasma protein binding and pharmacokinetic parameters based on unbound levels, 
the values of which are presented in Tables 7.4,7.5 and 7.6. The mean percentage 
unbound values for the (R)- and (, Y)-ibuprofen are 0.30 and 0.76 °'o respectively, the 
difference being statistically different (p < 0.001), an observation also found with 
the young volunteers (Chapter 6). However, a direct comparison of the protein 
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the unbound fraction of the R-enantiomer was similar for both the young (0.25 
0.08) and elderly (0.30 ± 0.12), the elderly, shoved a significantl\ higher traction 
for (S)-ibuprofen (young, 0.51 ± 0.19: elderly- 0.76 ± 0.30; p< (1) 0001 ) 
The pharmacokinetic parameters based on unbound concentrations (Table 
7.5) showed the same enantioselectivity between (R)- and (S)- ibuprofen as found 
with the young volunteer group, with differences in AUC1, . tip . and 
Cl, (see 'rabic 
7.5 for p values) between the 1? - and S- enantiomers. A statistical comparison 
between the young and elderly again reveal age-related differences in 
stereoselectivity. Although there were no differences in the unbound 
phan-nacokinetic parameters of (R)-ibuprofen between the two grroups, major 
differences were observed in the case of the . ti-enantiomcr for Al IC and Cl, . 
indicating that the elderly have a poorer clearance of the active (, ý)-ibuproten (Cl, , 
young 15.9 L/min; elderly 9.7 L/ -nin ). 
The age-related differences in the unbound clearance of (. ' )-ibuprofen are 
also reflected in the unbound formation clearances of the oxidative metabolites 
derived from the S-enantiorner (Table 7.6). While there \ýere no a<ie-related 
differences in the unbound formation clearances of the oxidati\ e metabolites 
derived from (R)-ibuprofen, the unbound formation clearances for (I )- 
hydroxyibuprofen, (2'1?, 2k' )- and (2's, 2)-carboxvibuprofen for the elderly \\ere 
sionificantly lower (p < 0.05) which indicates that clearance through the major 
metabolic pathways are reduced in the elderly Clearance through direct 
glucuronidation of ibuprofen, a relati\ el\ minor pathway, tends towards lower 
unbound clearances for both enantiorners in the elderly, but these differences did not 
achieve statistical significance. 
A close examination of the unbound formation clearances of the individual 
carbox\'ibuprofen diastereoisomers also reveal some age related differences. In the 
young group, substrate related product selectivity was observed,. but the difference 
wwas markedly reduced in the elderly. The differences in the unbound formation 
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Table 7.5: Pharmacokinetic parameters based on unbound concentrations of ibuprofen 
enantiomers following the oral administration of the racemic drug (400 mg) to eight 
healthy elderly volunteers. 
Subject 
No: 
_ % unbound AUCu 
(mg/ml hr) 
(R )-ibuprofen 








es 1 0.29 0.16 0.98 1793.5 21.05 11.79 ý 9.26 
es2 0.23 0.18 1.56 2446.8 18.12 11.96 ' 6.16 
es-3 0.41 0.29 1.70 1664.3 1 1.1 8.71 ? 60 
es4 0.29 0.20 1.84 2669.3 16.76 10.05 6.70 
es5 0.19 0.13 2.02 4505.5 -1-5.76 
18.29 7.47 
es6 0.41 0.19 1.43 2193.0 17.71 1 1.34 6. I8 
es7 0.25 0.13 2.60 5620.7 24.97 14.23 10.74 
es8 0.36 0.26 1.97 2154.5 12.63 7.96 4.67 
mean 0.30 0.19 1.76 2881.0 18.54 11.79 6.75 
A. 0.08 0.06 0.47 1416.4 522 29 2.5 3 





Y vs E** n. s n. s n. s n. s n. s n. s n. s 
p value 
(S)-ibuprofen 
es l 0.76 0.62 1.14 828.6 8.40 
es2 0.89 0.69 2.15 1487.6 7.99 
es-) 0.87 0.73 1.62 1140.5 8.13 
es4 i 0.50 0.52 3.80 3374.4 10.26 
esS 1 0.57 0.35 3.79 5370.5 16.37 
es6 1.12 1.05 2.49 11-2-5.4 5 .» 
es7 0.47 0.46 2.67 ? 642'. 7 11.43 
es8 0.89 0.55 2.12 1798.6 9.80 
mean 0.76 0.62 2.47 2221.0 9.70 
s. d. 0.23 j 0.21 0.95 1 1533.0 3.27 
cv (° 0) 30.02 34.09 38.27 69.0 33.73 
p value* Jp<0.0005 £p< 0.0005 1) < 0.051 n. s. p<0.001 
YvsE** 
p <0.0001 p <0.01 n. s. n. s. <0.001 
p value I 
Comparison between the means of the enantiomers of ibuprofen and hydroxyibuprofen and that of the 
individual stereoisomers of carboxyibuprofen and the stereoisomers of carboxyibuprofen derived from (R )- and 
(S )-ibuprofen were carried out using Student's t-test for paired samples. n, s=p>0.05. 
" Comparison between respective means for young and elderly volunteers ý%ere carried out using Student's t- 




ý; d U 
OU 







L ß ~ 













.. ý a! 



























_l - - - 1 r", - r1 r] (' ý. rte,  f'1 
r" r C ý^ "t 'im -- ^- Oý rte, * ^ý ti Qý 
-- rl -t O 1 r r ý -T 
v 
ý rl 1 ý 
Oj M 00 M 00 fN 
.. O o4 \p 00 O ^- 00 ON ý. O -- [N W vi . c3 
UiN 
c` 1 p (ýj rr, - rj r- r! ^ r' 1 'r = 
O M A O N x O 
O C) ('14 -T 
I 
1 . 
h CD -It Ö (ON 00 
CO: ) 
o 




-- vý oo cýJ cý tý cý r t` ý^ 
M M M '7 M '-r (' r^, -- ßr1 = 
-r - -- oý 'n (-I oc r- 0 ý- W-ý t- "C o O', in [- t- O r 
O r r" 1 O- N V (V N- --- -f 1.0 M 
77 -, 
'r, I- 'ý tf) r- I '7 -O r'1 C- Q\ n, 
ýrl 
T 
oN - W-) M M C`7 M 'n r"l r- O N 
f ^ N "O [- Wn N O O M 
w 
p 
2 ) . 
O - 
- -. O O I- O 'n lam- ' v1 'n .O 1 vi M 'TT -- N M M M 
0 0 0 0 0 0 0 O O Itil 
U 
- O -- 




















> C3 :f 
































U \: yl 
t I. 
199 
clearances between the 2'. ß', 2R- and 2'R, 2R- diastereoisomers in the voun, T and that 
in elderly are similar (Table 7.6). However, the difference in unbound formation 
clearances between the 2'1?, 2. ''- and 2', ß', 2S- diastereoisomers which was sienificant 
in the young (p < 0.005) with the 2'S2. ß'- diastereoisomer being the preferred 
product, disappeared in the elderly. The formation of both the 2'R. 2, ß'- and (2 
diastereoisomers were markedly lower in the elderly, but a greater decrease was 
recorded for the 2'S2. `ß'- isomer, ageing resulting in reduced formation of the 
diastereoisomers arising from (S)-ibuprofen and also a reduction in product 
stereoselectivity. 
7.4 Discussion 
Previous studies comparing the pharmacokinetics of ibuprofen in the ý'oun`g 
and elderly were mainly based on non-stereoselective drub; determinations, and have 
reported conflicting results. Ibuprofen clearance was found to be slightly but 
significantly lower in elderly men than in young male subjects (Greenblatt et al., 
1984). In another study, however trends towards a higher total clearance, but lower 
clearance and volume of distribution based on unbound levels, were found in the 
elderly, although these did not reach statistical significance (Albert ct a/., 1984). 
Two major factors appear to influence the total clearance of ibuprofen, 
protein binding and unbound or intrinsic clearance. A consideration of the influence 
of these two processes are further complicated when the stereochemistry of the drug 
is taken into account, with the additional problem of chiral inversion of 
(/? )- ibuprofen In the case of the R-enantiomer, there appears to be no significant 
age associated effects in protein binding, total unbound clearance and inversion 
clearance. However, in the case of (S)-ibuprofen, protein binding and unbound 
clearance appear to operate in opposite directions v*hich results in no apparent 
differences with age when total drug enantiomer concentrations are determined. 
Thus, the increase in fraction unbound with age (young, 0.51; elderly 0.76) negates 
the observed decrease in unbound clearance (young. 15.9 L/min; elderly. 9.7 I. ''min). 
0( ) 
A similar observation has also been reported for the related NS. \ID naproxen 
(Upton ei ul., 1984). 
The decrease in the unbound clearance of (S)- ibuprofen with age can either 
be due to reduced metabolic function and/or reduced renal elimination of the readily, 
hydrolysable glucuronide conjugates (Upton et a!., 1984). However, the parallel 
reduction in the respective unbound formation clearances of the oxidatke 
metabolites derived from (S)-ibuprofen, but not the extent of excretion of the 
metabolites over 24 hours strongly suggests that the former is the most probable 
cause. As the clearance of the S-enantiomer by oxidation represents the main 
metabolic pathways, this stereoselective reduction in clearance of the (S)-ibuprofen 
but not that of the R-antipode suggests that the more active metabolising enzyme(s) 
or sites of the enzyme(s) are principally affected with ageing. This age-related 
effect also influenced product stereoselectivity in the case of (2'R, 2- and 
(2'S', 2, ß')- carboxyibuprofen, where the product stereoselectivit` for the formation of 
(2 S, 2S')- isomer observed in the young was lost in the elderly. In the study of ageing 
on the stereoselctive disposition of hexobarbital, it was postulated that separate 
isoenzymes may be involved in the metabolism of the (+)- and (-)- enantiomers and 
that ageing alters the activity of the isoenzymes responsible for (-)- hexobarbital 
metabolism (Chandler el u/.. 1988). 
In contrast to the age-related differences in clearance of the major oxidati%e 
metabolites, clearance via the minor glucuronidation pathway did not exhibit any 
significant differences, although there was a trend towards a lower clearance for 
both enantiomers in the elderly. It has been suggested that Phase II glucuronidation 
is not generally affected by ageing (Mooney a a!., 1985) and if this assumption 
holds true in the case of ibuprofen, then the small reduction may be attributed to 
reduction in renal clearance, which is generally observed in the elderly. As 
glucuronidation represents only a minor elimination pathway, any slight decrease in 
renal clearance will not manifest itself clearly, thus explaining the slightly lower but 
not significantly different clearance in the elderly. With ketoprofen, a 2-APA 
principally cleared by glucuronidation, clearance was reduced in elderly subjects 
() I 
(Advenier ci ul., 1985, Dennis el ul., 1985). Whether this decrease was caused by a 
decrease in glucuronidation or reduced renal elimination could not be ascertained 
but the weight of evidence in these studies seems to suggest renal causes. 
In the elderly, increases in the unbound fraction of drugs such as diazeparn. 
phenytoin and warfarin have been well documented (Tregaskis and Ste\ enson, 
1990). With the 2-APAs, a significant increase in the unbound fraction of naproxen 
has been reported (Upton et al., 1984). The results presented here indicate that 
ageing stereoselectively increased the unbound fraction of (, S')-ibuprofen, but not 
that of (R)-ibuprofen. Whilst it is generally accepted that the increase in fraction 
unbound may be due to lower serum albumin concentrations in the elderly (Wallace 
and Verbeeck, 1987), this does not seem to be the case here as the serum albumin 
concentrations (see Appendix 8) measured did not show appreciable differences 
between the two groups, an observation also reported for naproxen \t here the small 
difference in serum albumin could not account for the large difference in protein 
binding (Upton el ul., 1984). Also the unbound fraction of (J? )-ibuprofen was not 
significantly affected, which would be expected if lower serum albumin had been 
the cause. It has also been suggested that the increase in unbound (S)-ibuprofen in 
the elderly may be due to the displacement of protein binding by the oxidative 
metabolites (Rudy et al., 1995). If this is the case then the difference with the 
elderly would be because of higher amounts of oxidative metabolites generated 
compared to the young group, leading to increased displacement. However as the 
formation clearances of the metabolites are actually decreased in the elderly, as 
reflected in the lower unbound formation clearances, this explanation seems 
unlikely. 
In contrast to the observed differences in plasma protein binding, there was 
no significant change in the Vd, . 
Generally one would expect changes in plasma 
protein binding to be accompanied by parallel changes in Vd,, provided that the 
fraction unbound in tissue does not alter. The quantitative relationship betxv, een Vd 
and protein binding is given by (see Chapter 6, section 6.4) : 
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V,, = 7.2+ 30 (fu/fr) (eqn 7.2) 
Thus from equation 7.2, it is apparent that Vd depends on f, as well as t, For a 
highly protein bound drug like ibuprofen, f, approaches zero and V; is 
approximately 7.2L, which is essentially the volume of distribution of albumnin, and 
changes in f, will not have a significant effect on the value of Vd (Lin el al., 1987 º. 
as illustrated in the results of this study. 
The fact that plasma protein binding and unbound clearance vary in opposite 
directions with age tend to present a false picture of the underlying pharmacokinetic 
changes that occur in the elderly. This illustrates the limited utility of performing 
pharmacokinetic studies based solely on total drug concentrations. Since it is the 
unbound concentrations that elicit pharmacological effects. the increase in unbound 
(S)-ibuprofen levels suggest that the elderly may experience an enhanced response 
and side-effects to the drug as compared to the young. The implications of this 
together with the effects of other pathophysiological conditions commonly 
associated with the elderly are discussed in Chapter 8. 
While this study was in progress, a report of the enantioselective disposition 
of ibuprofen in the elderly with and without renal impairment appeared in the 
literature (Rudy et al., 1995). Some of the reported findings support the 
observations of the present study. A stereoselective increase in the unbound fraction 
of (. ti)-ibuprofen was reported in both groups of elderly subjects. However, the 
decrease in the unbound clearance of (S)-ibuprofen was only significant in the 
renally impaired group, but not in the healthy elderly subjects, unlike the findings of 
this study and that of Upton et al (1984), for naproxen. Strangely, the reduction in 
unbound drug enantiomer clearances was not accompanied by the expected decrease 
in the formation clearances of the major oxidative metabolites as demonstrated in 
the present study. This anomaly was, however not addressed (Rudy ei al., 1995). 
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7.5 Conclusions 
The differences between the pharmacokinetics (K)- and (S -ibuprofen 
observed in the young were also observed in the elderly. A comparison between the 
young and elderly showed that ageing appeared to have a minimal effect on the 
pharmacokinetics based on total drug concentrations. However, N. hen unbound 
concentrations were used, various age-related changes in the stereoselecti\ c 
disposition were observed. The fraction unbound was higher for the (Y)-, but not 
(R)-ibuprofen in the elderly. The unbound clearance of the S-enantiomer was 
reduced in the elderly and its effect on plasma clearance was masked by the increase 
in unbound fraction. This decrease in unbound clearance was reflected in the 
decrease in unbound formation clearances of the major oxidative metabolites, while 
the minor glucuronidation pathway was not significantly affected. 
Thus the data presented above indicate that age associated differences in the 
pharmacokinctic properties of ibuprofen do occur and indicate the significance of' 
determining both free and total drug levels together with their enantiomeric 
composition. The significance of these observations will be examined in Chapter 8. 
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CHAPTER 8 
General Discussion and Conclusions 
-)0S 
8.1 Introduction 
The studies described in this thesis were initiated to inýestiýate the 
enantioselective disposition of ibuprofen in the young and elderly. There are many 
reports of the enantioselective disposition of ibuprofen in healthy \oung subjects 
using various experimental designs, but very few of them has e actual IN, attempted to 
obtain a comprehensive picture of the relative magnitudes of the N arious 
dispositional processes. This is especially true in the case of the major metabolite, 
carboxyibuprofen, where analytical difficulties have prevented the elucidation of the 
stereoselectivity in the formation of the four stereoisomers. These issues has e been 
addressed in this study. 
Despite the fact that ibuprofen and related NSAIDs are frequently 
administered to elderly patients for the relief of inflammation and pain associated 
with rheumatoid arthritis (Walt et ul., 1986; Johnson ei al.. 199-33), there is a curious 
lack of attention of the influence of ageing on drug disposition. Studies based on 
non-stereospecific assays on ibuprofen (Greenblatt e/ al., 1984, Albert e/ cal., 1984). 
ketoprofen (Advenier e/ ul., 1983) and naproxen (Upton e/ ul., 1984) have reported 
disparate findings of the effects of ageing and it was hoped that a study such as this 
would present a clearer picture. 
8.2 Enantioselective analysis of ibuprofen and its metabolites 
The indirect approach to enantioselective analysis offers an economical 
alternative towards an otherwise expensive procedure. The method used in this 
study, being based on a reversed phase Cix column is relatively cheap to operate and 
is v'erv robust, the same column being used for the urine and serum samples in both 
the young and elderly groups. Although not generally favoured because of long 
reaction times, derivatization with CDI and (RR)-NEA in the presence of HOBT is 
essentially quantitative and has not posed problems like racemization, which has 
been known to occur with the mixed anhydride method (Hutt ei al., 1994). This 
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reaction approaches that of a "universal" method applicable for the indirect analysis 
of the profens, an idea put for and by Spahn (1987). Using the same column and 
with minor modifications to the acetonitrile content in the mobile phase, other 
profens e. g. ketoprofen, carprofen, tiaprofenic acid were successfully' resolved 
(unpublished observations). (R)-1-(Naphthen-l-vi)ethvlanmine being a strong 
fluorophore affords an extra level of sensitivity when used with a fluorescence 
detector. Thus with the better mass delectability afforded b,,, a semi-microbore 
column, the methodology was adapted for the determination of unbound enantiomer 
concentrations. Although unbound concentrations of less than 5 ngiml could not he 
determined, the use of chiral amines with a stronger fluorescence properties k% ill 
help to improve detectability. Reagents based on anthracene or naphth`lamines. 
with strong electron donating substituents, are ideal for this purpose. With 
increased sensitivity, future studies on plasma protein binding of chiral acids can he 
carried out without resorting to the use of radiolabelled compounds. The ad antages 
of this approach are obvious, as unbound enantiomer concentrations can he 
determined directly without the hazards associated with the handling of radioacti%e 
substances. 
The main drawback of the indirect method, especially if strong fluorophores 
or chromophores are used, is that excess chiral amine, v hen injected into the HPLC 
system will yield a large reagent peak that inevitably causes interference problems 
of co-elution. However, a silica solid-phase extraction cartridge serves as a good 
scavenger as the excess amine «rill bind to the acidic silanol groups, while allowing 
the neutral diastereomeric amides to flow through. 
In addition to being commercially available in high purity, both the I? - and 
. ti-enantiomers of NFA are available. 
This adds flexibility to the approach as the 
order of elution of the enantiomers can be controlled by judicious choice of the 
chiral amine. In a reversed phase system, using (K)-NEA as derivatizing reagent, the 
order of elution of the diastereomeric amides is (R)-before (, ý)-ibuprofen derivative. 
When (Y)-NEA is used, the order of elution is reversed. In the method developed, 
(! l)-NEA was chosen as derivatizing reagent in order to elute the (R)-ibuprofen 
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derivative first as (K)-ibuprofen concentrations were expected to be lower than 
those of the S-enantiomer in serum, and earlier elution would reduce the effects of 
band broadening on a smaller peak. Under normal phase conditions, the order of 
elution is again the opposite of that for reversed phase systems (Hutt et a!., 1994), 
This flexibility is a useful aid in the assignment of stereochernical configuration to 
chromatographic peaks in a group of closely related compounds. 
Sensitivity of analytical procedures are often reported as minimum detection 
limits, which is not a true reflection of the ability of the method to quantify in a 
reproducible manner at those concentrations reported. A more useful method is to 
report the minimal quantifiable limit, which is the minimum concentration at which 
the procedure is able to quantify an analyte in a reproducible manner, as had been 
done with the method developed. In spite of the difficulties in comparing analytical 
sensitivity with those previously reported, the analytical method presented is more 
sensitive than those bioanalytical HPLC procedures based on CSPs (Nicoll-Griffith 
ei a!., 1988; Geisslinger et ul., 1989, Li el at., 1993; Naidong and Lee, 1994, de 
Vries ei ul., 1994), equally if not more sensitive than those based on indirect 
approaches with UV detection (Lee el ul., 1984: Aý gerinos and Hutt, 1987, Mehvar 
el cr!., 1988), and equally sensitive with the method based on fluorescent detection 
(Lemko er a!., 1993)). Examination of sample chromatograms presented in the 
literature indicates that the resolution between the diastereomer derivatives, and 
from co-extracted endogenous substances, obtained using the method presented in 
Chapter 2 were superior to those methods cited aboxe. In addition peak shape was 
more symmetrical than those obtained from use of CSPs. 
Separation of the stereoisomers of carboxvibuprofen by the indirect 
approach did not give good resolution and separation of the four stereoisomers was 
not possible within a reasonable run time due to co-elution of two of the 
stereoisomer derivatives, as has been reported by other workers (Kaiser el ul., 1976, 
Young a al., 1986; Nicoll-Griffith ei cal., 1988; Baillie et a!., 1989). This was 
solved by the use of the Chiralpak AD CSP which Dave baseline separation for both 
enantiomers of hydroxyibuprofen and all four stereoisomers of carbo\\ ibuprofen. 
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Also, unlike alternative CSPs such as those based on proteins. polysaccharide 
columns have a relatively high loading capacity so that larger amounts of material 
could be injected on-column without appreciable loss of resolution. This. coupled 
with the better than baseline resolution of the four carboxvibuprofen stereoisomers. 
enabled on-column injections of up to 500 µg of the racernate. In this manner 
milligram quantities of the individual diastereoisomers could be isolated from the 
analytical column and this allowed the chiroptical properties to be recorded for the 
individual isomers for the first time. It was hoped that the stereochemical 
configuration could be assigned on the basis of the CD spectra alone. Ilowever, 
although differences in the CD bands were observed at the 225 nm band, which 
corresponded to the n -i it` transition of the carbonyl group, the stereochemical 
assignment could not be carried out with certainty. This was only solved by a 
combination of stereoselectivve synthesis (carried out by Dr. K. Afarinkia of the 
Chemistry Department, King's College London), chromatographic separation using a 
polysaccharide chiral CSP and isolation of the ". ti' metabolites" after administration 
of ()-ibuprofen. After assigning the stereochemistry, it was clear that the ne\Ov 
formed chiral centre in the isobutyl moiety had a Cotton effect in a similar direction 
at the 225 region but of smaller intensity compared to the original chiral centre, for a 
similar stereochemical configuration. 
For the urine analysis of hydroxyibuprofen and carboxyibuprofen, the use of 
the sequential achiral-chiral chromatography approach ensured that only "clean" 
samples were introduced into the Chiralpak AD column, thus ensuring long term 
stability, efficiency and reproducibility. Although an extra chromatographic step 
was introduced into the methodology, sample clean-up steps were simplified, so that 
only a one-step solvent extraction was necessary. Also, time spent for the 
development of sample clean-up procedures were reduced. This procedure has the 
potential to be coupled and automated on-line. With the use of a switching valve, 
the eluent from the normal-phase column containing the peaks of interest can be 
diverted onto the CSP \vithout detriment to chromatographic resolution, as the 
mobile phases of both systems are compatible, differing only in the ethanol content. 
The sole cent strength of the achiral phase is much weaker (2 °o'. v, ethanol 
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compared to that of the chiral phase (8% v/v ethanol). Hence diverting I-2 ml of 
the achiral mobile phase onto the CSP should not affect resolution as there would 
be a concentration effect on the chiral column, resulting in peak sharpening. 
8.3 Pharmacokinetic investigations of ibuprofen in the young 
The development of enantioselective methods for the determination of 
ibuprofen and its metabolites in biological fluids facilitated pharmacokinetic studies 
following administration of the racemic drug in human volunteers. The 
pharmacokinetic data, based on serum, urinary and unbound drug concentrations 
enabled the stereoselectivity of various dispositional processes to be determined. 
(a) Effect of plasma protein binding 
The data presented in Chapter 6 derived from an examination of drug 
disposition in healthy young volunteers revealed enantioselective differences in the 
pharmacokinetics of ibuprofen, particularly in t1/2. CL and Vd , as 
has been reported 
previously (Van Giessen and Kaiser, 1975, Lee ci ul., 1985; Cox el ca/.. 1988; 
Avgerinos and Hutt, 1990). Before inherent stereoselectivity can be inferred, the 
effect of enantioselective protein binding has to be considered. The influence of 
plasma protein binding is obvious wehen the total and unbound CL and Vd are 
compared. As discussed in Chapter 6, the difference in Vd between the enantiomers 
was obviously due to protein binding, while there was evidence of stereoselectivitv 
favouring the (, S)- enantiomer in metabolic oxidation and glucuronidation Thus, 
because of the central modulating role of plasma protein binding, it is of utmost 
importance that unbound concentrations be determined in pharmacokinetic studies 
of the "profens". 
A comparison of the magnitudes between CL and CL,, demonstrates that 
plasma protein binding is the limiting feature in the clearance of ibuprofen, as CL, 
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is two orders of magnitude larger than CL. Therefore factors that decrease plasma 
protein binding would have a profound effect on drug clearance. However, because 
the inherent unbound clearance is unchanged, the increase in free drub; 
concentration would only be transient, and at steady state, free drug concentration 
would remain unchanged despite increased total clearance (Aarons and Rowland, 
1981) 
. 
Of greater importance is if the unbound clearance is decreased as would be 
expected with hepatic disorders. In such a case, higher free concentrations would 
result, leading to enhanced pharmacological effects and possibly toxicity. It is also 
important to consider the ability of ibuprofen and other 2-APAs to displace other 
drugs from protein binding sites. In-vivo and in-varu studies indicate that mutual 
displacement of the enantiomers of ibuprofen from protein binding sites occurs 
(Paliwal ei ul., 1993; Evans et ul., 1989) resulting in an increased unbound fraction, 
with a corresponding increase in total CL and a lower AUC. Thus, the AUC of (R)- 
ibuprofen after a 400 mg oral dose of is significantly greater than the corresponding 
value after 800 mg of the racemic drug (Lee ci al., 1985), an observation also 
reported for flurbiprofen (Knadler el a!., 1989). Hence the enantioselecti'ity in 
the pharrnacokinetics depends not only on the dose but also on the form 
administered i. e. individual enantiomer or racemate. 
(b) Chiral inversion 
The unidirectional chiral inversion process is unique to the 2-APA group of 
drugs and as such has been subject to much research attention as to its mechanism, 
extent and factors that affect it. The degree of inversion calculated in this study was 
0.68 ± 0.07, and falls within the range of reported values of between 0.51 to 0.71. 
(Lee et al, 1985; Baillie ei a4 1989; Geisslinger ei a(, 1990; Rudy (-ei al., 1991; Hall 
et a. 1,1993; Smith et a!., 1994). The wide range of values are probably a result of 
the different methods used to estimate F,,,,.. Also a wide v, ariet} of experimental 
designs were employed, leading to different estimates, which is a reflection of the 
complex processes involved in the enantiomeric disposition of ibuprofen. The 
fraction inverted estimated based on the AUCs of plasma-le\ el time cures after 
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separate administration of the RK- and N- enantiomers assumes that the clearance of 
the S- enantiomer is independent of (R)-ibuprofen, i. e. whether gi%en alone or 
derived from the R- enantiorner via inversion. Ho«ever, as mutually competitive 
protein binding displacement of enantiomers occurs in-vivo (PalMal e/ al.. 199 º. 
this assumption is not necessarily valid. The alternati\ e method aý ailable when 
racemic doses are used is based on the urinary recover- method, as was used in the 
present study. Implicit in this method are the assumptions that all the dose is 
ultimately recovered in the urine and that the metabolites do not undergo inversion 
to an appreciable extent. Of an orally administered dose of radiolabelled ibuprofen, 
about 95% has been recovered in urine (unpublished observation by Boots Co. Ltd, 
Nottingham, U. K., cited by Lee of al., 1985) and of this about 85°0 has been 
accounted for as ibuprofen and its major metabolites (Chapter 6). As such the first 
assumption of mass balance is not necessarily valid as the remaining cu 15°o of the 
dose may have an influence on F, n,., albeit small. The second assumption is 
supported by in-vitro evidence that neither hvdroxyibuprofen and carhoxyibuprofen 
inhibit the formation of (1? )-ibuprofenyl-CoA thioester (Tracy cl a!., 1993, Ilall cl 
al., 1993). However, this need not necessarily be true in-vivo. Theoretically, a 
method based on the administration of a pseudoracemic mixture would circumvent 
most of the problems encountered. However, a direct comparison between the 
pseudoracernic method and the urinary recovery method revealed that slightly higher 
but more consistent values were obtained with the urinary recover` method, the 
reasons behind this are not entirely clear (Rudy e> u!., 1991). As such, these 
determined values of F;,,, should be considered the best estimates of the magnitude 
of the inversion process under the experimental conditions involved. Of greater 
importance is the fact that the interindividual variation in the extent of inversion is 
relatively small, as shown in this study as well as others (Lee el uL, 1985; Smith el 
ur:, 1994), indicating that the chiral inversion is a relatively "stable" process, i. e. the 
fraction of the dose presented to the body in the active form is relatively predictable 
in healthy subjects. 
Although chiral inversion is generally accepted to be a unidirectional 
process, experiments in rats dosed with 2-phen\ lpropionic acid have shown 
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inversion in the reverse direction from . ''- to 1l- (Fournel and Caldwell. 1986). 
Recently, indirect evidence of this "reverse inversion" of ibuprofen in humans was 
provided in the form of the discovery of taurine conjugates in urine (Shirle\ ei al., 
1994). A pseudoracemate containing (S)-[2H3]-ibuprofen %vas administered and 
taurine conjugates predominantly consisting of (, 1; )-['H3}-ibuprofen \, ýere found in 
urine. As taurine conjugates are formed via the formation of the Co: A-thioester 
intermediate, this indicates that (. S)-ibuprofen forms the CoA-thioester in-viva, 
although this has not been reported in-vitro (Tracy et al., 1993, Menzel et at, 1994). 
In addition, small amounts of labelled (R)-ibuprofen and (1? )-ibuprofen-taurine 
conjugate were found, providing evidence of S to R inversion. Thus, it appears that 
the "unidirectional" chiral inversion process is the net result of the competing rate 
processes involved. The "reverse" inversion appears to be relatively unimportant 
because of the much slower rate of thioester formation and of the other competing 
pathways stereoselective for (X)-ibuprofen, like taurine conjugation. Glvcine 
conjugates of (. S')-2-phenylpropionic acid have also been reported in dogs, where 
chiral inversion of the 2-phenylpropionic acid is kno%%, n to occur to an equal extent 
in both directions (Tanaka et al., 1992). 
(c) Inversion and non-inversion clearance 
From the findings in the present study, it is clear that chiral inversion is the 
main route of clearance of (1? )-ibuprofen in man, as reflected by the relati\ e 
magnitudes of Cl-m,.,  which was two 
fold greater than CL, , _u. 
As CL,,,,  
determines the amount of (R)-ibuprofen that has been converted to the active form, 
factors which affect this pathway are of clinical importance. In-vitro studies have 
provided evidence that the rate-limiting step for chiral inversion appears to be the 
formation of the (R)-ibuprofen thioester (Knights and Jones, 1992). More recent 
evidence has indicated that the formation of (R)- ibuprofen-adenv late, prior to 
thioesterification, may be the actual rate-limiting step. (Menzel cl al., 1994). This 
process is modulated by hepatic long chain fatty acid CoA svnthetase (Muller e< (, /., 
1992). Thus, factors which modulate the activity of these enzymes would affect 
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inversion. Increased inversion has been shown to occur in rats following 
administration of clofibrate (Knights ei uL, 1991), while palmitic acid (Muller 0i u/., 
1992) pivalic acid (Xiaotao and Hall, 1993) and , alproic acid (Tracy ei u/., 1993) 
were inhibitors in the rat hepatocyte model. Theoreticall,., inhibition of the non- 
inversion clearance of (R)-ibuprofen would also increase chiral inversion. Proof of 
this is provided by in-vitro experiments using rat hepatocytes in which the broad 
spectrum cytochrome P45(0 inhibitors metapyrone and proadifen (SKF 525A) reduced 
the oxidation of (R)-ibuprofen and also increased fractional inversion (Xiatao and 
Hall, 1993). The effect of disease, especially hepatic dysfunction is another possible 
influence. To date decreased clearance of both enantiomers of ibuprofen has been 
reported in patients with liver cirrhosis although it is not clear whether the decrease 
in CL of (R)-ibuprofen is a result of a decrease in inversion and/or alternative 
pathways. Also plasma protein binding was not studied (Li cl a/., 1993), which is 
important as liver cirrhosis is usually associated with a decline in plasma albumin 
levels (Dawling and Crome, 1989). Evidence fron experiments using hepatoc)Aes 
from experimentally (streptozocin) induced type I diabetic and genetically (type 11) 
diabetic rats reveal that greater fractional inversion of ibuprofen and increased 
exposure to the CoA- thioesters occurs, implying that diabetic patients may he at 
greater risk of adverse effects associated with increase (S)-ibuprofen concentrations 
and hybrid triacylglycerol formation (Xiaotao and Hall, 1995). Thus, the effects of 
xenobiotics and disease on chiral inversion, either directly affecting the formation 
or hydrolysis of the CoA thioester or indirectly via modulation of the oxidative 
reactions of the IZ-enantiomer need to carefully studied in-view of the subsequent 
effects on unbound concentrations and the possibility of prolonged exposure to the 
CoA thioester. 
8.4 Comparison of the enantioselective pharmacokinetics of ibuprofen 
between the young and elderly 
Ageing is a natural phenomenon associated with changes occurring at the 
most basic and cellular level, leading to altered physiological responses and general 
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decline in the function of major organs. These changes x\il1 thus affect the ability of 
the body to handle administered drugs and cause changes in pharmacokinetics and 
pharmacodynamics. The physiological changes rele'. ant to phannacokinetics are 
summarised in Table 8.1 below: 
Table: 8.1 Physiological changes relevant to pharmacokinetics 
Process Type of Interaction with age 
Absorption reduced gastric absorption 
reduced gastric emptying rate 
reduced GI moti li t\ 
reduced GI blood flow 
Distribution decreased body mass 
increased proportion of body fat 
decreased proportion of body water 
decreased plasma albumin 
decreased tissue perfusion 
Metabolism reduced liver mass 
reduced li\ er blood flow 
reduced hepatic metabolic capacity 
Excretion reduced glomerular filtration 
reduced renal tubular function 
reduced kidney blood flow 
reduced kidney mass 
(Adapted from Dawling and Crome, (1989)) 
The way a particular drug will be affected by age will naturally depend on its 
properties with respect to protein binding, distribution, hepatic and renal clearance. 
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With the advent of stereospecific drug anal\ sis, a further dimension has been 
added to the effect of ageing. In experimental animals. age related effects in 
enantioselective disposition of propranolol is well documented (Vermeulen c'i at.. 
1992). In humans, stereoselective changes in the clearance of hexobarbital and 
mephobarbital can be expected with ageing (Chandler ei a/., 1988, Hooper and 
Qing, 1990). With a drug such as ibuprofen, it would be expected that ageing would 
affect clearance, particularly with respect to clearance via oxidation \%ith or \%ithout 
associated changes in stereoselectivity. Moreover, the extent of chiral inversion in 
the elderly has not been properly investigated. The pharmacokinetic parameters 
based on total (bound and unbound) drug concentrations did not show any 
significant differences between the two groups. Taken at face value, this would 
have easily led to an erroneous conclusion that there were no differences in the 
enantioselective disposition of ibuprofen between the young and elderly. Howe\ er, 
because of the central role played by plasma protein binding in modulating the 
disposition of a highly bound drug like ibuprofen, the unbound concentrations need 
to be determined before any firm conclusions can be arrived at. Indeed, important 
and significant differences were observed with the protein binding, and hence AUCu 
and CLu. for (. S')-ibuprofen. Thus, the decrease in unbound clearance of the 
S- enantiomer was masked by the increased unbound fraction, resulting in no net 
change in total body clearance. Equally important is the fact that these changes are 
stereoselective, affecting the S- but not the I? - enantiomer. Further evidence for 
these changes were provided by the reduction of unbound formation clearances of 
the metabolites derived from (S)-ibuprofen in the elderly, 'chile formation 
clearances based on total drug concentrations did not show any change. 
An increased unbound fraction together with a reduction in unbound 
clearance would mean that at steady state the total drug serum concentrations 
would remain the same but that the unbound concentration would increase. As it is 
the unbound concentrations that are important in determining pharmacological 
effect, the elderly are therefore potentially exposed to increased effect and risk of 
toxicity on a normal therapeutic dose. In extreme cases where unbound clearance is 
drasticall\' decreased, a reduction in dose should be considered (Upton ei al.. 1984). 
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Caution with dosing of ibuprofen in the elderly should also be exercised in view of 
the fact that the protein binding, of the drug is dose dependent, with the unbound 
fraction increasing with increasing dose (Fans ci ul., 1990. Smith et al.. 1994). 
The implications of this are that in elderly subjects, an increase in dose would lead 
to a disproportionate increase and accumulation of unbound (Sº-ibuprofen 
concentrations, leading to increased risk of adverse effects such as GIT and 
haematological disturbances and renal toxicity. Evidence for this is pro\ided from 
epidemiological studies which indicate that the elderly have a significantly higher 
odds-ratio of risk of gastrointestinal and other disorders with NSAIDs (Carson and 
Willet, 1993). 
As ageing is associated with decreased liver perfusion and mass, hepatic 
metabolism would be expected to be reduced, especially for those drugs \ýith a high 
hepatic extraction ratio, e. g. propranolol. However. ibuprofen is poorly extracted 
from the systemic circulation and coupled with the fact that the decrease in unbound 
clearance is stereoselective for the S- enantiomer. the underlying change seems to he 
due to lowered enzyme activity or affinity. There have been some suggestions that 
specific isoforms of the cytochrome P4ß, enzymes mad' be selectively impaired with 
ageing (Woodhouse and James, 1990). Results from in-vi/ro experiments show that 
ibuprofen is metabolised by the CYP 2C9 isoenzvme (Leemann et al., 1993). 
However, to date no age-related effects on enzyme activity have yet been reported 
for this isoenzyme (Rudy et al., 1995), and this would certainly have been the 
conclusion drawn form the present study had the unbound concentrations of the 
enantiomers not been determined. 
The elderly are a very diverse population group. Ageing occurs at different 
rates, which may be affected by genetic predisposition e. g. type lI diabetes, or by 
environmental factors and lifestyle. In addition the ageing process is often 
superimposed by various disease conditions to which the elderly are more 
susceptible e. g. renal dysfunction and musculoskeletal disorders. As a result of these 
multiple pathologies, the elderly are generally prescribed more drugs than the 
young. This co-medication would certainly give rise to interactions that affect drug 
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disposition, especially with interactions in protein binding. Thus the tindinL's of this 
study should be considered with these factors in mind. Studies on patients \% ith 
moderate renal dysfunction have demonstrated higher AVCs for (. ")-ibuprofen and 
increased S 1, "1? ratios for serum concentrations, indicating that these patients hav e 
increased exposure to (, ý)-ibuprofen. This may exacerbate renal d" sfunction by 
inducing ischaemia via prostaglandin inhibition (Chen and Chen, 1994). 
Unfortunately, the mechanism(s) underlying this condition \\, ere not investiý, ated 
thoroughly. Moreover, these patients may be in greater risk than is obvious. In a 
separate study, elderly patients with mild renal dysfunction were found to have 
higher unbound concentrations of (S)-ibuprofen as compared to healthy elderly or 
young volunteers, even though the serum concentrations were "normal". This was 
found to be the result of decreased binding and concomitant reduction in unbound 
clearance in the elderly (Rudy et al., 1995). Thus, elderly patients with moderate 
and severe renal dysfunction may face double risk of increased exposure to 0^)- 
ibuprofen through higher serum as well as higher unbound concentrations. Also, in a 
study to identify predisposing factors for ibuprofen-related renal toxicity, ad\ annced 
age and hypertension were identified as risk factors in patients with compromised 
renal haemodynamics (Chen and Chen, 1995). 
The results of the present study provides evidence that the concurrent 
decrease in protein binding and unbound clearance of the active S- enantiomer occur 
in healthy elderly volunteers, and this result taken collectively with those of patients 
with underlying disease states indicate that the elderly are particularly at risk from 
the adverse effects of a seemingly relatively non-toxic drug like ibuprofen. It is 
also obvious that many more studies regarding the effect of disease states on the 
stereoselective disposition of ibuprofen and related 2-APAs in the elderly population 
are needed, in order to increase the safety and efficacy of these drugs in the ever 
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Appendix 1: Fluorescence excitation (ex) and emission (em) spectra for 
(a) (R)-ibuprofenyl-(R)-1-(naphthen-l-ý I)ethv lamide (R acid: R amine) 
diastereoisomer and (b) (S)-ibuprofenyl-(R)-1-(naphthen-l-sI)ethylamide 
(S acid: R amine) diastereoisomer. 
a) 
200 22() 2,1() 260 28() 1()1) 120 11() 1(. 0 1Q0 
im 
b) 
260 220 210 2(O 2R0 1OO 120 110 160 ! RO 
IM) 
160 280 300 320 340 360 380 400 420 440 
11111 
260 280 300 320 340 360 380 400 420 440 
n 
-)ýl 
Appendix 2: Synthetic route adopted by Dr. J. A. Baker (Dept. of Pharmacy, 
t niversity of Brighton) for the preparation of " racemic" (2'RS, 2RS)- 
carboxyibuprofen 1(2'R. S; 2RS)-2-14-(2-carboxypropyl)phenylipropionic acid;. 
Reagents: (1) NaOEt, CH31; (2) N-bromosuccinimide, benzoy lperoxide, CC'I3; 
(3) diethyl 2-methylmalonate, NaH, THF; (4) NaOH, EtOH 50%; H2SO4; (5) heat. 
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Appendix 4: Physical dimensions of perspex cells used in equilibrium dials' is. 
The cells are made from 6 mm thick perspex sheet. (All dimensions in mm). 
connecting 
42 
sample holes membrane 
11 
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Appendix 5: Characteristics, serum albumin and creatinine concentrations 
for the young and elderly volunteers. 











sl F 36 61 157 55.2 0.69 
s2 M 36 59 175 58.4 0.84 
s3 M 22 77 179 53.2 1.48 
s4 F 29 68 163 5 3.2 0.93 
s5 M 27 100 178 56.4 0.81 
s6 F 28 68 163 60.4 0.65 
s7 F 23 65 165 56.8 0.77 
s8 M 24 62 169 X3.6 L 0.68 
mean - 28.1 70.0 168.6 55. q 0.9 
sd - 
I 5.4 13.4 8.0 2.6 0.3 
Elderly 
es] F 67 1 71 159 54.4 1.07 
es2 F 67 80 168 54.4 0.88 
es3 F 67 66 164 51.6 j 0.4 3 
es4 M 78 76 169 51.6 1.18 
es5 F 75 61 156 5 5.6 0.83 
es6 M 68 81 171 56.4 1.09 
es7 F 68 72 173 54 0.22 
es8 M 66 69 169 53.2 0.71 
mean - 69.5 72.0 166.1 53.9 j 0.8 
sd -i 4.4 
i 6.8 6.0 1.7 0.3 
Comparison of the means for serum creatinine, serum albumin, weight and height 
between the young and elderly was carried out using Student's t-test for 
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Appendix 7: Cumulative urinary excretion of total ibuprofen enantiomers in individual 
healthy young volunteers following the oral administration of 400 mg racemic ibuprofen 
(results expressed as a percentage of dose). 
Subject Enantiomer 
0-2h 0-4h 0-6h 
Time 
0-8h 0- l0h 0-? 4h 
sl 1R 0.28 0.50 1 0.61 0.66 0.68 0.70 
S 0.94 2.22 j 3.30 4.13 4.46 4., cº 
-- 
s2 R 0.09 0.44 0.63 0.71 0.75 1.05 
.S 0.55 2.68 4.79 5.98 6.55 9.89 
s3 R 1.01 1.39 1.67 1.82 1.82 1.82 
2.63 5.91 7.47 15 8.30 8.76 
s4 R 0.29 0.62 0.75 0.8 0.85 0.89 
. ý' 1.52 3.74 5.25 6.3 3 6.51) 6.98 
s5 Iz 0.21 0.92 1.15 1. 1.44 1.44 
S 1.72 6.51 8.52 11.4O 13 11 13.86 
s6 0.26 0.61 0.87 1-27 1 42 1.4 
ti 1.74 4.17 5.87 8.3; 1O22 11.47 
s7 R 0.60 0.87 0.90 0.95 1.0O 1.01 
. ti 2.65 4.87 5.22 5.88 6.59 0.98 
s8 Il 0.49 0.49 0.68 0.73 0.80 0.85 
S' 1.68 1.68 3.09 1.82 4.48 4.97 
mean R 0.4 _3 
0.63 0.87 1.00 1.05 1.15 
. ti 1.67 3.37 5.00 
6.09 6.74 8.4 5 
s. d. R 0.29 0.41 0.36 0.41 0.41 0.38 
5 0.73 2.11 1.87 2.50 2.99 3.19 
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Appendix 8: Cumulative urinary excretion of ibuprofen enantiomers (as the 
glucuronide) in_individual healthy young volunteers following the oral administration of 




0-6h 0-8h j0 - 10h 
1 0-: -1"h 
sl R 0.27 0.47 0.58 0.62 0.64 0.66 
S 0.88 2.02 3.10 3.91 4.24 4.47 
s2 R 0.08 0.40 0.58 0.66 0.70 0.99 
S 0.52 2.47 4.48 5.64 6.20 9.48 
s3 R 0.98 1.34 1.63 1.77 1.75 1.74 
S 2.52 !15.70 7.21 7.86 7.98 8- 27 
s4 R 0.27 0.60 0.73 0.80 0.8 3 0.86 
S 1.40 3.53 5.01 6.08 6.4 6.71 
s5 1? 0.19 0.81 1.03 1 1.21 1.28 1.24 
. 5' -- 
1.60 5.92 
-- 
7.80 10.71 12.50 12.95 
s6 1? 0.25 
T 0.59 0.8-3) 1 1.23 1.38 1.38 
. 5' 1.70 4.04 5.69 8.11 9.98 1 1.2 2 
s7 Il 0.58 0.84 0.87 0.92 0.97 0.98 
2.58 4.76 5.09 5.73 6.4 3 6.80 
s8 R 0.48 0.48 0.67 0.72 0.78 0.84 
'S 1.57 H 1.57 2.87 3.60 4.25 4.70 - - -- mean R 0.4 2 0.60 0.84 0.96 1.01 1.09 
5 1.60 3.22 4.78 5.85 6.49 j 8.07 
s. d. 1? 0.29 0.39 0.34 0.39 0.39 0. -'-' 
s 0.71 2.00 1.75 13 5 2.84 3.01 
260 
Appendix 9: Cumulative urinary excretion of free ibuprofen enantiomers in individual 
healthy young volunteers following the oral administration of 400 mg racemic ibuprofen 




0-6h 0-8h 1 0- 10h 0- 4h 







-ý __ -- 
0.21 






s2 1? 0.01 0.04 0.05 0.05 0.05 0.06 
,S 0.03 0.21 0.31 0.3 40.3 5 0.41 
s3 R 0.03 0.05 0.05 0.05 1 0.05 0.09 
S 0.11 L 0.21 0.26 0.29 0.32 0.49 
s4 R 0.02 0.02 0.02 0.03 0.03 º0 
5 0.13 0.21 0.24 0.26 0.26 0.27 
s5 1Z-- 0.02 0.11 0.13 0.14 0.16 0.21 
S' 0.12 0.59 0.73 0.78 0.81 0.91 
s6 1? 0.01 0.02 0.0' 0.04 0.04 0.04 
, ti 0.04 0.13 0.18 0.22 0.? ý 
0.25 
s7 1? 0.02 0.0 3 0.03 0.03 0.03 0.03 
ti 0.06 0.11 0.13 0.15 0.16 0.18 
s8 R 0.01 0.01 0.01 0.01 0.01 0.01 
S 0.11 0.11 0.22 0.2 1 0.23 0.27 
mean R 0.01 1 0.03 0.03 0.03 0.04 0.06 
S 0.08 0.15 0.22 0.24 0.25 0.38 
A. R 0.01 0.03 0.03 0.04 0.05 0.06 
, 5' 0.04 0.08 
0.06 0.06 0.06 0.11 
"61 
Appendix 10 : Cumulative urinary excretion of total hydroxyibuprofen enantiomers in 
individual healthy young volunteers following the oral administration of 400 mg racemic 
ibuprofen (results expressed as a percentage of dose). 
Subject Enantiorner 
0-2h 0-4h 0-6h 
Time 
0-8h 0-10h 0-24h 
s1 R 0.25 0.47 1.51 3.02 4.12 5.28 
S 2.20 5.78 12.88 18.18 18.84 27.05 
s2 R 0.07 0.56 1.70 2.69 3.36 4.2 
S 0.50 3.44 8.10 11.74 15.04 20.39 
s3 1z 0.30 0.68 133 2.14 2.0 , 2.66 
S 1.87 5.61 1 7.57 11.08 14.15 17.54 
A IZ 0.18 0.46 1.47 1 3.34 :. 05 3.02 
S 1.57 4.68 8.25 11.71 14.66 20.3 3 
s5 R 0.15 0.89 1.77 2.08 3.16 46 
S 1.56 6.80 10.78 13.88 16.91 19 85 
- t- . s6 R 0.66 
i 





3.33 8.21 12.71 15.9 18.20 25.19 
s7 I? 0.68 0.88 1.49 1.98 2.28 2.64 
. ti 4.08 5.15 8.87 14.29 18.64 24 07 - 
s8 ll 0.36 0.36 0.77 1.54 1 
1.61 2.57 
S 3.16 3.16 5.59 7.47 1 10 63 16.99 
mean R 0.33 0.73 1.52 2.40 ; 2.77 3.57 
S 2.28 5.67 8.84 13.03 15.88 21.50 
s. d. R 0.23 j 0.27 0.42 0.59 0.86 1.24 
s 1.16 1.53 2.30 3.28 2.82 3.70 
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Appendix 11: Cumulative urinary excretion of hydroxyibuprofen enantiomers (as the 
glucuronide) in individual healthy young volunteers following the oral administration of 
400 mg racemic ibuprofen (results expressed as a percentage of dose)- 
Subject Enantiomer 
0-2h 0-4h 1 0-6h 
Time 
ý 0-8h 0- IOh ' 0-24h 
sl R 0.14 0.31 0.52 0.92 1.8v 2-83 
S 1.87 5 26 10 84 13 30 13 43 21 42 
ýJ M . . . . . 
s2 1? 0.05 0.34 0.97 1.30 ' 1.58 1.41 
S 0.45 2.77 5.99 7.70 1 9.84 13.58 
s3 1? 0.18 I 0.44 ' 0.94 1.36 1.12 1.08 
S 1.66 5.10 6.62 9.42 11.97 14.13 
s4 R 0.14 0.34 1.07 2.63 1.98 1.27 
S 1.44 4.32 7.61 10.12 12.96 16.64 
s5 1? 0.12 0.74 1.21 __ 1.34 ?. 37 T 3.17 
S 1.49 6.41 9.5 33 1'. 25 14.58 15.61> 
s6 Il 0.54 0.75 0.78 i 0.99 0.65 1.10 
3.02 7.08 8.99 10.60 12.14 17.3) 
s7 R 0.32 0.3 1 0.67 0.9 3 0.82 1.42 
S 3.16 3.67 6.64 10.20 13.03 15 
S8 1? 0.28 0.28 0.51 1.1 3 0.82 0.63 
S 2.94 2.94 4.82 6.29 8.29 11.40 
mean R 0.22 0.44 0.88 1.47 1.46 1.61 
S 1.81 4.27 7.17 8.97 11.03 16.10 
s. d. 1? 0.16 _ 0.22 0.24 0.59 0.70 0.90 
.ý 1.13 ' 2.23 1.66 2.47 3.00 3.14 
26 33 
Appendix 12: Cumulative urinary excretion of free hydroxyibuprofen enantiomers in 
individual healthy young volunteers following the oral administration of 400 mg racemic 
ibuprofen (results expressed as a percentage of dose). 
Subject Enantiomer 
0-2h 0-4h 0-6h 
Time 
0-8h 0-10h 0-24h 
sl R 0.11 0.16 0.99 2.10 2.32 2.45 
S 0.32 0.52 2.04 4.88 5.40 5.64 
s2 R 0.02 0.22 0.73 1.39 1.77 2.81 
- 'ý - -0.05- -ý 
0.67 2.11 4.04 
- _5 
?0 6.82 
s3 R 0.12 0.24 0.39 0.78 0.91 1.58 
S 0.21 0.51 0.95 1.67 2.18 1.41 
-ý 
s4 1? 0.04 0.12 0.40 0.72 1.06 1.75 
S 0.13) 0.37 0.64 1.39 1.70 c, 9 
s5 R 0.03 0.15 0.56 0.75 1.09 x. 29 
0.07 0.39 1.26 1.62 1.16 
s6 IZ 0.12 0.44 1. 1.40 1.58 1.59 
1S 0.31 1.13 3.71 5.3 600 
1 7.8 5 
s7 1? 0.36 0.57 0.81 1.06 1.46 1.2 2 
S 0.92 1.49 2.24 03 5.60 6.02 - 
s8 1? 0.08 0.08 0.25 0.41 0.79 1.95 
s 0.21 L 0.21 0.77 1.18 2.34 5.59 
-- - 
mean R 0.11 0.27 0.69 1.07 1.37 1.96 
11; 0.28 0.72 1.71 
3.02 3.85 5.40 
s. d. Il 0.1 1 I 0.17 
1 0.36 0.54 0.51 0.53 
5 0.28 0.47 1.04 1 1.56 1.81 1.86 
'64 
Appendix 13: Cumulative urinary excretion of total carboxvibuprofen stereoisomers in 
individual healthy young volunteers following the oral administration of 400 mg racemic 
ibuprofen (results expressed as a percentage of dose). 
Subject Stereoisomer 
0-2h 0-4h 0-6h 
Time 
0-8h ! 0- 10h 0-24h 
sl 2'. S, 2R 0.32 1.23 3.54 5.25 4.70 499 
2'!?, 2R 0.33 1.37 3.75 5.92 6.35 
2'1?, 25 1.10 4.29 10.59 15.29 17.55 17.96 
2'S, 2S 1.68 ! 6.11 14.60 11.1- 3.71 25.85 
s2 2'. ';, 21? 0.12 1.01 2.07 2.78 2.88 2.58 
2'R, 2R 0.13 1.07 2.59 3.71 5.25 
2'Il, 2S 0.40 3.60 8.37 12.21 15.21 16.51 
2'S, 2S 0.59 4.97 10.78 14.21 17.90 ' 3.02 
s3 2'S, 21? 0.19 0.80 1.40 2.02 2.15 2.61 
2'x, 211 0.24 1.00 1.75 2.37 3.12 3.75 
2'R, 25 0.67 3.14 5.53 8.26 10.00 12.97 
2'S 25' 1.06 4.35 7.32 10.59 11.41) 17.3 2 
s4 2'S, 2R 0.10 0.48 1.26 2.09 2.24 2.92 
2R, 21? 0.18 0.84 1.92 3.74 4.41 5.48 
2'11,25 0.37 2.09 5.9 8.86 10.38 12.94 
2'S, 2S 0.61 2.65 5.92 9.10 11. -1 
4 1 3.87 
s5 2'S', 21? 0.18 1.24 2.09 2.70 3.03 3.58 
2'! l, 211 0.23 1.48 2.68 3.61 4.31 5.56 
27?, 2S 0.66 4.55 7.91 10.28 135.0 0 12.68 
2'S. 2S 0.97 6.23 10.71 l 
. 
45 15.15 17.21 
s6 2'', 21Z 0.47 1.18 1.64 1.83 I 3.08 1.80 
2'R, 21? 0.61 1.64 
. 
25 3.79 4.07 4.1 1 
2'K, 2.1; 1.67 5.3 3 9.74 12.89 14.59 -11.55 
2'. S', 25' ?. 34 6.04 10.62 13.30 14.08 23.08 
s7 2'S, 21? 0.62 0.74 1.29 2.16 4.14 1.96 
? 'IZ, 2R 0.80 1.03 2.55 4.49 5.47 4.47 
2'I?, 2S 2.20 3.36 7.63 15.26 19.61 2 3.4 5 
2'S 2S 3.08 3.80 8.33) 15.76 18.92 2 5.12 
, 
s8 211 0.40 0.40 0.89 1.66 1.6 3 1.85 
27?, 211 0.66 0.66 2.63 2.99 
1 
3.59 4.67 
2'!?, 1.68 1.68 6.20 9.80 12.89 13.5 2 
TS, 2S 2.04 2.04 7.02 8.41 10.64 13.36 
mean 2/z 0.30 0.95 1.77 2.56 2.98 2.79 
2'Il, 211 0.40 1.20 2.64 3.77 4.21 4.96 
2'R, 25 1.09 3.76 7.67 11.61 14.15 16.45 
2'. ti'. 25' 1.55 4.88 9.41 13 27 
15.65 L 19 85 _ 
A 2'. ti 211 19 0 0 26 0 42 41 0 0.76 0 62 . , . . . . . 
2'I?, /? 0.25 0.28 0.47 0.63 0.70 0.65 
2'R, 25' 0.68 1.03 1.50 2.1 03 4.17 
"S. 25' 0.89 1.25 1.90 2.56 2.90 4.39 
-)(I1 
Appendix 14: Cumulative urinary excretion of carboxyibuprofen stereoisomers (as the 
glucuronide) in individual healthy young volunteers following the oral administration of 
400 mg racemic ibuprofen (results expressed as a percentage of dose). 
Subject Time Stereoisomer 
0-2h 0-4h 0-6h 0-8h 0-10h 0-_24h 
sl 2'. S', 2R 0.07 0.44 1.56 2.03 1.49 0.88 
2'R, 21? 0.15 0.75 2.14 2.94 2.3 3 2.88 
2'1l, 2.5' 0.35 2.09 5.47 7.28 8.42 9.16 
2'S, 2S 0.59 3.13 7.58 9.91 11.12 9.89 
s2 2'S, 2R 0.06 0.57 0.98 1.38 1.3 3 0.92 
27?, 2R 0.09 0.62 1.33 1.48 1.71 2.68 
27?, 2S 0.23 2.06 4.77 6.38 7.92 8.16 
2'S, 2S 0.34 2.83 6.40 6.71 8.79 11.50 
s3 2'S, 21? 0.12 0.55 0.71 1.09 0.81 1.28 
2'1?, 2R 0.18 0.78 1.13 1.4 4 1.98 2.35 
2'R, 2S 0.41 1.98 3.30 4.94 6.12 7.51 
2'. 5', 2S 0.72 3.09 4.42 6.40 7.71 9.18 
s4 2'S, 2R 0.05 0.28 0.77 1.30 1.31 1.49 
27?, 21Z 0.13 0.55 1.18 2.52 2.84 3.40 
2'1?, 25 0.22 1.26 3.32 5.62 6.26 7.16 
2'. x', 2.5 0.1)11 1.77 x. 88 6.2 3 7.39 7.41 
s5 2'S, 2R 0.11 0.60 0.79 1.11 1.24 1.23) 
27?, 21? 0.16 0.80 1.30 1.65 1.87 2.80 
2'R, 25 0.43) 2.48 3.64 5.04 6.59 5.21 
2'S, ?. 5' 0.62 3.29 5.12 6.2-1 6.81 7.14 
s6 2'. S', 2R 0.24 0.54 0.7 3 0.8 3 2.03 0.55 
27?, 21? 0.38 0.84 1.66 1.8-3) 2.00 1.39 
27?, 2S 0.93 I 2.96 4.54 5.79 6.60 10.79 
2S 1.30 3.12 5.25 6.22 5.93) 11.88 
s7 2'S, 2R 0.29 0.25 0.61 1.00 2.73 0.60 
2'R, 2R 0.47 0.4 3 1.36 2.20 2.70 1.21 
2'R, 2S 1.12 
1 
1.55 3.75 6.98 8.89 11.01 
? ', ý 2S 1 57 57 1 4`. 32 7.48 8.00 12.32 , . . 
s8 2'2R 0.25 0.25 0.04 0.69 0.48 0.68 
2'R, 2R 0.35 0.35 1.29 0.98 1.04 1.39 
211? 2S 0.8 3 0.83 1.86 4.27 5.66 5. ý7 
2'S, 2 ti' 1.24 1.24 3.34 3.03 4.15 5.29 
mean 2'S, 2R 0.15 0.46 0.77 1.18 1.4 0.95 
27?, 2R 0.24 0.68 1,42 1.88 2.06 2.27 
2!? 2 0 57 2 06 3.8 3i 5.79 7.06 8.07 
, . . 
? ', ti', 25 0.84 2.69 5.04 1 6.5 3 7.49 9.3 5 
A. 2'S, 2R 0.46 0.68 0.95 1.31 14 2.5 
2'R, 2R 0.14 0.15 0.16 0.48 0.56 0.78 
2'!?, 2S 0. 0.56 0.89 0.85 1.05 2.16 
2'S. 2S 0.46 0.68 0.95 
jj` 
1.31 1.13 '. 53 
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Appendix 15: Cumulative urinary excretion of free carboxyibuprofen stereoisomers for 
individual healthy young volunteers following the oral administration of 400 mg racemic 
ibuprofen (results expressed as a percentage of dose). 
Subject I Stereoisomer I Time 











2', 5,2R 0.25 0.79 
2'R, 2R 0.19 0.62 
2'1?, 2. S' 0.75 2.20 
2', S', 2S 1.09 2.98 
2'S, 2R 0.06 0.44 
2'R, 2R 0.05 0.44 
2'1?, 2S 0.16 1.53 
2'S, 2S 0.25 2.15 
2', 5,2R 0.07 0.25 
2'R, 2R 0.07 0.22 
2'R, 2. S 0.26 1.16 
2'. ';, 2.5 0.33 1.26 
2'S, 2R 0.05 0.20 
2'1l, 21? 0.05 0.29 
2'!?, 25 0.16 0.84 
2'S'. 25' 0.29 0.89 
2', ', 2R 0.07 0.63 
2'1?, 21? 0.07 0.68 
2'!?, 25 0.2 3 2.07 
2'S 25' 0.36 2.9 3 
2'S, 21? 0.23 0.64 
2'R, 2R 0.23 0.79 
2'll, 2S 0.74 2.37 
2'. S', 25' 1.04 2.92 
2'S, 21? 0.3 3 0.49 
? 'R, 21? 0.3, 0.61 
2'R, 25 1.08 1.81 
2'S 25 1.52 2.23 
S 2R 0.15 0.15 
2'R, 21? 0.30 
1 0.10 




2'. ti, 21l 
- 
0.15 i 0.49 
2'R, 2R 0.16 0.52 
2'R, 25 0.53 , 1.71 
2'S. 25' 0.71 2.19 
I'S, IR 0.10 0.17 
21R, -IR 
0.12 0.21 
) '/?, ?, ý; 0.36 0.5 2 
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Appendix 17: Cumulative urinary excretion of total ibuprofen enantiomers in individual 
healthy elderly volunteers following the oral administration of 400 mg racemic ibuprofen 
(results expressed as a percentage of dose). 
Subject I Enantiomer Time 
0-2h 0-4h 0-6h 0-8h 0-10h 0-24h 
es 1 1? 0.11 0.20 0.20 0.52 0.62 0.7 3 
S 1.26 2.49 2.49 7.4 3 9.15 11.09 
es2 1? 0.56 0.77 0.91 1.02 1.06 1.09 
S 5.21 7.41 8.77 9.74 10.39 12.58 
es3 IZ 0.23 ! 0.34 0.38 0.41 0.11 0.43 
S 2.58 j 4.12 4.67 5.43 6.11 
-1 
7.12 
es4 R 0.11 0.49 0.61 0.66 0.7 3f 0.80 
S' 0.97 117 3.06 3.77 i 4.49 5.66 
es5 R 0.39 0.56 
r 0.64 0.71 0.74 0.76 
S 3.90 5.77 6.72 7.58 8.25 8.50 
es6 1? 0.23 0.39 0.68 0.77 0.84 0.85 
S' 1.72 3.03 5.57 6.50 7.29 8.14 
es7 1? 0.41 0.89 1.09 1.2 1.27 1.30 
5 2.05 4.51 6.06 7 30 7 89 46 8 
. . . - es8 1? 0.50 1.06 1.22 1.36 1.37 1.48 
-- - 
S--- 3.06 4`58 5.233 6.19 6.23 8.77 
mean R 0.32 0.59 0.69 0.83 0.88 0.93 
. 1; 2.59 4.26 5.01 6.74 7.48 8.79 
s. d. R 0.17 0.30 0.39 
1- 
0.34 0.33 0.34 
5 1.433 1.75 2.61 1.75 1.87 2.17 
70 
Appendix 18: Cumulative urinary excretion of ibuprofen enantiomers (as the 
glucuronide) in individual healthy elderly volunteers following the oral administration of 
400 mg racemic ibuprofen (results expressed as a percentage of dose). 
Subject Enantiomer Time 
0-2h0-4h0-6h 0-8h 0- 10h 0-24h 
esl R 0.11 0.18 0.18 0.47 0.57 0.68 
S 1.22 2.34 234 
. 
6.98 8.65 10.54 
es2 Il 0.52 0.73 0.86 0.96 1.01 1.04 
S 4.88 7.02 8.3 3 9.26 9.90 12.06 
es3 R 0.22 0.3^ 0.36 0.39 
j 0.40 0.41 
S 2.49 3.93 4.45 5.17 5.8 6.81 
es4 1z 0.11 0.47 0.58 0.64 0.70 0.7 
0.93 1.85 2.69 4.09 5.27 
- - es5 1? 0.37 0.5 3 0.61 0.68 0.70 
j 
0.7 
S 3.69 5.48 6.39 7.21 7.86 8.08 
es6 1? 0.20 0.35 0.64 0.73 0.79 0.80 
5 1.39 2.6 3 5.15 6.00 6.76 7.58 
es7 1? 0.38 0.84 1.03 1.16 1.20 1.2 3 
S 1.91 4.15 5.64 6 76 7.14 7.89 
es8 1? 0.47 1.02 1.18 1.32 1.13 1.44 
5 2.7-1 4.21 4.84 5.73 5.77 8.30 
mean R 0.30 0.56 j 0.66 0.79 0.84 0.89 
S 2.41 3.95 4.69 6.31 7.03 8.31 
s. d. R 0.16 0.29 0.38 0.33 0.32 0. i3 
s 1.35 1.72 2.49 1.71 1.83 2.11 
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Appendix 19: Cumulative urinary excretion of free ibuprofen enantiomers in individual 
healthy elderly volunteers following the oral administration of 400 mg racemic ibuprofen 
(results expressed as a percentage of dose). 
Subject Enantiomer 
0-2h 0-4h 0-6h 
Time 
0-8h 0-10h 0-_'4h 
es] R 0.01 0.02 0.02 0.04 0.05 0.05 
S' 0.04 0.15 0.15 0.45 0.50 0.56 
es2 R 0.03 0.04 0.05 0.05 0.05 0.05 
S 0.33 0.39 0.45 0.47 0.49 0.52 
es3 R 0.01 0.01 0.02 1 0.02 0.02 0.02 
S 0.09 0.19 0.22 0.26 
1 
0.28 0.11 
es4 R 0.00 0.02 0.02 0.02 0.02 0.02 
. S' 0.04 0.32 0.36 0.38 0.40 0.40 
es5 R 0.02 0.03 0.0 3 0.03 0.03 0-04 
0.21 I 0.29 0.33 0.37 0.3ý> 0.42 
es6 R _ 
-} I 0.03 0 
. 
04 0.04 -T--- --ý 0.05 __ 0.05 0.05 
S 0.33) 0.40 0.42 0.50 0.53 0.56 
es7 R 0.02 0.05 0.06 0.07 0.07 0.07 
S 0.14 0.36 0.42 J 0.54 0.55 0.57 
-------- ---- ------ - - es8 R 0.03 0.0 3 0.04 0.04 0.04 0.04 
S 0.33 0.37 0.39 0.46 0.46 0.48 
mean R 0.02 0.0 3 0.0 3 0.04 0.04 0.04 
S' 0.19 0.31 0.3 2 0.44 0.46 0.48 
s. d. R 0.01 0.01 0.02 0.02 0.02 0.02 
.S 0.13 0.09 0.15 0.09 0.09 0.09 
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Appendix 20: Cumulative urinary excretion of total hydroxyibuprofen enantiomers in 
individual healthy elderly volunteers following the oral administration of 400 mg racemic 
ibuprofen (results expressed as a percentage of dose). 
Subject Enantiomer 
0-2h 0-4h 0-6h 
Time 
0-8h 0- 10h 0-24h 
es l R 0.21 0.51 0.51 3.36 4.54 6.02 
S 2.01 5.30 5.30 21.01 26.08 32.5 3 
es2 R 0.59 1.08 1.31 1.56 1.90 4.75 
s 4.47 7.74 9.66 11.32 13.10 28.43 
es3 K 0.19 0.41 0.50 ' 0.93 1-48 ! 2.16 
S' 1.89 4.01 4.86 8.54 12.66 17.81 
es4 1? 0.18 0.52 0.84 1.3 1.71 4.54 
S 1.68 4.87 7.07 9.14 10.79 i 22.68 
es5 R 0.33 0.63 0.79 t 1.14 1.39 2.41< 
,S 2.88 6.06 8.2 10.23 12.55 
i 21.36 
es6 1? 0.33 0.68 







7.73 ! 9.34 11,41 15.03 
es7 Iz 0.33 1.06 1.62 3.60 4.59 7.35 
s 2.05 6.62 9.15 13.48 16.34 24.15 
es8 Il 1.13 1.82 2.43 3.88 4.04 5.17 
5 4.81 8.25 10 92 17 13 87 17 23 13 . . . . 
mean R 0.41 0.84 1.31 2.25 2.81 4.56 
5 2.71 5.82 8.23 12.52 15.10 23.14 
s. d. R 0.32 











S 1.24 1.65 1.96 4.44 5.05 5.54 
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\ppendix 21: Cumulative urinary excretion of hydroxyibuprofen enantiomers (as the 
glucuronide) in individual healthy elderly volunteers following the oral administration of 
400 mg racemic ibuprofen (results expressed as a percentage of dose). 
Subject Enantiomer 
0-2h 0-4h 0-6h 
Time 
0-8h T 0- 10h 0-24h 
esl R 0.18 0.47 0.47 1.68 2.10 2-60 
S 1.87 5.06 5.06 16.26 19.58 23.70 
es2 R -- --7-- 0.30 1 
- 0.40 0.50 -I- - -- - 0.73 0.84 -_ 3.01 
S 3.68 5.98 7.53 9.05 10.3 3 24.0 




1.13 2.64 3.47 6.19 9.55 13.58 
es4 R 0.11 0.38 0.60 ,--0.79 
---ý ` 0.99 2.72 
S 1.37 4.24 6.15 7.67 9.01 18.97 
es5 R 0.19 0.39 0.53 0.59 T 0.68 1. )4 
5 2.40 5.20 7.30 8.36 10.1- 17.31 
es6 K 0.13 0.29 0.69 _ 0.60 0.86 1.39 
S 1.28 
- 
2.65 5.42 5.8 3 7.15 9.53 
es7 K 0.16 0.64 0.95 1.51 1.9 3 3.86 
s 1.48 5.11 7.17 9.02 10.84 17.26 
es8 R 0.15 0.38 0.78 1.55 1.60 1.84 
. 5' 2.07 4.40 6.48 10.83 11.28 13.87 
mean K 0.15 0.37 0.60 0.97 1.21 2.24 
s 1.91 4.11 6.22 9.15 10.98 17.28 
A. R 0.08 0.17 0.26 0.52 0.58 I 0.96 
s 0.8 3, 1.21 1.42 3.30 3.70 5.00 
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Appendix 22: Cumulative urinary excretion of free hydroxyibuprofen enantiomers in 
individual healthy elderly volunteers following the oral administration of 400 mg racemic 
ibuprofen (results expressed as a percentage of dose). 
Subject Enantiomer Time 
0-2h 0-4h 0-6h 0-8h 0-10h O-24h 
esl R 0.03 0.05 0.05 1.68 2.44 x. 42 
S 0.14 L 0.24 0.24 4.75 6.50 8.83 
es2 R 0.30 0.68 0.81 0.83 
J 1.05 1.74 




2.27 ". 78 4.40 
-ý- esa R----0.19 
--0.37 0.37 0.60 0.79 ! 0.99 
S' 0.76 1.37 1.39 2.16 -3.11 
4.? 
es4 R 0.07 0.13 0.24 0.54 0.72 1.82 
S 0.31 0.63 0.92 1.47 1.78 ,. 71 
es5 R 0.14 0.25 0.26 0.56 
~ 0.71 1.10 
0.48 0.86 I 0.93 1.87 '. 1 4.04 
es6 




S 0.6 3,1.08 2.30 i x. 52 1.25 5.50 
es7 R 0.18 0.42 0.68 2.09 2.67 3.49 
s 0.57 1.51 1.98 3.47 5.50 6.88 
es8 R 0.98 1.45 1.65 2.3 2.44 3.3 3 
S 2.75 3.86 4.45 1 6.30 6.59 9.26 
1.28 1.60 ! ?. ,1 mean 
--R -- 0.26 0.47 0.71 
5' 0.80 J 1.41- 2.01 -, 7 4.12 5.86 
s. d. R 0.30 0.44 0.50 0.73 0.86 1.04 
S 0.81 1.10 1.21 1.68 1.88 2.21 
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Appendix 23: Cumulative urinary excretion of total carboxvibuprofen stereoisomers in 
individual healthy elderly volunteers following the oral administration of 400 mg racemic 
ibuprofen (results expressed as a percentage of dose). 
Subject Stereoisomer 
0-2h 0-4h 0-6h 
Time 
0-8h r 0- 10 Ü 1-24h 
esl 2'. ';. 21? 0.09 0.54 0.54 2.29 -1.97 ,. ;4 
2'R, 211 0.20 0.78 0.78 288 ',. 7"' 4.29 
2'R, 2S 0.57 2.58 2.58 10.22 13.24 15.1 1 
2'S, 2, S' 0.46 2.91 2.91 12.13 15.82 17.77 
es2 2'S, 2R 0.45 0.92 1.20 I. 36 i 1.73 3.10 
2'R, 211 0.95 1.94 2.60 3.00 1. ý) 3 7.25 
2'R, 2S 2.30 4.74 6.41 7.10 9.28 15.27 
2'. S, 25 2.68 5.48 7.13 8.07 10.17 17.55 
es3 2'S, 2R -- ~-~ 0.20 
; 0.46 0.56 0.97 L-17 ' _- 1.53 
2'1?, 21? 0.39 0.88 1.1 3 º 1.94 2.63 3.59 
2'1?, 2S 1.29 3.21 4.2 8.22 11.78 16.96 
2', S, 2S 1.59 3.63 4.71 8.32 11.70 16.36 
es4 2', ß', 21? 0.63 1.12 1.6" 2.08 4.19 
2'1?, 21? 0.18 0.92 1.58 ? 3? 2.94 6.20 
2'R, 2. S 0.52 1.60 4.78 6.80 8.42 17.07 
2'. S', 25 0.66 3.29 5.49 7.97 9.85 19.61 
es5 2', S', 2k 0.27 0.57 0.69 0.97 1-27 2.59 
2'1z, 211 0.46 1.01 1.28 1.89 -. 57 
6.19 
2'R, 2S 1.27 3.09 4.02 6.28 8.83 21.49 
2', S, 25' 1.53) 3.39 4.32 6.42 8.72 19.24 
es6 2'S, 21? 0.30 0.79 2.03 2.61 2.99 3.92 
2'!?, 2R 0.3 5 0.93 2.33 3.05 3.55 5.16 
2'/?, 2S 1.08 2.94 7.49 9.67 10.99 14.70 
2'S', 2S 1.55 3.79 8.78 17.17 22.44 26.86 
es7 2'S. 21? 0.21 1.44 ?. 20 2.76 3.21 4.07 
2'R, 21? 0.27 2.1 1 x 
. 
18 4.01 4.66 5.89 
2'1?, 2S 0.95 5.98 8.82 11.28 12.99 16.39 
2'S. 2S 1.15 6.77 9.84 12.62 14.49 18.24 
es8 2'N, 21? 0.7 3 1.46 104 3.24 3.39 3.94 
27?, 21? 1.29 2.50 3.15 5.43 5.67 6.43 
2'IZ, 2S 













mean 2'S, 2R 0.30 0.85 1.41 1.98 j 2.36 3.37 
0.51 1.38 2.22 3.07 3.72 5.62 
2'/z, 25' 1.48 4.11 6.66 9.58 11.67 { 17.15 2,1' 1.76 4.76 7.51 11.52 14.19 ý 19.83 
s. d. ? '. ti', 2/l -! p 22 0.7 0.74 3.00 3.91 4.2 4 
2'Il, 21? 0.36 0.86 0.99 3.41 4.42 4.49 
IN 1.11 2.16 3.26 453 4.68 5.58 
2S 1.26 2.30 3.49 5.54 6.14 5.65 
_I' 
Appendix 24: Cumulative urinary excretion of carboxyibuprofen stereoisomers (as the 
glucuronide) in individual healthy elderly volunteers following the oral administration of 





0-6h 0-8h 0-10h 0-24h 
es l 2'S, 21? 0.00 0.19 0.19 0.24 0.20 0.25 
2'!?, 21? 0.09 0.40 0.40 0.40 0.58 0.78 
2'Il, 2. S 0.14 0.88 0.88 1.63 1.98 2.51 
2'. S', 2S 0.00 0.96 0.96 1.20 1.81 x. 27 
es2 2'S, 2/? 0.28 0.32 0.30 0.14 0.29 0.84 
2'R, 2/? 0.76 i 1.08 1.27 1.51 1.82 3.64 
2'1ß, 2.5 1.47 1.47 1.47 1.56 1.56 3, . 
02 
2'. S', 2. S' 1.97 2.91 3.35 3 88 4.49 8.51 
es3 2', S', 21? 0.08 0.12 0.15 0.38 0.60 0.74 
2'!?, 2R 0.2 3 0.34 0.45 1 0.91 1.40 2.14 
2'1l, 25 0.66 1.02 1. ý 3.71 6.25 10.70 
2'S, 2.5 0.91 1.54 2.12 i 4.30 6.80 10.51 
c,,, 4 2'5,21? 0.09 0.25 0.39 0.5 3 0.74 2.57 
2'1?, 21? 0.1-1 0.50 0.76 1.08 1.40 3.89 
2'R, 2. ý' 0-34 1.21 -1.14 2.99 3.83 10.60 
2', S', 25 0.22 1.42 2.2 3 3.38 4.35 12.27 
es5 2'5,21? 0.16 0.26 0.30 0.35 0.44 0.91 
2'1?, 21? 0.27 0.52 0.66 0.80 1.03 2.8 3 
2'R, 2 0.85 1.67 2.07 2.75 3.77 10.06 
2'S, 25' 1.11 l 2.07 2.56 3.36 4.34 9.54 
es6 5,2R 0.09 0.30 0.79 0.94 0.98 1.55 
2'R, 2R 0.16 0.47 1.13 1-37 1.54 2.76 
2'R, 25' 0.47 1.35 3. ,6 4.08 4.44 7.10 
2'S, 2. S 0.76 1 1.86 4.12 10.82 15.04 18-35 
ßs7 2', ';, 2R 0.08 0.47 0.67 0.69 0.72 1.26 
2'1?, 21? 0.11 0.84 1.21 1.25 1.3 2 2.14 
2. S ' 0.54 ! 2.15 1.61 3.69 3.80 5.48 
2'. ', 25 0.47 2.57 3.87 4.27 4.46 6.44 
es8 2'S, 21? 0.05 0.05 0.05 0.20 0.21 0.45 
2'R, 2R 0.51 0.81 1.11 1.78 1.86 2.23 
2'R, 25 1.19 2.01 ?. 40 3.79 3.94 I 4.42 
4 
2'5,25 1.63 2.73 ,. 75 6.14 6.41 7.12 
_ me: uý 2: S, 2R 0.10 0.25 0.38 0.46 0.52 1.07 
2'1z, 21? 0.28 0.62 0.94 1.14 1.37 2.5 5 
2'R, ?S 0.71 1.51 2.37 3.02 3.70 6.74 
2's, 25 0.88 2.01 x. 14 4.67 5.96 ; 9.38 
- - s. d 2 ti 2R 0.05 0.26 0.29 0.48 0.57 
i 0.88 
. , , 
2'R, 2R 0.16 0.23 0.31 0.41 0.42 0.87 
27?, 0.34 0.67 1.75 3.80 
2'ti. 2. ti' 0.51 0.65 1.08 3.05 4.21 5.1 3 
" 
Appendix 25: Cumulative urinary excretion of free carboxv ibuprofen stereoisomers for 
individual healthy elderly volunteers following the oral administration of 400 mg racemic 
ibuprofen (results expressed as a percentage of dose). 
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